<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta charset="utf-8">
<title>DailyMed - CRIXIVAN- indinavir sulfate capsule</title>
<!--[if lt IE 9]>
        <script src="/dailymed/scripts/html5shiv.min.js"></script>
    <![endif]-->

<script src="/dailymed/scripts/modernizr-2.0.6.min.js">
</script>
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/skeleton.min.css">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/jquery.jqzoom.min.css">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/style.min.css?v=2">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/header-search.min.css">
<link rel="stylesheet" type="text/css" media="all" href=
"/dailymed/css/responsive.min.css">
<link rel="stylesheet" type="text/css" media="print" href=
"/dailymed/css/print.min.css"><!--[if !IE]><!-->
<link rel="stylesheet" type="text/css" media="all" href=
"/dailymed/css/responsive-tables.min.css"><!--<![endif]-->
<link rel="icon" href="/dailymed/images/favicons/favicon.ico" type=
"image/x-icon">
<link rel="shortcut icon" href=
"/dailymed/images/favicons/favicon.ico" type="image/x-icon">
<link rel="apple-touch-icon" sizes="57x57" href=
"/dailymed/images/favicons/apple-touch-icon-57x57.png">
<link rel="apple-touch-icon" sizes="114x114" href=
"/dailymed/images/favicons/apple-touch-icon-114x114.png">
<link rel="apple-touch-icon" sizes="72x72" href=
"/dailymed/images/favicons/apple-touch-icon-72x72.png">
<link rel="apple-touch-icon" sizes="144x144" href=
"/dailymed/images/favicons/apple-touch-icon-144x144.png">
<link rel="apple-touch-icon" sizes="60x60" href=
"/dailymed/images/favicons/apple-touch-icon-60x60.png">
<link rel="apple-touch-icon" sizes="120x120" href=
"/dailymed/images/favicons/apple-touch-icon-120x120.png">
<link rel="apple-touch-icon" sizes="76x76" href=
"/dailymed/images/favicons/apple-touch-icon-76x76.png">
<link rel="apple-touch-icon" sizes="152x152" href=
"/dailymed/images/favicons/apple-touch-icon-152x152.png">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-196x196.png" sizes="196x196">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-160x160.png" sizes="160x160">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-96x96.png" sizes="96x96">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-16x16.png" sizes="16x16">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-32x32.png" sizes="32x32">
<meta name="msapplication-config" content=
"/dailymed/images/favicons/browserconfig.xml">
<meta name="msapplication-TileColor" content="#da532c">
<meta name="msapplication-TileImage" content=
"/dailymed/images/favicons/mstile-144x144.png">
<meta name="description" content="">
<meta name="keywords" content="">
<meta name="robots" content="noimageindex, noodp, noydir">
<meta name="viewport" id="viewport" content=
"width=device-width,minimum-scale=1.0,maximum-scale=10.0,initial-scale=1.0"><!-- Magnific Popup core CSS file -->
<link rel="stylesheet" href="/dailymed/css/magnific-popup.min.css">
<meta name="format-detection" content="telephone=no">
</head>
<body class="inner drug-info">
<div class="container_1000 bg_shadow">
<div style="width: 0; height: 0;"><a href="#" id=
"top-of-page"></a></div>
<header>
<div class="topHeader">
<ul id="skip">
<li><a href="#skip-main-content">Skip to Main Content</a></li>
</ul>
<nav class="topHeaderNav">
<div class="topNIHLogo mobileview"><a href="http://www.nih.gov"
class="top-logo" title="National Institutes of Health" target=
"_blank"><img src="/dailymed/images/nih-toplogo.png" alt=
"NIH Logo"></a> <a href="//www.nlm.nih.gov" title=
"U.S. National Library of Medicine" target="_blank">U.S. National
Library of Medicine</a></div>
<div class="container">
<div class="sixteen columns">
<div class="topNIHLogo"><a href="http://www.nih.gov" title=
"National Institutes of Health" target="_blank"><img src=
"/dailymed/images/nih-toplogo.png" alt="NIH Logo"></a> <a href=
"//www.nlm.nih.gov" title="U.S. National Library of Medicine"
target="_blank">U.S. National Library of Medicine</a></div>
<ul>
<li class="safety"><a title="Report Adverse Events" href=
"//www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report
Adverse Events</a> <span>|</span><a title=
"FDA Safety Reporting and Recalls" href=
"http://www.fda.gov/Safety/Recalls" target=
"_blank">Recalls</a></li>
</ul>
</div>
</div>
</nav>
<div class="divider"></div>
</div>
<div class="dailymedlogoprint"><img src="/dailymed/images/logo.png"
alt="DailyMed"></div>
<div class="bottomHeader">
<div class="header-image">
<div class="mobile-menu-btn closed hasjs" tabindex="0"></div>
<div class="mobile-menu">
<div class="mobile-menu-container">
<div class="pro-menu active">
<div class="first half">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><a href="/dailymed/about-dailymed.cfm">About Dailymed</a></li>
<li><a href="/dailymed/contact-us.cfm">Contact Us</a></li>
<li>Safety Reporting &amp; Recalls
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/">Report
Adverse Events</a></li>
<li><a href="http://www.fda.gov/Safety/Recalls">FDA Saftey
Recalls</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
</ul>
</div>
<div class="last half">
<ul>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">- All
Drug Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">- All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">- All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-all-mapping-files.cfm">Articles &amp;
Presentations</a></li>
</ul>
</li>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">- Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">- Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
</div>
</div>
</div>
<a href="/dailymed/index.cfm" class="logo" title=
"DailyMed">DailyMed</a>
<div class="header-search-container">
<div id="header-search">
<form action="/dailymed/search.cfm">
<div class="searchNav">
<ul class="searchType">
<li class="all active"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-all" value="all"> <label for=
"labeltype-all">All Drugs</label></li>
<li class="human"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-human" value="human"> <label for=
"labeltype-human">Human Drugs</label></li>
<li class="animal"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-animal" value="animal"> <label for=
"labeltype-animal">Animal Drugs</label></li>
<li class="more-ways" id="header-search-more-ways"><a href="#" id=
"more-ways-button" class="more-ways-label">More ways to search</a>
<ul id="more-ways-dropdown" class="dropdown" style="display:none;">
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Label Archives</a></li>
<li><a class="external-link" href="http://pillbox.nlm.nih.gov"
target="_blank">Tablet/Capsule ID Tool</a></li>
</ul>
</li>
</ul>
</div>
<div class="searchForm">
<div class="searchInput"><input id="searchQuery" name="query"
tabindex="0" type="text" placeholder=
"Enter drug, NDC code, drug class, or Set ID" autocorrect="off"
autocapitalize="off"></div>
<input class="search" tabindex="0" title="Search" type="submit"
value="Search"></div>
</form>
</div>
</div>
<div class="mobile-search-btn" tabindex="0"></div>
<div class="header-bg"></div>
<div class="divider"></div>
</div>
<div class="bottomHeaderContent">
<div class="search mobile-search">
<div class="divider_10 nomargin mobileview"></div>
<form action="/dailymed/search.cfm">
<div class="searchNav">
<ul class="searchType">
<li class="all active"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-all-2" value="all"> <label for=
"labeltype-all-2">All Drugs</label></li>
<li class="human"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-human-2" value="human"> <label for=
"labeltype-human-2">Human Drugs</label></li>
<li class="animal"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-animal-2" value="animal"> <label for=
"labeltype-animal-2">Animal Drugs</label></li>
</ul>
</div>
<div class="searchForm">
<div class="searchInput"><input id="searchToolsQuery" name="query"
tabindex="0" type="text" placeholder=
"Enter drug, NDC code, drug class, or Set ID" autocorrect="off"
autocapitalize="off"></div>
<input class="search" tabindex="0" title="Search" type="submit"
value="Search"></div>
</form>
<div class="divider"></div>
<nav class="bottomHeaderNav"><noscript>
<div class="tabletnav no-js">
<div class="col">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li>Search
<ul>
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Labels Archives</a></li>
<li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Index Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
</div>
</noscript>
<ul class="webview hasjs">
<li><a href="/dailymed/index.cfm" title="Home">Home</a></li>
<li><a href="#" title="News">News</a>
<ul class="sub-menu">
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm" title=
"FDA Guidances &amp; Info">FDA Guidances &amp; Info</a></li>
<li><a href="#" title=
"Structured Product Labeling (SPL) resources for industry professionals.">
NLM SPL Resources</a>
<ul class="sub-menu">
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li><a href="#" title="Application Development Support">Application
Development Support</a>
<ul class="sub-menu">
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm" title="Help">Help</a></li>
</ul>
<ul class="tabletview hasjs">
<li><a href="/dailymed/advanced-search.cfm" title=
"Advanced Search">Advanced Search</a></li>
<li class="viewmore"><a href="#" title="View More">View More</a>
<ul>
<li><span>News</span>
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><span>Safety Reporting and Recalls</span>
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a></li>
<li><a href="//www.fda.gov/Safety/Recalls" target="_blank">FDA
Saftey Recalls</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li><span>NLM SPL Resources</span>
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">- All
Drug Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">- All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">- All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li><span>Application Development Support</span>
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">- Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">- Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm" title="Help">Help</a></li>
</ul>
</li>
<li class="mobileview viewmore" tabindex="0"><a title="View More"
href="#">More ways to search</a>
<ul>
<li tabindex="0"><a title="Browse Drug Classes" href=
"/dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>
<li tabindex="0"><a title="Label Archives" href=
"/dailymed/archives/index.cfm">Label Archives</a></li>
<li tabindex="0"><a target="_blank" title="Tablet/Capsule ID Tool"
href="http://pillbox.nlm.nih.gov/">Tablet/Capsule ID Tool</a></li>
</ul>
</li>
</ul>
<ul class="mobileview hasjs">
<li><a href="/dailymed/advanced-search.cfm" title=
"Advanced Search">Advanced Search</a></li>
<li tabindex="0" class="viewmore"><a href="#" title=
"View More">View More</a>
<ul>
<li tabindex="0"><a href="/dailymed/browse-drug-classes.cfm" title=
"Browse Drug Classes">Browse Drug Classes</a></li>
<li tabindex="0"><a href="/dailymed/archives/index.cfm" title=
"Label Archives">Label Archives</a></li>
<li tabindex="0"><a href="http://pillbox.nlm.nih.gov/" title=
"Tablet/Capsule ID Tool" target="_blank">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
</ul>
</nav>
<div class="divider_10 nomargin"></div>
</div>
</div>
<div class="divider"></div>
</div>
</header>
<div id="skip-main-content"></div>
<div class="container">
<div class="main-content">
<div class="header long">
<div class="header-top">
<h1>Label: <span class="long-title">CRIXIVAN- indinavir sulfate
capsule<br></span></h1>
</div>
<ul class="tools">
<li class="rss"><a href="#modal-label-rss" class="modal-open">Label
RSS</a></li>
<li class="share">Share <noscript>: JavaScript needed for Sharing
tools</noscript> <!-- AddThis Button BEGIN -->
<div class=
"addthis_toolbox addthis_default_style addthis_16x16_style">
<a class="email-share" href=
"mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0ACRIXIVAN%2D%20Indinavir%20Sulfate%20Capsule%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3De19405d9%2Dd9a1%2D4072%2D5b9e%2D40cd3ae4bf1f%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E"
title="Share by Email"></a> <a class="addthis_button_facebook"></a>
<a class="addthis_button_twitter"></a> <a class=
"at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share"
href=
"//www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed"
target="_blank" style="display: block;"><span style=
"left: -9999px; position: absolute;">Bookmark &amp;
Share</span><img style="width:17px" src=
"/dailymed/images/addthis-image.jpg"></a></div>
<script type="text/javascript">
var addthis_config = {"data_track_addressbar":false};
</script> <script type="text/javascript" src=
"//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5">
</script> <!-- AddThis Button END --></li>
</ul>
</div>
<div class="four columns sidebar" id="leftmenu">
<section>
<article>
<div class="w-photos">
<div class="mod drug-photos">
<h2><a>View Package Photos</a></h2>
<ul>
<li>
<ul>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=crixivan-09.jpg&amp;setid=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="0"><img id="zoom_1" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=crixivan-09.jpg&amp;setid=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f"
src=
"image.cfm?type=img&amp;name=crixivan-09.jpg&amp;setid=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f"
data-photo-type="package"> </a></li>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=crixivan-10.jpg&amp;setid=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="1"><img id="zoom_2" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=crixivan-10.jpg&amp;setid=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f"
src=
"image.cfm?type=img&amp;name=crixivan-10.jpg&amp;setid=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f"
data-photo-type="package"> </a></li>
</ul>
</li>
</ul>
<h4 class="more closed">VIEW MORE</h4>
<div class="show-more">
<ul>
<li>
<ul>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=crixivan-11.jpg&amp;setid=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="2"><img id="zoom_3" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=crixivan-11.jpg&amp;setid=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f"
src=
"image.cfm?type=img&amp;name=crixivan-11.jpg&amp;setid=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f"
data-photo-type="package"> </a></li>
</ul>
</li>
</ul>
</div>
</div>
<div class="mod drug-photos">
<h2><a>VIEW DRUG PHOTOS</a></h2>
<div class="no-pill-photo-warning-drug-info">DailyMed is no longer
displaying pill images from RxImage. For more information, <a href=
"#no-pill-photo-warning-modal" class="modal-open">click
here</a>.</div>
</div>
</div>
<div class="mod-wrap">
<div class="mod blue-list page-jump">
<h2><a href="#drug-information">Drug Label Info</a></h2>
</div>
<div class="mod blue-list orange">
<h2><a href="#">Safety</a></h2>
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a></li>
<li><a href="http://www.fda.gov/Safety/Recalls/" target=
"_blank">FDA Safety Recalls</a></li>
<li><a href=
"http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22INDINAVIR%20ANHYDROUS%22+%29"
target="_blank">Presence in Breast Milk</a></li>
</ul>
</div>
<div class="mod blue-list">
<h2><a href="#">Related Resources</a></h2>
<ul>
<li><a href=
"//vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&amp;query=INDINAVIR%20ANHYDROUS"
target="_blank">Medline Plus</a></li>
<li><a href=
"//www.clinicaltrials.gov/ct/search?submit=Search&amp;term=INDINAVIR%20ANHYDROUS"
target="blank">Clinical Trials</a></li>
<li><a href="#" id="pubmed-menu">PubMed</a>
<ul>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=INDINAVIR%20ANHYDROUS[All%20Fields]"
title="Link opens new window for All Citations" target="pubmed">All
Citations</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=INDINAVIR%20ANHYDROUS/AE"
title="Link opens new window for Adverse Effects" target=
"pubmed">Adverse Effects</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=INDINAVIR%20ANHYDROUS/TU"
title="Link opens new window for Therapeutic Use" target=
"pubmed">Therapeutic Use</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=INDINAVIR%20ANHYDROUS/PD"
title="Link opens new window for Pharmacology" target=
"pubmed">Pharmacology</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=INDINAVIR%20ANHYDROUS[All%20Fields]%20AND%20Clinical%20Trial[ptyp]"
title="Link opens new window for Clinical Trials" target=
"pubmed">Clinical Trials</a></li>
</ul>
</li>
<li><a href=
"http://www.drugbank.ca/search?utf8=%E2%9C%93&amp;query=INDINAVIR+SULFATE&amp;search_type=drugs&amp;button="
target="_blank">Biochemical Data Summary</a></li>
</ul>
</div>
<div class="mod blue-list">
<h2><a href="#">More Info For This Drug</a></h2>
<ul>
<li><a href="#modal-label-archives" class="modal-open">View Label
Archives</a></li>
<li><a href="#modal-rx-norm" class="modal-open">RxNorm</a></li>
<li><a href="#modal-label-rss" class="modal-open">Get Label RSS
Feed</a></li>
</ul>
</div>
</div>
</article>
</section>
</div>
<div class="content-wide">
<article>
<ul class="drug-information">
<li><strong><a class="tip" rel="tooltip" title=
"&lt;b&gt;NDC (National Drug Code)&lt;/b&gt; - Each drug product is assigned this unique number which can be found on the drug's outer packaging."
href="#">NDC Code(s):</a></strong> <span id=
"item-code-s">0006-0570-62, 0006-0571-43, 0006-0573-62</span></li>
<li style="list-style: none"><span id="item-code-s"></span></li>
<li><span id="item-code-s"></span></li>
<li><span id="item-code-s"><strong>Packager:</strong> Merck Sharp
&amp; Dohme Corp.</span></li>
</ul>
<ul class="drug-information">
<li><span id="item-code-s"><strong>Category:</strong> <span id=
"category" class="orangetext">HUMAN PRESCRIPTION DRUG
LABEL</span></span></li>
<li><strong>DEA Schedule:</strong> <span id=
"dea-schedule">None</span></li>
<li><strong>Marketing Status:</strong> <span id=
"marketing-status">New Drug Application</span></li>
</ul>
<div id="drug-information" class="toggle">
<h2><a id="druglabel"></a>Drug Label Information</h2>
<p class="date">Updated March 27, 2015</p>
<p class="orangetext">If you are a consumer or patient please visit
<a class="audience-context-switch consumer" href=
"/dailymed/drugInfo.cfm?setid=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f&amp;audience=consumer">
this version.</a></p>
<ul class="tools">
<li class="download">Download DRUG LABEL INFO: <a download=""
class="pdf" href=
"/dailymed/getFile.cfm?setid=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f&amp;type=pdf&amp;name=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f"
target="_blank">PDF</a> <a download="" class="xml" href=
"/dailymed/getFile.cfm?setid=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f&amp;type=zip&amp;name=CRIXIVAN"
target="_blank">XML</a></li>
<li class="print"><a href=
"/dailymed/fda/fdaDrugXsl.cfm?setid=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f&amp;type=display"
target="_blank">Print Drug Label Info</a></li>
</ul>
<div class="drug-label-sections">
<div class="control-nav show-js"><a class="open-all" href="#">View
All Sections</a><a class="close-all" href="#">Close All
Sections</a></div>
<ul>
<li><a href="#">DESCRIPTION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34089-3"><a name=
"i4i_description_id_c79dd6d1-208b-4fbf-94e8-7de6816553ac" id=
"i4i_description_id_c79dd6d1-208b-4fbf-94e8-7de6816553ac"></a>
<a name="section-1" id="section-1"></a>
<p class="First">CRIXIVAN<span class="Sup">®</span> (indinavir
sulfate) is an inhibitor of the human immunodeficiency virus (HIV)
protease. CRIXIVAN Capsules are formulated as a sulfate salt and
are available for oral administration in strengths of 200 and 400
mg of indinavir (corresponding to 250 and 500 mg indinavir sulfate,
respectively). Each capsule also contains the inactive ingredients
anhydrous lactose and magnesium stearate. The capsule shell has the
following inactive ingredients and dyes: gelatin and titanium
dioxide.</p>
<p>The chemical name for indinavir sulfate is [1(1<span class=
"Italics">S</span>,2<span class="Italics">R</span>),5(<span class=
"Italics">S</span>)]-2,3,5-trideoxy-<span class=
"Italics">N</span>-(2,3-dihydro-2-hydroxy-1<span class=
"Italics">H</span>-inden-1-yl)-5-[2-[[(1,1-dimethylethyl)amino]carbonyl]-4-(3-pyridinylmethyl)-1-piperazinyl]-2-(phenylmethyl)-D-<span class="Italics">erythro</span>-pentonamide
sulfate (1:1) salt. Indinavir sulfate has the following structural
formula:</p>
<div class="Figure"><img src=
"image.cfm?setid=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f&amp;name=crixivan-01.jpg"
alt="image of indinavir sulfate chemical structure"></div>
<p>Indinavir sulfate is a white to off-white, hygroscopic,
crystalline powder with the molecular formula C<span class=
"Sub">36</span>H<span class="Sub">47</span>N<span class=
"Sub">5</span>O<span class="Sub">4</span> • H<span class=
"Sub">2</span>SO<span class="Sub">4</span> and a molecular weight
of 711.88. It is very soluble in water and in methanol.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">MICROBIOLOGY</a>
<div class="Section toggle-content closed" data-sectioncode=
"49489-8"><a name=
"i4i_microbiology_id_9f248f7f-fb40-403b-a4f4-2cb891d23ab8" id=
"i4i_microbiology_id_9f248f7f-fb40-403b-a4f4-2cb891d23ab8"></a>
<a name="section-2" id="section-2"></a>
<div class="Section" data-sectioncode="43679-0"><a name=
"i4i_mechanism_action_id_8f9b1190-954d-4bf1-9e51-a9d4da54259e" id=
"i4i_mechanism_action_id_8f9b1190-954d-4bf1-9e51-a9d4da54259e"></a>
<a name="section-2.1" id="section-2.1"></a>
<h2>Mechanism of Action:</h2>
<p class="First">HIV-1 protease is an enzyme required for the
proteolytic cleavage of the viral polyprotein precursors into the
individual functional proteins found in infectious HIV-1. Indinavir
binds to the protease active site and inhibits the activity of the
enzyme. This inhibition prevents cleavage of the viral polyproteins
resulting in the formation of immature non-infectious viral
particles.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_2bc89f1b-16fc-4aa2-a6b1-3ba7014ab459" id=
"i4i_section_id_2bc89f1b-16fc-4aa2-a6b1-3ba7014ab459"></a> <a name=
"section-2.2" id="section-2.2"></a>
<h2>Antiretroviral Activity <span class="Italics">In
Vitro:</span></h2>
<p class="First">The <span class="Italics">in vitro</span> activity
of indinavir was assessed in cell lines of lymphoblastic and
monocytic origin and in peripheral blood lymphocytes. HIV-1
variants used to infect the different cell types include
laboratory-adapted variants, primary clinical isolates and clinical
isolates resistant to nucleoside analogue and nonnucleoside
inhibitors of the HIV-1 reverse transcriptase. The IC<span class=
"Sub">95</span> (95% inhibitory concentration) of indinavir in
these test systems was in the range of 25 to 100 nM. In drug
combination studies with the nucleoside analogues zidovudine and
didanosine, indinavir showed synergistic activity in cell culture.
The relationship between <span class="Italics">in vitro</span>
susceptibility of HIV-1 to indinavir and inhibition of HIV-1
replication in humans has not been established.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_3ba1d416-5c17-4342-a390-b49f89ad1efd" id=
"i4i_section_id_3ba1d416-5c17-4342-a390-b49f89ad1efd"></a> <a name=
"section-2.3" id="section-2.3"></a>
<h2>Drug Resistance:</h2>
<p class="First">Isolates of HIV-1 with reduced susceptibility to
the drug have been recovered from some patients treated with
indinavir. Viral resistance was correlated with the accumulation of
mutations that resulted in the expression of amino acid
substitutions in the viral protease. Eleven amino acid residue
positions, (L10l/V/R, K20l/M/R, L24l, M46l/L, l54A/V, L63P, l64V,
A71T/V, V82A/F/T, l84V, and L90M), at which substitutions are
associated with resistance, have been identified. Resistance was
mediated by the co-expression of multiple and variable
substitutions at these positions. No single substitution was either
necessary or sufficient for measurable resistance (≥4-fold increase
in IC<span class="Sub">95</span>). In general, higher levels of
resistance were associated with the co-expression of greater
numbers of substitutions, although their individual effects varied
and were not additive. At least 3 amino acid substitutions must be
present for phenotypic resistance to indinavir to reach measurable
levels. In addition, mutations in the p7/ p1 and p1/ p6 gag
cleavage sites were observed in some indinavir resistant HIV-1
isolates.</p>
<p><span class="Italics">In vitro</span> phenotypic
susceptibilities to indinavir were determined for 38 viral isolates
from 13 patients who experienced virologic rebounds during
indinavir monotherapy. Pre-treatment isolates from five patients
exhibited indinavir IC<span class="Sub">95</span> values of 50-100
nM. At or following viral RNA rebound (after 12-76 weeks of
therapy), IC<span class="Sub">95</span> values ranged from 25 to
&gt;3000 nM, and the viruses carried 2 to 10 mutations in the
protease gene relative to baseline.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_d4fc5b92-6b18-4832-af2c-7d853392d4bd" id=
"i4i_section_id_d4fc5b92-6b18-4832-af2c-7d853392d4bd"></a> <a name=
"section-2.4" id="section-2.4"></a>
<h2>Cross-Resistance to Other Antiviral Agents:</h2>
<p class="First">Varying degrees of HIV-1 cross-resistance have
been observed between indinavir and other HIV-1 protease
inhibitors. In studies with ritonavir, saquinavir, and amprenavir,
the extent and spectrum of cross-resistance varied with the
specific mutational patterns observed. In general, the degree of
cross-resistance increased with the accumulation of
resistance-associated amino acid substitutions. Within a panel of
29 viral isolates from indinavir-treated patients that exhibited
measurable (≥4-fold) phenotypic resistance to indinavir, all were
resistant to ritonavir. Of the indinavir resistant HIV-1 isolates,
63% showed resistance to saquinavir and 81% to amprenavir.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">CLINICAL PHARMACOLOGY</a>
<div class="Section toggle-content closed" data-sectioncode=
"34090-1"><a name=
"i4i_clinical_pharmacology_id_7caf9387-ffb7-4044-bdcf-c354131c84b5"
id=
"i4i_clinical_pharmacology_id_7caf9387-ffb7-4044-bdcf-c354131c84b5">
</a> <a name="section-3" id="section-3"></a>
<div class="Section" data-sectioncode="43682-4"><a name=
"i4i_pharmacokinetics_id_03cf50f5-9e30-49da-9b71-51c1e3ebeee4" id=
"i4i_pharmacokinetics_id_03cf50f5-9e30-49da-9b71-51c1e3ebeee4"></a>
<a name="section-3.1" id="section-3.1"></a>
<h2>Pharmacokinetics</h2>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_25d29473-1e3b-41f8-a0c7-567157c18d88" id=
"i4i_section_id_25d29473-1e3b-41f8-a0c7-567157c18d88"></a> <a name=
"section-3.1.1" id="section-3.1.1"></a>
<h3>Absorption:</h3>
<p class="First">Indinavir was rapidly absorbed in the fasted state
with a time to peak plasma concentration (T<span class=
"Sub">max</span>) of 0.8 ± 0.3 hours (mean ± S.D.) (n=11). A
greater than dose-proportional increase in indinavir plasma
concentrations was observed over the 200-1000 mg dose range. At a
dosing regimen of 800 mg every 8 hours, steady-state area under the
plasma concentration time curve (AUC) was 30,691 ± 11,407 nM•hour
(n=16), peak plasma concentration (C<span class="Sub">max</span>)
was 12,617 ± 4037 nM (n=16), and plasma concentration eight hours
post dose (trough) was 251 ± 178 nM (n=16).</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_59d110fd-2d4f-4a1f-8bca-252a08546749" id=
"i4i_section_id_59d110fd-2d4f-4a1f-8bca-252a08546749"></a> <a name=
"section-3.1.1.1" id="section-3.1.1.1"></a>
<h4>Effect of Food on Oral Absorption:</h4>
<p class="First">Administration of indinavir with a meal high in
calories, fat, and protein (784 kcal, 48.6 g fat, 31.3 g protein)
resulted in a 77% ± 8% reduction in AUC and an 84% ± 7% reduction
in C<span class="Sub">max</span> (n=10). Administration with
lighter meals (e.g., a meal of dry toast with jelly, apple juice,
and coffee with skim milk and sugar or a meal of corn flakes, skim
milk and sugar) resulted in little or no change in AUC,
C<span class="Sub">max</span> or trough concentration.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_4dcdc55c-1c77-4493-bb7e-e1bbd4461214" id=
"i4i_section_id_4dcdc55c-1c77-4493-bb7e-e1bbd4461214"></a> <a name=
"section-3.1.2" id="section-3.1.2"></a>
<h3>Distribution:</h3>
<p class="First">Indinavir was approximately 60% bound to human
plasma proteins over a concentration range of 81 nM to 16,300
nM.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_b8548cdf-401f-4f2b-8fe0-a7209f4a2b50" id=
"i4i_section_id_b8548cdf-401f-4f2b-8fe0-a7209f4a2b50"></a> <a name=
"section-3.1.3" id="section-3.1.3"></a>
<h3>Metabolism:</h3>
<p class="First">Following a 400-mg dose of <span class=
"Sup">14</span>C-indinavir, 83 ± 1% (n=4) and 19 ± 3% (n=6) of the
total radioactivity was recovered in feces and urine, respectively;
radioactivity due to parent drug in feces and urine was 19.1% and
9.4%, respectively. Seven metabolites have been identified, one
glucuronide conjugate and six oxidative metabolites. <span class=
"Italics">In vitro</span> studies indicate that cytochrome P-450
3A4 (CYP3A4) is the major enzyme responsible for formation of the
oxidative metabolites.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_b2c9f99e-c8f5-406a-bfcc-3e779a78b6d0" id=
"i4i_section_id_b2c9f99e-c8f5-406a-bfcc-3e779a78b6d0"></a> <a name=
"section-3.1.4" id="section-3.1.4"></a>
<h3>Elimination:</h3>
<p class="First">Less than 20% of indinavir is excreted unchanged
in the urine. Mean urinary excretion of unchanged drug was 10.4 ±
4.9% (n=10) and 12.0 ± 4.9% (n=10) following a single 700-mg and
1000-mg dose, respectively. Indinavir was rapidly eliminated with a
half-life of 1.8 ± 0.4 hours (n=10). Significant accumulation was
not observed after multiple dosing at 800 mg every 8 hours.</p>
</div>
</div>
<div class="Section" data-sectioncode="43684-0"><a name=
"i4i_specific_populations_id_fff662be-a475-491b-89ac-8697dfd37c6a"
id=
"i4i_specific_populations_id_fff662be-a475-491b-89ac-8697dfd37c6a"></a>
<a name="section-3.2" id="section-3.2"></a>
<h2>Special Populations</h2>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_c6a08675-e92c-4553-aefb-6b12b8e48e0f" id=
"i4i_section_id_c6a08675-e92c-4553-aefb-6b12b8e48e0f"></a> <a name=
"section-3.2.1" id="section-3.2.1"></a>
<h3>Hepatic Insufficiency:</h3>
<p class="First">Patients with mild to moderate hepatic
insufficiency and clinical evidence of cirrhosis had evidence of
decreased metabolism of indinavir resulting in approximately 60%
higher mean AUC following a single 400-mg dose (n=12). The
half-life of indinavir increased to 2.8 ± 0.5 hours. Indinavir
pharmacokinetics have not been studied in patients with severe
hepatic insufficiency (see <a href=
"#i4i_section_id_3ac79c87-4364-4c4a-85fe-f7d7e00bccac">DOSAGE AND
ADMINISTRATION, Hepatic Insufficiency</a>).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_91fb48fa-f8df-47dd-9f61-e4a548389d71" id=
"i4i_section_id_91fb48fa-f8df-47dd-9f61-e4a548389d71"></a> <a name=
"section-3.2.2" id="section-3.2.2"></a>
<h3>Renal Insufficiency:</h3>
<p class="First">The pharmacokinetics of indinavir have not been
studied in patients with renal insufficiency.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_6d03d47c-1f50-42f8-a3f3-64c16dcfb824" id=
"i4i_section_id_6d03d47c-1f50-42f8-a3f3-64c16dcfb824"></a> <a name=
"section-3.2.3" id="section-3.2.3"></a>
<h3>Gender:</h3>
<p class="First">The effect of gender on the pharmacokinetics of
indinavir was evaluated in 10 HIV seropositive women who received
CRIXIVAN 800 mg every 8 hours with zidovudine 200 mg every 8 hours
and lamivudine 150 mg twice a day for one week. Indinavir
pharmacokinetic parameters in these women were compared to those in
HIV seropositive men (pooled historical control data). Differences
in indinavir exposure, peak concentrations, and trough
concentrations between males and females are shown in <a href=
"#id_75b1ae80-ffb6-41a1-bca6-59e7c05cd5ab">Table 1</a> below:</p>
<a name="id_75b1ae80-ffb6-41a1-bca6-59e7c05cd5ab" id=
"id_75b1ae80-ffb6-41a1-bca6-59e7c05cd5ab"></a>
<div class="scrollingtable">
<table class="Noautorules" width="764.000">
<caption><span>Table 1</span></caption>
<colgroup>
<col width="31.7%">
<col width="37.4%">
<col width="30.9%"></colgroup>
<thead>
<tr>
<td align="center" valign="top">PK Parameter</td>
<td align="center" valign="top">% change in PK parameter for
females<br>
relative to males</td>
<td align="center" valign="top">90% Confidence Interval</td>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="3" valign="top">↓Indicates a decrease in
the PK parameter; ↑indicates an increase in the PK parameter.</td>
</tr>
</tfoot>
<tbody>
<tr>
<td align="center" valign="top">AUC<span class="Sub">0-8h</span>
(nM•hr)</td>
<td align="center" valign="top">↓13%</td>
<td align="center" valign="top">(↓32%, ↑12%)</td>
</tr>
<tr>
<td align="center" valign="top">C<span class="Sub">max</span>
(nM)</td>
<td align="center" valign="top">↓13%</td>
<td align="center" valign="top">(↓32%, ↑10%)</td>
</tr>
<tr class="Botrule">
<td align="center" valign="top">C<span class="Sub">8h</span>
(nM)</td>
<td align="center" valign="top">↓22%</td>
<td align="center" valign="top">(↓47%, ↑15%)</td>
</tr>
</tbody>
</table>
</div>
<p>The clinical significance of these gender differences in the
pharmacokinetics of indinavir is not known.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_08d283c1-3028-430f-93ef-4c438dfebf36" id=
"i4i_section_id_08d283c1-3028-430f-93ef-4c438dfebf36"></a> <a name=
"section-3.2.4" id="section-3.2.4"></a>
<h3>Race:</h3>
<p class="First">Pharmacokinetics of indinavir appear to be
comparable in Caucasians and Blacks based on pharmacokinetic
studies including 42 Caucasians (26 HIV-positive) and 16 Blacks (4
HIV-positive).</p>
</div>
<div class="Section" data-sectioncode="34081-0"><a name=
"i4i_pediatric_use_id_8e5d1fc5-1698-4034-a400-2fc18ce95e34" id=
"i4i_pediatric_use_id_8e5d1fc5-1698-4034-a400-2fc18ce95e34"></a>
<a name="section-3.2.5" id="section-3.2.5"></a>
<h3>Pediatric:</h3>
<p class="First">The optimal dosing regimen for use of indinavir in
pediatric patients has not been established. In HIV-infected
pediatric patients (age 4-15 years), a dosage regimen of indinavir
capsules, 500 mg/m<span class="Sup">2</span> every 8 hours,
produced AUC<span class="Sub">0-8hr</span> of 38,742 ± 24,098
nM•hour (n=34), C<span class="Sub">max</span> of 17,181 ± 9809 nM
(n=34), and trough concentrations of 134 ± 91 nM (n=28). The
pharmacokinetic profiles of indinavir in pediatric patients were
not comparable to profiles previously observed in HIV-infected
adults receiving the recommended dose of 800 mg every 8 hours. The
AUC and C<span class="Sub">max</span> values were slightly higher
and the trough concentrations were considerably lower in pediatric
patients. Approximately 50% of the pediatric patients had trough
values below 100 nM; whereas, approximately 10% of adult patients
had trough levels below 100 nM. The relationship between specific
trough values and inhibition of HIV replication has not been
established.</p>
</div>
<div class="Section" data-sectioncode="42228-7"><a name=
"i4i_pregnancy_id_a2f05ba2-3961-4c48-8aa4-28f765dabbb2" id=
"i4i_pregnancy_id_a2f05ba2-3961-4c48-8aa4-28f765dabbb2"></a>
<a name="section-3.2.6" id="section-3.2.6"></a>
<h3>Pregnant Patients:</h3>
<p class="First">The optimal dosing regimen for use of indinavir in
pregnant patients has not been established. A CRIXIVAN dose of 800
mg every 8 hours (with zidovudine 200 mg every 8 hours and
lamivudine 150 mg twice a day) has been studied in 16 HIV-infected
pregnant patients at 14 to 28 weeks of gestation at enrollment
(study PACTG 358). The mean indinavir plasma AUC<span class=
"Sub">0-8hr</span> at weeks 30-32 of gestation (n=11) was 9231
nM•hr, which is 74% (95% CI: 50%, 86%) lower than that observed 6
weeks postpartum. Six of these 11 (55%) patients had mean indinavir
plasma concentrations 8 hours post-dose (C<span class=
"Sub">min</span>) below assay threshold of reliable quantification.
The pharmacokinetics of indinavir in these 11 patients at 6 weeks
postpartum were generally similar to those observed in non-pregnant
patients in another study (see <a href=
"#i4i_pregnancy_id_b1604860-5576-453e-8eab-64b159945be9">PRECAUTIONS,
Pregnancy</a>).</p>
</div>
</div>
<div class="Section" data-sectioncode="34073-7"><a name=
"i4i_interactions_id_d2bf28f1-de8a-42e5-8f0d-5511455a45a6" id=
"i4i_interactions_id_d2bf28f1-de8a-42e5-8f0d-5511455a45a6"></a>
<a name="section-3.3" id="section-3.3"></a>
<h2>Drug Interactions:</h2>
<p class="First">(also see <a href=
"#i4i_contraindications_id_822eea92-c7b1-4462-83c0-948313a14695">CONTRAINDICATIONS</a>,
<a href=
"#i4i_warnings_id_d7b709bb-7551-4a58-a56e-836a0bef4b58">WARNINGS</a>,
<a href="#PRE_DI">PRECAUTIONS, Drug Interactions</a>)</p>
<p>Indinavir is an inhibitor of the cytochrome P450 isoform CYP3A4.
Coadministration of CRIXIVAN and drugs primarily metabolized by
CYP3A4 may result in increased plasma concentrations of the other
drug, which could increase or prolong its therapeutic and adverse
effects (see <a href=
"#i4i_contraindications_id_822eea92-c7b1-4462-83c0-948313a14695">CONTRAINDICATIONS</a>
and <a href=
"#i4i_warnings_id_d7b709bb-7551-4a58-a56e-836a0bef4b58">WARNINGS</a>).
Based on <span class="Italics">in vitro</span> data in human liver
microsomes, indinavir does not inhibit CYP1A2, CYP2C9, CYP2E1 and
CYP2B6. However, indinavir may be a weak inhibitor of CYP2D6.</p>
<p>Indinavir is metabolized by CYP3A4. Drugs that induce CYP3A4
activity would be expected to increase the clearance of indinavir,
resulting in lowered plasma concentrations of indinavir.
Coadministration of CRIXIVAN and other drugs that inhibit CYP3A4
may decrease the clearance of indinavir and may result in increased
plasma concentrations of indinavir.</p>
<p>Drug interaction studies were performed with CRIXIVAN and other
drugs likely to be coadministered and some drugs commonly used as
probes for pharmacokinetic interactions. The effects of
coadministration of CRIXIVAN on the AUC, C<span class=
"Sub">max</span> and C<span class="Sub">min</span> are summarized
in <a href="#id_fb7ba932-878d-4285-bc07-a950bcdf934f">Table 2</a>
(effect of other drugs on indinavir) and <a href=
"#id_5ee46c12-daf5-432b-9867-5daff2876dc2">Table 3</a> (effect of
indinavir on other drugs). For information regarding clinical
recommendations, see <a href=
"#id_475b25fa-86e3-4b92-b606-66a613746db9">Table 9</a> in
PRECAUTIONS.</p>
<a name="id_fb7ba932-878d-4285-bc07-a950bcdf934f" id=
"id_fb7ba932-878d-4285-bc07-a950bcdf934f"></a>
<div class="scrollingtable">
<table width="829.000">
<caption><span>Table 2: Drug Interactions: Pharmacokinetic
Parameters for Indinavir in the Presence of the Coadministered Drug
(See <a href=
"#id_475b25fa-86e3-4b92-b606-66a613746db9">PRECAUTIONS, Table 9</a>
for Recommended Alterations in Dose or Regimen)</span></caption>
<colgroup>
<col width="12.5%">
<col width="17.9%">
<col width="17.2%">
<col width="6.6%">
<col width="14.6%">
<col width="15.9%">
<col width="15.2%"></colgroup>
<thead>
<tr class="Botrule First">
<td class="Toprule" align="center" valign="bottom"><span class=
"Bold">Coadministered drug</span></td>
<td class="Toprule" align="center" valign="bottom"><span class=
"Bold">Dose of Coadministered drug (mg)</span></td>
<td class="Toprule" align="center" valign="bottom"><span class=
"Bold">Dose of CRIXIVAN<br>
(mg)</span></td>
<td class="Toprule" align="center" valign="bottom"><span class=
"Bold">n</span></td>
<td align="center" colspan="3" valign="bottom"><span class=
"Bold">Ratio (with/without coadministered drug) of Indinavir<br>
Pharmacokinetic Parameters<br>
(90% CI); No Effect = 1.00</span></td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="center" valign="top">C<span class="Sub">max</span></td>
<td align="center" valign="top">AUC</td>
<td align="center" valign="top">C<span class="Sub">min</span></td>
</tr>
</thead>
<tfoot>
<tr class="Last">
<td align="left" colspan="7" valign="top">All interaction studies
conducted in healthy, HIV-negative adult subjects, unless otherwise
indicated.</td>
</tr>
<tr>
<td align="left" colspan="7">
<dl class="Footnote">
<dt><a href="#footnote-reference-1" name="footnote-1" id=
"footnote-1">*</a></dt>
<dd>Relative to indinavir 800 mg three times daily alone.</dd>
<dt><a href="#footnote-reference-2" name="footnote-2" id=
"footnote-2">†</a></dt>
<dd>Study conducted in HIV-positive subjects.</dd>
<dt><a href="#footnote-reference-3" name="footnote-3" id=
"footnote-3">‡</a></dt>
<dd>Comparison to historical data on 16 subjects receiving
indinavir alone.</dd>
<dt><a href="#footnote-reference-4" name="footnote-4" id=
"footnote-4">§</a></dt>
<dd>95% CI.</dd>
<dt><a href="#footnote-reference-5" name="footnote-5" id=
"footnote-5">¶</a></dt>
<dd>Parallel group design; n for indinavir + coadministered drug, n
for indinavir alone.</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">
Cimetidine</td>
<td class="Botrule" align="center" valign="top">600 twice
daily,<br>
6 days</td>
<td class="Botrule" align="center" valign="top">400 single
dose</td>
<td class="Botrule" align="center" valign="top">12</td>
<td class="Botrule" align="center" valign="top">1.07<br>
(0.77, 1.49)</td>
<td class="Botrule" align="center" valign="top">0.98<br>
(0.81, 1.19)</td>
<td class="Botrule" align="center" valign="top">0.82<br>
(0.69, 0.99)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Clarithromycin</td>
<td class="Botrule" align="center" valign="top">500 q12h,<br>
7 days</td>
<td class="Botrule" align="center" valign="top">800 three times<br>
daily, 7 days</td>
<td class="Botrule" align="center" valign="top">10</td>
<td class="Botrule" align="center" valign="top">1.08<br>
(0.85, 1.38)</td>
<td class="Botrule" align="center" valign="top">1.19<br>
(1.00, 1.42)</td>
<td class="Botrule" align="center" valign="top">1.57<br>
(1.16, 2.12)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Delavirdine</td>
<td class="Botrule" align="center" valign="top">400 three times
daily</td>
<td class="Botrule" align="center" valign="top">400 three times<br>
daily, 7 days</td>
<td class="Botrule" align="center" valign="top">28</td>
<td class="Botrule" align="center" valign="top">0.64<a class="Sup"
href="#footnote-1" name="footnote-reference-1" id=
"footnote-reference-1">*</a><br>
(0.48, 0.86)</td>
<td class="Botrule" align="center" valign="top">No significant
change<a class="Sup" href="#footnote-1">*</a></td>
<td class="Botrule" align="center" valign="top">2.18<a class="Sup"
href="#footnote-1">*</a><br>
(1.16, 4.12)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Delavirdine</td>
<td class="Botrule" align="center" valign="top">400 three times
daily</td>
<td class="Botrule" align="center" valign="top">600 three times<br>
daily, 7 days</td>
<td class="Botrule" align="center" valign="top">28</td>
<td class="Botrule" align="center" valign="top">No significant
change</td>
<td class="Botrule" align="center" valign="top">1.53<a class="Sup"
href="#footnote-1">*</a><br>
(1.07, 2.20)</td>
<td class="Botrule" align="center" valign="top">3.98<a class="Sup"
href="#footnote-1">*</a><br>
(2.04, 7.78)</td>
</tr>
<tr>
<td align="left" valign="top">Efavirenz<a class="Sup" href=
"#footnote-2" name="footnote-reference-2" id=
"footnote-reference-2">†</a></td>
<td align="center" valign="top">600 once daily,<br>
10 days</td>
<td align="center" valign="top">1000 three times<br>
daily, 10 days</td>
<td align="center" valign="top">20</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top">After morning dose</td>
<td align="center" valign="top"></td>
<td align="center" valign="top">No significant change<a class="Sup"
href="#footnote-1">*</a></td>
<td align="center" valign="top">0.67<a class="Sup" href=
"#footnote-1">*</a><br>
(0.61, 0.74)</td>
<td align="center" valign="top">0.61<a class="Sup" href=
"#footnote-1">*</a><br>
(0.49, 0.76)</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top">After afternoon dose</td>
<td align="center" valign="top"></td>
<td align="center" valign="top">No significant change<a class="Sup"
href="#footnote-1">*</a></td>
<td align="center" valign="top">0.63<a class="Sup" href=
"#footnote-1">*</a><br>
(0.54, 0.74)</td>
<td align="center" valign="top">0.48<a class="Sup" href=
"#footnote-1">*</a><br>
(0.43, 0.53)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top">After evening
dose</td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top">0.71<a class="Sup"
href="#footnote-1">*</a><br>
(0.57, 0.89)</td>
<td class="Botrule" align="center" valign="top">0.54<a class="Sup"
href="#footnote-1">*</a><br>
(0.46, 0.63)</td>
<td class="Botrule" align="center" valign="top">0.43<a class="Sup"
href="#footnote-1">*</a><br>
(0.37, 0.50)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Fluconazole<a class=
"Sup" href="#footnote-2">†</a></td>
<td class="Botrule" align="center" valign="top">400 once daily,<br>
8 days</td>
<td class="Botrule" align="center" valign="top">1000 three times
daily, 7 days</td>
<td class="Botrule" align="center" valign="top">11</td>
<td class="Botrule" align="center" valign="top">0.87<br>
(0.72, 1.05)</td>
<td class="Botrule" align="center" valign="top">0.76<br>
(0.59, 0.98)</td>
<td class="Botrule" align="center" valign="top">0.90<br>
(0.72, 1.12)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Grapefruit Juice</td>
<td class="Botrule" align="center" valign="top">8 oz.</td>
<td class="Botrule" align="center" valign="top">400 single
dose</td>
<td class="Botrule" align="center" valign="top">10</td>
<td class="Botrule" align="center" valign="top">0.65<br>
(0.53, 0.79)</td>
<td class="Botrule" align="center" valign="top">0.73<br>
(0.60, 0.87)</td>
<td class="Botrule" align="center" valign="top">0.90<br>
(0.71, 1.15)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Isoniazid</td>
<td class="Botrule" align="center" valign="top">300 once daily in
the morning,<br>
8 days</td>
<td class="Botrule" align="center" valign="top">800 three times
daily, 7 days</td>
<td class="Botrule" align="center" valign="top">11</td>
<td class="Botrule" align="center" valign="top">0.95<br>
(0.88, 1.03)</td>
<td class="Botrule" align="center" valign="top">0.99<br>
(0.87, 1.13)</td>
<td class="Botrule" align="center" valign="top">0.89<br>
(0.75, 1.06)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Itraconazole</td>
<td class="Botrule" align="center" valign="top">200 twice
daily,<br>
7 days</td>
<td class="Botrule" align="center" valign="top">600 three times<br>
daily, 7 days</td>
<td class="Botrule" align="center" valign="top">12</td>
<td class="Botrule" align="center" valign="top">0.78<a class="Sup"
href="#footnote-1">*</a><br>
(0.69, 0.88)</td>
<td class="Botrule" align="center" valign="top">0.99<a class="Sup"
href="#footnote-1">*</a><br>
(0.91, 1.06)</td>
<td class="Botrule" align="center" valign="top">1.49<a class="Sup"
href="#footnote-1">*</a><br>
(1.28, 1.74)</td>
</tr>
<tr>
<td align="left" valign="top">Ketoconazole</td>
<td align="center" valign="top">400 once daily,<br>
7 days</td>
<td align="center" valign="top">600 three times<br>
daily, 7 days</td>
<td align="center" valign="top">12</td>
<td align="center" valign="top">0.69<a class="Sup" href=
"#footnote-1">*</a><br>
(0.61, 0.78)</td>
<td align="center" valign="top">0.80<a class="Sup" href=
"#footnote-1">*</a><br>
(0.74, 0.87)</td>
<td align="center" valign="top">1.29<a class="Sup" href=
"#footnote-1">*</a><br>
(1.11, 1.51)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="center" valign="top">400 once daily,<br>
7 days</td>
<td class="Botrule" align="center" valign="top">400 three times<br>
daily, 7 days</td>
<td class="Botrule" align="center" valign="top">12</td>
<td class="Botrule" align="center" valign="top">0.42<a class="Sup"
href="#footnote-1">*</a><br>
(0.37, 0.47)</td>
<td class="Botrule" align="center" valign="top">0.44<a class="Sup"
href="#footnote-1">*</a><br>
(0.41, 0.48)</td>
<td class="Botrule" align="center" valign="top">0.73<a class="Sup"
href="#footnote-1">*</a><br>
(0.62, 0.85)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Methadone</td>
<td class="Botrule" align="center" valign="top">20-60 once daily in
the morning,<br>
8 days</td>
<td class="Botrule" align="center" valign="top">800 three times<br>
daily, 8 days</td>
<td class="Botrule" align="center" valign="top">10</td>
<td class="Botrule" align="center" colspan="3" valign="top">See
text below for discussion of interaction.</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Quinidine</td>
<td class="Botrule" align="center" valign="top">200 single
dose</td>
<td class="Botrule" align="center" valign="top">400 single
dose</td>
<td class="Botrule" align="center" valign="top">10</td>
<td class="Botrule" align="center" valign="top">0.96<br>
(0.79, 1.18)</td>
<td class="Botrule" align="center" valign="top">1.07<br>
(0.89, 1.28)</td>
<td class="Botrule" align="center" valign="top">0.93<br>
(0.73, 1.19)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Rifabutin</td>
<td class="Botrule" align="center" valign="top">150 once daily in
the morning,<br>
10 days</td>
<td class="Botrule" align="center" valign="top">800 three times<br>
daily, 10 days</td>
<td class="Botrule" align="center" valign="top">14</td>
<td class="Botrule" align="center" valign="top">0.80<br>
(0.72, 0.89)</td>
<td class="Botrule" align="center" valign="top">0.68<br>
(0.60, 0.76)</td>
<td class="Botrule" align="center" valign="top">0.60<br>
(0.51, 0.72)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Rifabutin</td>
<td class="Botrule" align="center" valign="top">300 once daily in
the morning,<br>
10 days</td>
<td class="Botrule" align="center" valign="top">800 three times<br>
daily, 10 days</td>
<td class="Botrule" align="center" valign="top">10</td>
<td class="Botrule" align="center" valign="top">0.75<br>
(0.61, 0.91)</td>
<td class="Botrule" align="center" valign="top">0.66<br>
(0.56, 0.77)</td>
<td class="Botrule" align="center" valign="top">0.61<br>
(0.50, 0.75)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Rifampin</td>
<td class="Botrule" align="center" valign="top">600 once daily in
the morning,<br>
8 days</td>
<td class="Botrule" align="center" valign="top">800 three times<br>
daily, 7 days</td>
<td class="Botrule" align="center" valign="top">12</td>
<td class="Botrule" align="center" valign="top">0.13<br>
(0.08, 0.22)</td>
<td class="Botrule" align="center" valign="top">0.08<br>
(0.06, 0.11)</td>
<td class="Botrule" align="center" valign="top">Not Done</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Ritonavir</td>
<td class="Botrule" align="center" valign="top">100 twice
daily,<br>
14 days</td>
<td class="Botrule" align="center" valign="top">800 twice<br>
daily, 14 days</td>
<td class="Botrule" align="center" valign="top">10, 16<a class=
"Sup" href="#footnote-3" name="footnote-reference-3" id=
"footnote-reference-3">‡</a></td>
<td class="Botrule" align="center" colspan="3" valign="top">See
text below for discussion of interaction.</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Ritonavir</td>
<td class="Botrule" align="center" valign="top">200 twice
daily,<br>
14 days</td>
<td class="Botrule" align="center" valign="top">800 twice<br>
daily,14 days</td>
<td class="Botrule" align="center" valign="top">9, 16<a class="Sup"
href="#footnote-3">‡</a></td>
<td class="Botrule" align="center" colspan="3" valign="top">See
text below for discussion of interaction.</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Sildenafil</td>
<td class="Botrule" align="center" valign="top">25 single dose</td>
<td class="Botrule" align="center" valign="top">800 three times
daily</td>
<td class="Botrule" align="center" valign="top">6</td>
<td class="Botrule" align="center" colspan="3" valign="top">See
text below for discussion of interaction.</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">St. John's wort<br>
(<span class="Italics">Hypericum perforatum</span>,<br>
standardized to 0.3 % hypericin)</td>
<td class="Botrule" align="center" valign="top">300 three times
daily with meals,<br>
14 days</td>
<td class="Botrule" align="center" valign="top">800 three times
daily</td>
<td class="Botrule" align="center" valign="top">8</td>
<td class="Botrule" align="center" valign="top">Not Available</td>
<td class="Botrule" align="center" valign="top">0.46<br>
(0.34, 0.58)<a class="Sup" href="#footnote-4" name=
"footnote-reference-4" id="footnote-reference-4">§</a></td>
<td class="Botrule" align="center" valign="top">0.19<br>
(0.06, 0.33)<a class="Sup" href="#footnote-4">§</a></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Stavudine
(d4T)<a class="Sup" href="#footnote-2">†</a></td>
<td class="Botrule" align="center" valign="top">40 twice daily,<br>
7 days</td>
<td class="Botrule" align="center" valign="top">800 three times<br>
daily, 7 days</td>
<td class="Botrule" align="center" valign="top">11</td>
<td class="Botrule" align="center" valign="top">0.95<br>
(0.80, 1.11)</td>
<td class="Botrule" align="center" valign="top">0.95<br>
(0.80, 1.12)</td>
<td class="Botrule" align="center" valign="top">1.13<br>
(0.83, 1.53)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Trimethoprim/<br>
Sulfamethoxazole</td>
<td class="Botrule" align="center" valign="top">800
Trimethoprim/<br>
160 Sulfamethoxazole q12h, 7 days</td>
<td class="Botrule" align="center" valign="top">400 four times<br>
daily, 7 days</td>
<td class="Botrule" align="center" valign="top">12</td>
<td class="Botrule" align="center" valign="top">1.12<br>
(0.87, 1.46)</td>
<td class="Botrule" align="center" valign="top">0.98<br>
(0.81, 1.18)</td>
<td class="Botrule" align="center" valign="top">0.83<br>
(0.72, 0.95)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Zidovudine<a class=
"Sup" href="#footnote-2">†</a></td>
<td class="Botrule" align="center" valign="top">200 three times
daily, 7 days</td>
<td class="Botrule" align="center" valign="top">1000 three
times<br>
daily, 7 days</td>
<td class="Botrule" align="center" valign="top">12</td>
<td class="Botrule" align="center" valign="top">1.06<br>
(0.91, 1.25)</td>
<td class="Botrule" align="center" valign="top">1.05<br>
(0.86, 1.28)</td>
<td class="Botrule" align="center" valign="top">1.02<br>
(0.77, 1.35)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Zidovudine/<br>
Lamivudine<br>
(3TC)<a class="Sup" href="#footnote-2">†</a></td>
<td class="Botrule" align="center" valign="top">200/150 three times
daily, 7 days</td>
<td class="Botrule" align="center" valign="top">800 three times<br>
daily, 7 days</td>
<td class="Botrule" align="center" valign="top">6, 9<a class="Sup"
href="#footnote-5" name="footnote-reference-5" id=
"footnote-reference-5">¶</a></td>
<td class="Botrule" align="center" valign="top">1.05<br>
(0.83, 1.33)</td>
<td class="Botrule" align="center" valign="top">1.04<br>
(0.67, 1.61)</td>
<td class="Botrule" align="center" valign="top">0.98<br>
(0.56, 1.73)</td>
</tr>
</tbody>
</table>
</div>
<a name="id_5ee46c12-daf5-432b-9867-5daff2876dc2" id=
"id_5ee46c12-daf5-432b-9867-5daff2876dc2"></a>
<div class="scrollingtable">
<table width="807.000">
<caption><span>Table 3: Drug Interactions: Pharmacokinetic
Parameters for Coadministered Drug in the Presence of Indinavir
(See <a href=
"#id_475b25fa-86e3-4b92-b606-66a613746db9">PRECAUTIONS, Table 9</a>
for Recommended Alterations in Dose or Regimen)</span></caption>
<colgroup>
<col align="left" width="14.3%">
<col width="10.2%">
<col width="17.7%">
<col width="8.2%">
<col width="17.7%">
<col width="15.6%">
<col width="16.4%"></colgroup>
<thead>
<tr class="Botrule First">
<td class="Toprule" align="center" valign="bottom"><span class=
"Bold">Coadministered drug</span></td>
<td class="Toprule" align="center" valign="bottom"><span class=
"Bold">Dose of Coadministered drug (mg)</span></td>
<td class="Toprule" align="center" valign="bottom"><span class=
"Bold">Dose of CRIXIVAN (mg)</span></td>
<td class="Toprule" align="center" valign="bottom"><span class=
"Bold">n</span></td>
<td align="center" colspan="3" valign="bottom"><span class=
"Bold">Ratio (with/without CRIXIVAN) of Coadministered Drug<br>
Pharmacokinetic Parameters<br>
(90% CI); No Effect = 1.00</span></td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top">C<span class="Sub">max</span></td>
<td align="center" valign="top">AUC</td>
<td align="center" valign="top">C<span class="Sub">min</span></td>
</tr>
</thead>
<tfoot>
<tr class="Last">
<td align="left" colspan="7" valign="top">All interaction studies
conducted in healthy, HIV-negative adult subjects, unless otherwise
indicated.</td>
</tr>
<tr>
<td align="left" colspan="7">
<dl class="Footnote">
<dt><a href="#footnote-reference-6" name="footnote-6" id=
"footnote-6">*</a></dt>
<dd>Registered trademark of Ortho Pharmaceutical Corporation.</dd>
<dt><a href="#footnote-reference-7" name="footnote-7" id=
"footnote-7">†</a></dt>
<dd>Study conducted in subjects on methadone maintenance.</dd>
<dt><a href="#footnote-reference-8" name="footnote-8" id=
"footnote-8">‡</a></dt>
<dd>Parallel group design; n for coadministered drug + indinavir, n
for coadministered drug alone.</dd>
<dt><a href="#footnote-reference-9" name="footnote-9" id=
"footnote-9">§</a></dt>
<dd>C <span class="Sub">6hr</span></dd>
<dt><a href="#footnote-reference-10" name="footnote-10" id=
"footnote-10">¶</a></dt>
<dd>Study conducted in HIV-positive subjects.</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">
Clarithromycin</td>
<td class="Botrule" align="center" valign="top">500 twice
daily,<br>
7 days</td>
<td class="Botrule" align="center" valign="top">800 three times
daily, 7 days</td>
<td class="Botrule" align="center" valign="top">12</td>
<td class="Botrule" align="center" valign="top">1.19<br>
(1.02, 1.39)</td>
<td class="Botrule" align="center" valign="top">1.47<br>
(1.30, 1.65)</td>
<td class="Botrule" align="center" valign="top">1.97<br>
(1.58, 2.46)<br>
n=11</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Efavirenz</td>
<td class="Botrule" align="center" valign="top">200 once daily,<br>
14 days</td>
<td class="Botrule" align="center" valign="top">800 three times
daily, 14 days</td>
<td class="Botrule" align="center" valign="top">20</td>
<td class="Botrule" align="center" valign="top">No significant
change</td>
<td class="Botrule" align="center" valign="top">No significant
change</td>
<td class="Botrule" align="center" valign="top">--</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Ethinyl Estradiol<br>
(ORTHO-NOVUM 1/35)<a class="Sup" href="#footnote-6" name=
"footnote-reference-6" id="footnote-reference-6">*</a></td>
<td class="Botrule" align="center" valign="top">35 mcg, 8 days</td>
<td class="Botrule" align="center" valign="top">800 three times
daily, 8 days</td>
<td class="Botrule" align="center" valign="top">18</td>
<td class="Botrule" align="center" valign="top">1.02<br>
(0.96, 1.09)</td>
<td class="Botrule" align="center" valign="top">1.22<br>
(1.15, 1.30)</td>
<td class="Botrule" align="center" valign="top">1.37<br>
(1.24, 1.51)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Isoniazid</td>
<td class="Botrule" align="center" valign="top">300 once daily in
the morning,<br>
8 days</td>
<td class="Botrule" align="center" valign="top">800 three times
daily, 8 days</td>
<td class="Botrule" align="center" valign="top">11</td>
<td class="Botrule" align="center" valign="top">1.34<br>
(1.12, 1.60)</td>
<td class="Botrule" align="center" valign="top">1.12<br>
(1.03, 1.22)</td>
<td class="Botrule" align="center" valign="top">1.00<br>
(0.92, 1.08)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Methadone<a class=
"Sup" href="#footnote-7" name="footnote-reference-7" id=
"footnote-reference-7">†</a></td>
<td class="Botrule" align="center" valign="top">20-60 once daily in
the morning,<br>
8 days</td>
<td class="Botrule" align="center" valign="top">800 three times
daily, 8 days</td>
<td class="Botrule" align="center" valign="top">12</td>
<td class="Botrule" align="center" valign="top">0.93<br>
(0.84, 1.03)</td>
<td class="Botrule" align="center" valign="top">0.96<br>
(0.86, 1.06)</td>
<td class="Botrule" align="center" valign="top">1.06<br>
(0.94, 1.19)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Norethindrone<br>
(ORTHO-NOVUM 1/35)<a class="Sup" href="#footnote-6">*</a></td>
<td class="Botrule" align="center" valign="top">1 mcg, 8 days</td>
<td class="Botrule" align="center" valign="top">800 three times
daily, 8 days</td>
<td class="Botrule" align="center" valign="top">18</td>
<td class="Botrule" align="center" valign="top">1.05<br>
(0.95, 1.16)</td>
<td class="Botrule" align="center" valign="top">1.26<br>
(1.20, 1.31)</td>
<td class="Botrule" align="center" valign="top">1.44<br>
(1.32, 1.57)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Rifabutin<br>
150 mg once daily in the morning, 11 days + indinavir compared to
300 mg once daily in the morning, 11 days alone</td>
<td class="Botrule" align="center" valign="top">150 once daily in
the morning,<br>
10 days<br>
<br>
300 once daily in the morning,<br>
10 days</td>
<td class="Botrule" align="center" valign="top">800 three times
daily, 10 days<br>
<br>
<br>
800 three times daily, 10 days</td>
<td class="Botrule" align="center" valign="top">14<br>
<br>
<br>
<br>
10</td>
<td class="Botrule" align="center" valign="top">1.29<br>
(1.05, 1.59)<br>
<br>
<br>
2.34<br>
(1.64, 3.35)</td>
<td class="Botrule" align="center" valign="top">1.54<br>
(1.33, 1.79)<br>
<br>
<br>
2.73<br>
(1.99, 3.77)</td>
<td class="Botrule" align="center" valign="top">1.99<br>
(1.71, 2.31)<br>
n=13<br>
<br>
3.44<br>
(2.65, 4.46)<br>
n=9</td>
</tr>
<tr>
<td align="left" valign="top">Ritonavir</td>
<td align="center" valign="top">100 twice daily,<br>
14 days</td>
<td align="center" valign="top">800 twice daily,<br>
14 days</td>
<td align="center" valign="top">10, 4<a class="Sup" href=
"#footnote-8" name="footnote-reference-8" id=
"footnote-reference-8">‡</a></td>
<td align="center" valign="top">1.61<br>
(1.13, 2.29)</td>
<td align="center" valign="top">1.72<br>
(1.20, 2.48)</td>
<td align="center" valign="top">1.62<br>
(0.93, 2.85)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="center" valign="top">200 twice
daily,<br>
14 days</td>
<td class="Botrule" align="center" valign="top">800 twice
daily,<br>
14 days</td>
<td class="Botrule" align="center" valign="top">9, 5<a class="Sup"
href="#footnote-8">‡</a></td>
<td class="Botrule" align="center" valign="top">1.19<br>
(0.85, 1.66)</td>
<td class="Botrule" align="center" valign="top">1.96<br>
(1.39, 2.76)</td>
<td class="Botrule" align="center" valign="top">4.71<br>
(2.66, 8.33)<br>
n=9, 4</td>
</tr>
<tr>
<td align="left" valign="top">Saquinavir</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Hard gel formulation</td>
<td align="center" valign="top">600 single dose</td>
<td align="center" valign="top">800 three times daily, 2 days</td>
<td align="center" valign="top">6</td>
<td align="center" valign="top">4.7<br>
(2.7, 8.1)</td>
<td align="center" valign="top">6.0<br>
(4.0, 9.1)</td>
<td align="center" valign="top">2.9<br>
(1.7, 4.7)<a class="Sup" href="#footnote-9" name=
"footnote-reference-9" id="footnote-reference-9">§</a></td>
</tr>
<tr>
<td align="left" valign="top">Soft gel formulation</td>
<td align="center" valign="top">800 single dose</td>
<td align="center" valign="top">800 three times daily, 2 days</td>
<td align="center" valign="top">6</td>
<td align="center" valign="top">6.5<br>
(4.7, 9.1)</td>
<td align="center" valign="top">7.2<br>
(4.3, 11.9)</td>
<td align="center" valign="top">5.5<br>
(2.2, 14.1)<a class="Sup" href="#footnote-9">§</a></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Soft gel
formulation</td>
<td class="Botrule" align="center" valign="top">1200 single
dose</td>
<td class="Botrule" align="center" valign="top">800 three times
daily, 2 days</td>
<td class="Botrule" align="center" valign="top">6</td>
<td class="Botrule" align="center" valign="top">4.0<br>
(2.7, 5.9)</td>
<td class="Botrule" align="center" valign="top">4.6<br>
(3.2, 6.7)</td>
<td class="Botrule" align="center" valign="top">5.5<br>
(3.7, 8.3)<a class="Sup" href="#footnote-9">§</a></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Sildenafil</td>
<td class="Botrule" align="center" valign="top">25 single dose</td>
<td class="Botrule" align="center" valign="top">800 three times
daily</td>
<td class="Botrule" align="center" valign="top">6</td>
<td class="Botrule" align="center" colspan="3" valign="top">See
text below for discussion of interaction.</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Stavudine<a class=
"Sup" href="#footnote-10" name="footnote-reference-10" id=
"footnote-reference-10">¶</a></td>
<td class="Botrule" align="center" valign="top">40 twice daily,<br>
7 days</td>
<td class="Botrule" align="center" valign="top">800 three times
daily, 7 days</td>
<td class="Botrule" align="center" valign="top">13</td>
<td class="Botrule" align="center" valign="top">0.86<br>
(0.73, 1.03)</td>
<td class="Botrule" align="center" valign="top">1.21<br>
(1.09, 1.33)</td>
<td class="Botrule" align="center" valign="top">Not Done</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Theophylline</td>
<td class="Botrule" align="center" valign="top">250 single dose (on
Days 1 and 7)</td>
<td class="Botrule" align="center" valign="top">800 three times
daily, 6 days (Days 2 to 7)</td>
<td class="Botrule" align="center" valign="top">12, 4<a class="Sup"
href="#footnote-8">‡</a></td>
<td class="Botrule" align="center" valign="top">0.88<br>
(0.76, 1.03)</td>
<td class="Botrule" align="center" valign="top">1.14<br>
(1.04, 1.24)</td>
<td class="Botrule" align="center" valign="top">1.13<br>
(0.86, 1.49)<br>
n=7, 3</td>
</tr>
<tr>
<td align="left" valign="top">Trimethoprim/<br>
Sulfamethoxazole</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Trimethoprim</td>
<td class="Botrule" align="center" valign="top">800
Trimethoprim/<br>
160 Sulfamethoxazole q12h, 7 days</td>
<td class="Botrule" align="center" valign="top">400 q6h, 7
days</td>
<td class="Botrule" align="center" valign="top">12</td>
<td class="Botrule" align="center" valign="top">1.18<br>
(1.05, 1.32)</td>
<td class="Botrule" align="center" valign="top">1.18<br>
(1.05, 1.33)</td>
<td class="Botrule" align="center" valign="top">1.18<br>
(1.00, 1.39)</td>
</tr>
<tr>
<td align="left" valign="top">Trimethoprim/<br>
Sulfamethoxazole</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Sulfamethoxazole</td>
<td class="Botrule" align="center" valign="top">800
Trimethoprim/<br>
160 Sulfamethoxazole q12h, 7 days</td>
<td class="Botrule" align="center" valign="top">400 q6h, 7
days</td>
<td class="Botrule" align="center" valign="top">12</td>
<td class="Botrule" align="center" valign="top">1.01<br>
(0.95, 1.08)</td>
<td class="Botrule" align="center" valign="top">1.05<br>
(1.01, 1.09)</td>
<td class="Botrule" align="center" valign="top">1.05<br>
(0.97, 1.14)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Vardenafil</td>
<td class="Botrule" align="center" valign="top">10 single dose</td>
<td class="Botrule" align="center" valign="top">800 three times
daily</td>
<td class="Botrule" align="center" valign="top">18</td>
<td class="Botrule" align="center" colspan="3" valign="top">See
text below for discussion of interaction.</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Zidovudine<a class=
"Sup" href="#footnote-10">¶</a></td>
<td class="Botrule" align="center" valign="top">200 three times
daily, 7 days</td>
<td class="Botrule" align="center" valign="top">1000 three times
daily, 7 days</td>
<td class="Botrule" align="center" valign="top">12</td>
<td class="Botrule" align="center" valign="top">0.89<br>
(0.73, 1.09)</td>
<td class="Botrule" align="center" valign="top">1.17<br>
(1.07, 1.29)</td>
<td class="Botrule" align="center" valign="top">1.51<br>
(0.71, 3.20)<br>
n=4</td>
</tr>
<tr>
<td align="left" valign="top">Zidovudine/<br>
Lamivudine<a class="Sup" href="#footnote-10">¶</a></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Zidovudine</td>
<td class="Botrule" align="center" valign="top">200/150 three times
daily, 7 days</td>
<td class="Botrule" align="center" valign="top">800 three times
daily, 7 days</td>
<td class="Botrule" align="center" valign="top">6, 7<a class="Sup"
href="#footnote-8">‡</a></td>
<td class="Botrule" align="center" valign="top">1.23<br>
(0.74, 2.03)</td>
<td class="Botrule" align="center" valign="top">1.39<br>
(1.02, 1.89)</td>
<td class="Botrule" align="center" valign="top">1.08<br>
(0.77, 1.50)<br>
n=5, 5</td>
</tr>
<tr>
<td align="left" valign="top">Zidovudine/<br>
Lamivudine<a class="Sup" href="#footnote-10">¶</a></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Lamivudine</td>
<td class="Botrule" align="center" valign="top">200/150 three times
daily, 7 days</td>
<td class="Botrule" align="center" valign="top">800 three times
daily, 7 days</td>
<td class="Botrule" align="center" valign="top">6, 7<a class="Sup"
href="#footnote-8">‡</a></td>
<td class="Botrule" align="center" valign="top">0.73<br>
(0.52, 1.02)</td>
<td class="Botrule" align="center" valign="top">0.91<br>
(0.66, 1.26)</td>
<td class="Botrule" align="center" valign="top">0.88<br>
(0.59, 1.33)</td>
</tr>
</tbody>
</table>
</div>
<p><span class="Italics">Delavirdine:</span> Delavirdine inhibits
the metabolism of indinavir such that coadministration of 400-mg or
600-mg indinavir three times daily with 400-mg delavirdine three
times daily alters indinavir AUC, C<span class="Sub">max</span> and
C<span class="Sub">min</span> (see <a href=
"#id_fb7ba932-878d-4285-bc07-a950bcdf934f">Table 2</a>). Indinavir
had no effect on delavirdine pharmacokinetics (see <a href=
"#i4i_section_id_167b8246-5532-4d98-83f5-e9e9051cecd4">DOSAGE AND
ADMINISTRATION, Concomitant Therapy, Delavirdine</a>), based on a
comparison to historical delavirdine pharmacokinetic data.</p>
<p><span class="Italics">Methadone:</span> Administration of
indinavir (800 mg every 8 hours) with methadone (20 mg to 60 mg
daily) for one week in subjects on methadone maintenance resulted
in no change in methadone AUC. Based on a comparison to historical
data, there was little or no change in indinavir AUC.</p>
<p><span class="Italics">Ritonavir:</span> Compared to historical
data in patients who received indinavir 800 mg every 8 hours alone,
twice-daily coadministration to volunteers of indinavir 800 mg and
ritonavir with food for two weeks resulted in a 2.7-fold increase
of indinavir AUC<span class="Sub">24h</span>, a 1.6-fold increase
in indinavir C<span class="Sub">max,</span> and an 11-fold increase
in indinavir C<span class="Sub">min</span> for a 100-mg ritonavir
dose and a 3.6-fold increase of indinavir AUC<span class=
"Sub">24h</span>, a 1.8- fold increase in indinavir C<span class=
"Sub">max</span>, and a 24-fold increase in indinavir C<span class=
"Sub">min</span> for a 200-mg ritonavir dose. In the same study,
twice-daily coadministration of indinavir (800 mg) and ritonavir
(100 or 200 mg) resulted in ritonavir AUC<span class=
"Sub">24h</span> increases versus the same doses of ritonavir alone
(see <a href="#id_5ee46c12-daf5-432b-9867-5daff2876dc2">Table
3</a>).</p>
<p><span class="Italics">Sildenafil:</span> The results of one
published study in HIV-infected men (n=6) indicated that
coadministration of indinavir (800 mg every 8 hours chronically)
with a single 25-mg dose of sildenafil resulted in an 11% increase
in average AUC<span class="Sub">0-8hr</span> of indinavir and a 48%
increase in average indinavir peak concentration (C<span class=
"Sub">max</span>) compared to 800 mg every 8 hours alone. Average
sildenafil AUC was increased by 340% following coadministration of
sildenafil and indinavir compared to historical data following
administration of sildenafil alone (see <a href=
"#i4i_contraindications_id_822eea92-c7b1-4462-83c0-948313a14695">CONTRAINDICATIONS</a>,
<a href=
"#i4i_interactions_id_9aee44b1-f055-4cb3-ab26-cf5aecf41683">WARNINGS,
Drug Interactions</a> and <a href="#PRE_DI">PRECAUTIONS, Drug
Interactions</a>).</p>
<p><span class="Italics">Vardenafil:</span> Indinavir (800 mg every
8 hours) coadministered with a single 10-mg dose of vardenafil
resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase
in vardenafil C<span class="Sub">max</span>, and a 2-fold increase
in vardenafil half-life (see <a href=
"#i4i_interactions_id_9aee44b1-f055-4cb3-ab26-cf5aecf41683">WARNINGS,
Drug Interactions</a> and <a href="#PRE_DI">PRECAUTIONS, Drug
Interactions</a>).</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">INDICATIONS AND USAGE</a>
<div class="Section toggle-content closed" data-sectioncode=
"34067-9"><a name=
"i4i_indications_id_d5e8c64b-6a39-42a5-970d-7da4265d26a1" id=
"i4i_indications_id_d5e8c64b-6a39-42a5-970d-7da4265d26a1"></a>
<a name="section-4" id="section-4"></a>
<p class="First">CRIXIVAN in combination with antiretroviral agents
is indicated for the treatment of HIV infection.</p>
<p>This indication is based on two clinical trials of approximately
1 year duration that demonstrated: 1) a reduction in the risk of
AIDS-defining illnesses or death; 2) a prolonged suppression of HIV
RNA.</p>
<div class="Section" data-sectioncode="34092-7"><a name=
"i4i_clinical_studies_id_b65f0b09-2c51-44dc-b941-7baed978b270" id=
"i4i_clinical_studies_id_b65f0b09-2c51-44dc-b941-7baed978b270"></a>
<a name="section-4.1" id="section-4.1"></a>
<h2>Description of Studies</h2>
<p class="First">In all clinical studies, with the exception of
ACTG 320, the AMPLICOR HIV MONITOR assay was used to determine the
level of circulating HIV RNA in serum. This is an experimental use
of the assay. HIV RNA results should not be directly compared to
results from other trials using different HIV RNA assays or using
other sample sources.</p>
<p>Study ACTG 320 was a multicenter, randomized, double-blind
clinical endpoint trial to compare the effect of CRIXIVAN in
combination with zidovudine and lamivudine with that of zidovudine
plus lamivudine on the progression to an AIDS-defining illness
(ADI) or death. Patients were protease inhibitor and lamivudine
naive and zidovudine experienced, with CD4 cell counts of ≤200
cells/mm<span class="Sup">3</span>. The study enrolled 1156
HIV-infected patients (17% female, 28% Black, 18% Hispanic, mean
age 39 years). The mean baseline CD4 cell count was 87
cells/mm<span class="Sup">3</span>. The mean baseline HIV RNA was
4.95 log<span class="Sub">10</span> copies/mL (89,035 copies/mL).
The study was terminated after a planned interim analysis,
resulting in a median follow-up of 38 weeks and a maximum follow-up
of 52 weeks. Results are shown in <a href=
"#id_46674498-7e8e-45de-8353-1dc29c310c44">Table 4</a> and <a href=
"#fig1">Figures 1</a> <a href="#fig2">&amp; 2</a>.</p>
<a name="id_46674498-7e8e-45de-8353-1dc29c310c44" id=
"id_46674498-7e8e-45de-8353-1dc29c310c44"></a>
<div class="scrollingtable">
<table class="Noautorules" width="703.000">
<caption><span>Table 4: ACTG 320</span></caption>
<colgroup>
<col width="15.4%">
<col width="40.1%">
<col align="center" width="22.6%">
<col align="center" width="21.9%"></colgroup>
<thead>
<tr>
<td align="left" colspan="2" valign="top"></td>
<td align="center" colspan="2" valign="top">Number (%) of Patients
with AIDS-defining Illness or Death</td>
</tr>
<tr>
<td align="center" colspan="2" valign="top">Endpoint</td>
<td align="center" valign="top">IDV+ZDV+L<br>
(n=577)</td>
<td align="center" valign="top">ZDV+L<br>
(n=579)</td>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="4">IDV = Indinavir, ZDV = Zidovudine, L =
Lamivudine</td>
</tr>
<tr>
<td align="left" colspan="4">
<dl class="Footnote">
<dt><a href="#footnote-reference-11" name="footnote-11" id=
"footnote-11">*</a></dt>
<dd>The number of deaths is inadequate to assess the impact of
Indinavir on survival.</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody>
<tr>
<td align="left" colspan="2" valign="top">HIV Progression or
Death</td>
<td align="center" valign="top">35 (6.1)</td>
<td align="center" valign="top">63 (10.9)</td>
</tr>
<tr>
<td class="Botrule" align="left" colspan="2" valign="top">
Death<a class="Sup" href="#footnote-11" name=
"footnote-reference-11" id="footnote-reference-11">*</a></td>
<td class="Botrule" align="center" valign="top">10 (1.7)</td>
<td class="Botrule" align="center" valign="top">19 (3.3)</td>
</tr>
</tbody>
</table>
</div>
<div class="Figure"><a name="Fig1" id="Fig1"></a> <img src=
"image.cfm?setid=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f&amp;name=crixivan-02.jpg"
alt="image of study ACTG 320 figure 1">
<p class="MultiMediaCaption">Study ACTG 320: Figure 1 - Indinavir
Protocol ACTG 320 Zidovudine Experienced Plasma Viral RNA -
Proportions Below 400 copies/mL</p>
</div>
<div class="Figure"><a name="fig2" id="fig2"></a> <img src=
"image.cfm?setid=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f&amp;name=crixivan-03.jpg"
alt="image of study ACTG 320 Figure 2">
<p class="MultiMediaCaption">Study ACTG 320: Figure 2 - ACTG 320
Zidovudine Experienced CD4 Cell Counts - Mean Change from
Baseline</p>
</div>
<p>Study 028, a double-blind, multicenter, randomized, clinical
endpoint trial conducted in Brazil, compared the effects of
CRIXIVAN plus zidovudine with those of CRIXIVAN alone or zidovudine
alone on the progression to an ADI or death, and on surrogate
marker responses. All patients were antiretroviral naive with CD4
cell counts of 50 to 250 cells/mm<span class="Sup">3</span>. The
study enrolled 996 HIV-1 seropositive patients [28% female, 11%
Black, 1% Asian/Other, median age 33 years, mean baseline CD4 cell
count of 152 cells/mm<span class="Sup">3</span>, mean serum viral
RNA of 4.44 log<span class="Sub">10</span> copies/mL (27,824
copies/mL)]. Treatment regimens containing zidovudine were modified
in a blinded manner with the optional addition of lamivudine
(median time: week 40). The median length of follow-up was 56 weeks
with a maximum of 97 weeks. The study was terminated after a
planned interim analysis, resulting in a median follow-up of 56
weeks and a maximum follow-up of 97 weeks. Results are shown in
<a href="#id_3aba7c28-ee8a-4a52-8c3f-60405e16d8ed">Table 5</a> and
<a href="#fig3">Figures 3</a> and <a href="#fig4">4</a>.</p>
<a name="id_3aba7c28-ee8a-4a52-8c3f-60405e16d8ed" id=
"id_3aba7c28-ee8a-4a52-8c3f-60405e16d8ed"></a>
<div class="scrollingtable">
<table class="Noautorules" width="753.000">
<caption><span>Table 5: Protocol 028</span></caption>
<colgroup>
<col width="42.4%">
<col width="19.7%">
<col width="19.0%">
<col width="19.0%"></colgroup>
<thead>
<tr>
<td align="left" valign="top"></td>
<td align="center" colspan="3" valign="top">Number (%) of Patients
with AIDS-defining Illness or Death</td>
</tr>
<tr>
<td align="center" valign="top">Endpoint</td>
<td align="center" valign="top">IDV+ZDV<br>
(n=332)</td>
<td align="center" valign="top">IDV<br>
(n=332)</td>
<td align="center" valign="top">ZDV<br>
(n=332)</td>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="4">
<dl class="Footnote">
<dt><a href="#footnote-reference-12" name="footnote-12" id=
"footnote-12">*</a></dt>
<dd>The number of deaths is inadequate to assess the impact of
Indinavir on survival.</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody>
<tr>
<td align="left" valign="top">HIV Progression or Death</td>
<td align="center" valign="top">21 (6.3)</td>
<td align="center" valign="top">27 (8.1)</td>
<td align="center" valign="top">62 (18.7)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Death<a class="Sup"
href="#footnote-12" name="footnote-reference-12" id=
"footnote-reference-12">*</a></td>
<td class="Botrule" align="center" valign="top">8 (2.4)</td>
<td class="Botrule" align="center" valign="top">5 (1.5)</td>
<td class="Botrule" align="center" valign="top">11 (3.3)</td>
</tr>
</tbody>
</table>
</div>
<div class="Figure"><a name="fig3" id="fig3"></a> <img src=
"image.cfm?setid=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f&amp;name=crixivan-04.jpg"
alt="image of study 028 figure 3">
<p class="MultiMediaCaption">Study 028: Figure 3 - Indinavir
Protocol 028 Zidovudine Naive Viral RNA - Proportions Below 500
Copies/mL in Serum</p>
</div>
<div class="Figure"><a name="fig4" id="fig4"></a> <img src=
"image.cfm?setid=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f&amp;name=crixivan-05.jpg"
alt="image of study 028 figure 4">
<p class="MultiMediaCaption">Study 028: Figure 4 - Indinavir
Protocol 028 Zidovudine Naive CD4 Cell Counts - Mean Change from
Baseline</p>
</div>
<p>Study 035 was a multicenter, randomized trial in 97 HIV-1
seropositive patients who were zidovudine-experienced (median
exposure 30 months), protease-inhibitor- and lamivudine-naive, with
mean baseline CD4 count 175 cells/mm<span class="Sup">3</span> and
mean baseline serum viral RNA 4.62 log<span class="Sub">10</span>
copies/mL (41,230 copies/mL). Comparisons included CRIXIVAN plus
zidovudine plus lamivudine vs. CRIXIVAN alone vs. zidovudine plus
lamivudine. After at least 24 weeks of randomized, double-blind
therapy, patients were switched to open-label CRIXIVAN plus
lamivudine plus zidovudine. Mean changes in log<span class=
"Sub">10</span> viral RNA in serum, the proportions of patients
with viral RNA below 500 copies/mL in serum, and mean changes in
CD4 cell counts, during 24 weeks of randomized, double-blinded
therapy are summarized in <a href="#fig5">Figures 5</a>, <a href=
"#fig6">6</a>, and <a href="#fig7">7</a>, respectively. A limited
number of patients remained on randomized, double-blind treatment
for longer periods; based on this extended treatment experience, it
appears that a greater number of subjects randomized to CRIXIVAN
plus zidovudine plus lamivudine demonstrated HIV RNA levels below
500 copies/mL during one year of therapy as compared to those in
other treatment groups.</p>
<div class="Figure"><a name="fig5" id="fig5"></a> <img src=
"image.cfm?setid=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f&amp;name=crixivan-06.jpg"
alt="image of study 035 figure 5">
<p class="MultiMediaCaption">Study 035: Figure 5 - Indinavir
Protocol 035 Zidovudine Experienced Viral RNA - Mean Log10 Change
from Baseline in Serum</p>
</div>
<div class="Figure"><a name="fig6" id="fig6"></a> <img src=
"image.cfm?setid=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f&amp;name=crixivan-07.jpg"
alt="image of study 035 figure 6">
<p class="MultiMediaCaption">Study 035: Figure 6 - Indinavir
Protocol 035 Zidovudine Experienced Viral RNA - Proportions Below
500 Copies/mL in Serum</p>
</div>
<div class="Figure"><a name="fig7" id="fig7"></a> <img src=
"image.cfm?setid=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f&amp;name=crixivan-08.jpg"
alt="image of study 035 figure 7">
<p class="MultiMediaCaption">Study 035: Figure 7 - Indinavir
Protocol 035 Zidovudine Experienced CD4 Cell Counts - Mean Change
from Baseline</p>
</div>
</div>
<div class="Section" data-sectioncode="34092-7"><a name=
"i4i_clinical_studies_id_1a76531b-5fd1-4c10-910d-293682024a15" id=
"i4i_clinical_studies_id_1a76531b-5fd1-4c10-910d-293682024a15"></a>
<a name="section-4.2" id="section-4.2"></a>
<h2>Genotypic Resistance in Clinical Studies</h2>
<p class="First">Study 006 (10/15/93-10/12/94) was a dose-ranging
study in which patients were initially treated with CRIXIVAN at a
dose of &lt;2.4 g/day followed by 2.4 g/day. Study 019
(6/23/94-4/10/95) was a randomized comparison of CRIXIVAN 600 mg
every 6 hours, CRIXIVAN plus zidovudine, and zidovudine alone.
<a href="#id_34e89148-ab82-4488-a91f-3f2c459dac11">Table 6</a>
shows the incidence of genotypic resistance at 24 weeks in these
studies.</p>
<a name="id_34e89148-ab82-4488-a91f-3f2c459dac11" id=
"id_34e89148-ab82-4488-a91f-3f2c459dac11"></a>
<div class="scrollingtable">
<table class="Noautorules" width="335.000">
<caption><span>Table 6: Genotypic Resistance at 24
Weeks</span></caption>
<colgroup>
<col width="32.8%">
<col align="center" width="34.3%">
<col align="center" width="32.8%"></colgroup>
<thead>
<tr>
<td align="left" valign="top">Treatment Group</td>
<td align="center" valign="top">Resistance<br>
to IDV<br>
n/N<a class="Sup" href="#footnote-13" name="footnote-reference-13"
id="footnote-reference-13">*</a></td>
<td align="center" valign="top">Resistance<br>
to ZDV<br>
n/N<a class="Sup" href="#footnote-13">*</a></td>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<dl class="Footnote">
<dt><a href="#footnote-reference-13" name="footnote-13" id=
"footnote-13">*</a></dt>
<dd>N - includes patients with non-amplifiable virus at 24 weeks
who had amplifiable virus at week 0.</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody>
<tr>
<td align="left" valign="top">IDV</td>
<td align="center" valign="top">—</td>
<td align="center" valign="top">—</td>
</tr>
<tr>
<td align="left" valign="top">&lt;2.4 g/day</td>
<td align="center" valign="top">31/37 (84%)</td>
<td align="center" valign="top">—</td>
</tr>
<tr>
<td align="left" valign="top">2.4 g/day</td>
<td align="center" valign="top">9/21 (43%)</td>
<td align="center" valign="top">1/17 (6%)</td>
</tr>
<tr>
<td align="left" valign="top">IDV/ZDV</td>
<td align="center" valign="top">4/22 (18%)</td>
<td align="center" valign="top">1/22 (5%)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">ZDV</td>
<td class="Botrule" align="center" valign="top">1/18 (6%)</td>
<td class="Botrule" align="center" valign="top">11/17 (65%)</td>
</tr>
</tbody>
</table>
</div>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">CONTRAINDICATIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34070-3"><a name=
"i4i_contraindications_id_822eea92-c7b1-4462-83c0-948313a14695" id=
"i4i_contraindications_id_822eea92-c7b1-4462-83c0-948313a14695"></a>
<a name="section-5" id="section-5"></a>
<p class="First">CRIXIVAN is contraindicated in patients with
clinically significant hypersensitivity to any of its
components.</p>
<p>Inhibition of CYP3A4 by CRIXIVAN can result in elevated plasma
concentrations of the following drugs, potentially causing serious
or life-threatening reactions:</p>
<a name="id_b00fccfc-e9f6-4b77-89eb-44bfc08b7885" id=
"id_b00fccfc-e9f6-4b77-89eb-44bfc08b7885"></a>
<div class="scrollingtable">
<table width="698.000">
<caption><span>Table 7: Drug Interactions With Crixivan:
Contraindicated Drugs</span></caption>
<colgroup>
<col width="28.4%">
<col width="71.6%"></colgroup>
<thead>
<tr class="First Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold"><span class="Emphasis">Drug
Class</span></span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class=
"Bold"><span class="Emphasis">Drugs Within Class That Are
Contraindicated With CRIXIVAN</span></span></td>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="2">
<dl class="Footnote">
<dt><a href="#footnote-reference-14" name="footnote-14" id=
"footnote-14">*</a></dt>
<dd>Registered trademark of Pfizer, Inc.</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
Alpha 1-adrenoreceptor antagonist</td>
<td class="Botrule Rrule" align="left" valign="top">alfuzosin</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
Antiarrhythmics</td>
<td class="Botrule Rrule" align="left" valign="top">amiodarone</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Ergot
derivatives</td>
<td class="Botrule Rrule" align="left" valign="top">
dihydroergotamine, ergonovine, ergotamine, methylergonovine</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">GI
motility agents</td>
<td class="Botrule Rrule" align="left" valign="top">cisapride</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">HMG-CoA
Reductase Inhibitors</td>
<td class="Botrule Rrule" align="left" valign="top">lovastatin,
simvastatin</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
Neuroleptics</td>
<td class="Botrule Rrule" align="left" valign="top">pimozide</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">PDE5
Inhibitors</td>
<td class="Botrule Rrule" align="left" valign="top">
Revatio<a class="Sup" href="#footnote-14" name=
"footnote-reference-14" id="footnote-reference-14">*</a>
(sildenafil) [for treatment of pulmonary arterial
hypertension]</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
Sedative/hypnotics</td>
<td class="Botrule Rrule" align="left" valign="top">oral midazolam,
triazolam, alprazolam</td>
</tr>
</tbody>
</table>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">WARNINGS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34071-1"><a name=
"i4i_warnings_id_d7b709bb-7551-4a58-a56e-836a0bef4b58" id=
"i4i_warnings_id_d7b709bb-7551-4a58-a56e-836a0bef4b58"></a>
<a name="section-6" id="section-6"></a>
<p class="First"><span class="Bold"><span class="Emphasis">ALERT:
Find out about medicines that should NOT be taken with
CRIXIVAN.</span></span> This statement is included on the product's
bottle label.</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_7f0b5c84-6d96-4bc2-b256-b23c888e28ed" id=
"i4i_section_id_7f0b5c84-6d96-4bc2-b256-b23c888e28ed"></a> <a name=
"section-6.1" id="section-6.1"></a>
<h2>Nephrolithiasis/Urolithiasis</h2>
<p class="First">Nephrolithiasis/urolithiasis has occurred with
CRIXIVAN therapy. The cumulative frequency of nephrolithiasis is
substantially higher in pediatric patients (29%) than in adult
patients (12.4%; range across individual trials: 4.7% to 34.4%).
The cumulative frequency of nephrolithiasis events increases with
increasing exposure to CRIXIVAN; however, the risk over time
remains relatively constant. In some cases,
nephrolithiasis/urolithiasis has been associated with renal
insufficiency or acute renal failure, pyelonephritis with or
without bacteremia. If signs or symptoms of
nephrolithiasis/urolithiasis occur, (including flank pain, with or
without hematuria or microscopic hematuria), temporary interruption
(e.g., 1-3 days) or discontinuation of therapy may be considered.
<span class="Bold"><span class="Emphasis">Adequate hydration is
recommended in all patients treated with CRIXIVAN. (See <a href=
"#i4i_adverse_effects_id_00275f3b-05a5-434d-9872-84c9a123dbe5">ADVERSE
REACTIONS</a> and <a href=
"#i4i_section_id_964d576f-de04-4baf-b06e-f3a596212da6">DOSAGE AND
ADMINISTRATION,
Nephrolithiasis/Urolithiasis</a>.)</span></span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_32f58485-eef1-43b2-a70e-e77618a68157" id=
"i4i_section_id_32f58485-eef1-43b2-a70e-e77618a68157"></a> <a name=
"section-6.2" id="section-6.2"></a>
<h2>Hemolytic Anemia</h2>
<p class="First">Acute hemolytic anemia, including cases resulting
in death, has been reported in patients treated with CRIXIVAN. Once
a diagnosis is apparent, appropriate measures for the treatment of
hemolytic anemia should be instituted, including discontinuation of
CRIXIVAN.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_29c73578-2201-480d-9032-26fa272f05de" id=
"i4i_section_id_29c73578-2201-480d-9032-26fa272f05de"></a> <a name=
"section-6.3" id="section-6.3"></a>
<h2>Hepatitis</h2>
<p class="First">Hepatitis including cases resulting in hepatic
failure and death has been reported in patients treated with
CRIXIVAN. Because the majority of these patients had confounding
medical conditions and/or were receiving concomitant therapy(ies),
a causal relationship between CRIXIVAN and these events has not
been established.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_ebda7e32-832a-4927-9502-6e2b24321bca" id=
"i4i_section_id_ebda7e32-832a-4927-9502-6e2b24321bca"></a> <a name=
"section-6.4" id="section-6.4"></a>
<h2>Hyperglycemia</h2>
<p class="First">New onset diabetes mellitus, exacerbation of
pre-existing diabetes mellitus and hyperglycemia have been reported
during post-marketing surveillance in HIV-infected patients
receiving protease inhibitor therapy. Some patients required either
initiation or dose adjustments of insulin or oral hypoglycemic
agents for treatment of these events. In some cases, diabetic
ketoacidosis has occurred. In those patients who discontinued
protease inhibitor therapy, hyperglycemia persisted in some cases.
Because these events have been reported voluntarily during clinical
practice, estimates of frequency cannot be made and a causal
relationship between protease inhibitor therapy and these events
has not been established.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_interactions_id_9aee44b1-f055-4cb3-ab26-cf5aecf41683" id=
"i4i_interactions_id_9aee44b1-f055-4cb3-ab26-cf5aecf41683"></a>
<a name="section-6.5" id="section-6.5"></a>
<h2>Risk of Serious Adverse Reactions Due to Drug Interactions</h2>
<p class="First">Initiation of CRIXIVAN, a CYP3A inhibitor, in
patients receiving medications metabolized by CYP3A or initiation
of medications metabolized by CYP3A in patients already receiving
CRIXIVAN, may increase plasma concentrations of medications
metabolized by CYP3A. Initiation of medications that inhibit or
induce CYP3A may increase or decrease concentrations of CRIXIVAN,
respectively. These interactions may lead to:</p>
<ul>
<li>Clinically significant adverse reactions, potentially leading
to severe, life-threatening, or fatal events from greater exposures
of concomitant medications.</li>
<li>Clinically significant adverse reactions from greater exposures
of CRIXIVAN.</li>
<li>Loss of therapeutic effect of CRIXIVAN and possible development
of resistance.</li>
</ul>
<p>See <a href="#id_475b25fa-86e3-4b92-b606-66a613746db9">Table
9</a> for steps to prevent or manage these possible and known
significant drug interactions, including dosing recommendations.
Consider the potential for drug interactions prior to and during
CRIXIVAN therapy; review concomitant medications during CRIXIVAN
therapy; and monitor for the adverse reactions associated with the
concomitant medications.</p>
<p>Concomitant use of CRIXIVAN with lovastatin or simvastatin is
contraindicated due to an increased risk of myopathy including
rhabdomyolysis. Caution should be exercised if CRIXIVAN is used
concurrently with atorvastatin or rosuvastatin. Titrate the
atorvastatin and rosuvastatin doses carefully and use the lowest
necessary dose with CRIXIVAN. (See <a href="#PRE_DI">PRECAUTIONS,
Drug Interactions</a>.)</p>
<p>Midazolam is extensively metabolized by CYP3A4.
Co-administration with CRIXIVAN with or without ritonavir may cause
a large increase in the concentration of this benzodiazepine. No
drug interaction study has been performed for the co-administration
of CRIXIVAN with benzodiazepines. Based on data from other CYP3A4
inhibitors, plasma concentrations of midazolam are expected to be
significantly higher when midazolam is given orally. Therefore
CRIXIVAN should not be co-administered with orally administered
midazolam (see <a href=
"#i4i_contraindications_id_822eea92-c7b1-4462-83c0-948313a14695">CONTRAINDICATIONS</a>),
whereas caution should be used with co-administration of CRIXIVAN
and parenteral midazolam. Data from concomitant use of parenteral
midazolam with other protease inhibitors suggest a possible 3-4
fold increase in midazolam plasma levels. If CRIXIVAN with or
without ritonavir is co-administered with parenteral midazolam, it
should be done in a setting which ensures close clinical monitoring
and appropriate medical management in case of respiratory
depression and/or prolonged sedation. Dosage reduction for
midazolam should be considered, especially if more than a single
dose of midazolam is administered.</p>
<p>Particular caution should be used when prescribing sildenafil,
tadalafil, or vardenafil in patients receiving indinavir.
Coadministration of CRIXIVAN with these medications is expected to
substantially increase plasma concentrations of sildenafil,
tadalafil, and vardenafil and may result in an increase in adverse
events, including hypotension, visual changes, and priapism, which
have been associated with sildenafil, tadalafil, and vardenafil
(see <a href=
"#i4i_contraindications_id_822eea92-c7b1-4462-83c0-948313a14695">CONTRAINDICATIONS</a>
and <a href="#PRE_DI">PRECAUTIONS, Drug Interactions</a> and
<a href=
"#i4i_info_patients_id_b3085e64-522d-4668-bbfb-7bab715765e0">Information
for Patients</a>, and the manufacturer's complete prescribing
information for sildenafil, tadalafil, or vardenafil).</p>
<p>Concomitant use of CRIXIVAN and St. John's wort (<span class=
"Italics">Hypericum perforatum</span>) or products containing St.
John's wort is not recommended. Coadministration of CRIXIVAN and
St. John's wort has been shown to substantially decrease indinavir
concentrations (see <a href=
"#i4i_interactions_id_d2bf28f1-de8a-42e5-8f0d-5511455a45a6">CLINICAL
PHARMACOLOGY, Drug Interactions)</a> and may lead to loss of
virologic response and possible resistance to CRIXIVAN or to the
class of protease inhibitors.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRECAUTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"42232-9"><a name=
"i4i_precautions_id_2622dd5b-549b-40eb-9624-106a1482dcc0" id=
"i4i_precautions_id_2622dd5b-549b-40eb-9624-106a1482dcc0"></a>
<a name="section-7" id="section-7"></a>
<div class="Section" data-sectioncode="34072-9"><a name=
"i4i_precautions_general_id_49a13949-a0cd-4fb1-852b-c266fd29bae6"
id=
"i4i_precautions_general_id_49a13949-a0cd-4fb1-852b-c266fd29bae6"></a>
<a name="section-7.1" id="section-7.1"></a>
<h2>General</h2>
<p class="First">Indirect hyperbilirubinemia has occurred
frequently during treatment with CRIXIVAN and has infrequently been
associated with increases in serum transaminases (see also <a href=
"#i4i_clinical_studies_id_1ab32415-3a51-4a20-accb-ea49302b5068">ADVERSE
REACTIONS, Clinical Trials</a> and <a href=
"#i4i_section_id_d541bb5c-75ef-40e0-941b-dee9113307e4">Post-Marketing
Experience</a>). It is not known whether CRIXIVAN will exacerbate
the physiologic hyperbilirubinemia seen in neonates. (See <a href=
"#i4i_pregnancy_id_b1604860-5576-453e-8eab-64b159945be9">Pregnancy</a>.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_4ee9bf00-4f90-4340-88ee-085dc1e1b9fb" id=
"i4i_section_id_4ee9bf00-4f90-4340-88ee-085dc1e1b9fb"></a> <a name=
"section-7.2" id="section-7.2"></a>
<h2>Tubulointerstitial Nephritis</h2>
<p class="First">Reports of tubulointerstitial nephritis with
medullary calcification and cortical atrophy have been observed in
patients with asymptomatic severe leukocyturia (&gt;100 cells/ high
power field). Patients with asymptomatic severe leukocyturia should
be followed closely and monitored frequently with urinalyses.
Further diagnostic evaluation may be warranted, and discontinuation
of CRIXIVAN should be considered in all patients with severe
leukocyturia.</p>
<p>Immune reconstitution syndrome has been reported in patients
treated with combination antiretroviral therapy, including
CRIXIVAN. During the initial phase of combination antiretroviral
treatment, patients whose immune system responds may develop an
inflammatory response to indolent or residual opportunistic
infections (such as <span class="Italics">Mycobacterium
avium</span> infection, cytomegalovirus, <span class=
"Italics">Pneumocystis jirovecii</span> pneumonia [PCP], or
tuberculosis), which may necessitate further evaluation and
treatment.</p>
<p>Autoimmune disorders (such as Graves' disease, polymyositis, and
Guillain-Barré syndrome) have also been reported to occur in the
setting of immune reconstitution; however, the time to onset is
more variable, and can occur many months after initiation of
treatment.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_d5cc06a5-8ae5-4bcd-b7e0-43b11a1ebb75" id=
"i4i_section_id_d5cc06a5-8ae5-4bcd-b7e0-43b11a1ebb75"></a> <a name=
"section-7.3" id="section-7.3"></a>
<h2>Coexisting Conditions</h2>
<p class="First">Patients with hemophilia: There have been reports
of spontaneous bleeding in patients with hemophilia A and B treated
with protease inhibitors. In some patients, additional factor VIII
was required. In many of the reported cases, treatment with
protease inhibitors was continued or restarted. A causal
relationship between protease inhibitor therapy and these episodes
has not been established. (See <a href=
"#i4i_section_id_d541bb5c-75ef-40e0-941b-dee9113307e4">ADVERSE
REACTIONS, Post-Marketing Experience</a>.)</p>
<p>Patients with hepatic insufficiency due to cirrhosis: In these
patients, the dosage of CRIXIVAN should be lowered because of
decreased metabolism of CRIXIVAN (see <a href=
"#i4i_dosage_admin_id_616e9e55-2879-4bca-ae8b-4d833f00d938">DOSAGE
AND ADMINISTRATION</a>).</p>
<p>Patients with renal insufficiency: Patients with renal
insufficiency have not been studied.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_076ab369-986f-4e55-9a9f-c8bf2887ad6d" id=
"i4i_section_id_076ab369-986f-4e55-9a9f-c8bf2887ad6d"></a> <a name=
"section-7.4" id="section-7.4"></a>
<h2>Fat Redistribution</h2>
<p class="First">Redistribution/accumulation of body fat including
central obesity, dorsocervical fat enlargement (buffalo hump),
peripheral wasting, facial wasting, breast enlargement, and
"cushingoid appearance" have been observed in patients receiving
antiretroviral therapy. The mechanism and long-term consequences of
these events are currently unknown. A causal relationship has not
been established.</p>
</div>
<div class="Section" data-sectioncode="34076-0"><a name=
"i4i_info_patients_id_b3085e64-522d-4668-bbfb-7bab715765e0" id=
"i4i_info_patients_id_b3085e64-522d-4668-bbfb-7bab715765e0"></a>
<a name="section-7.5" id="section-7.5"></a>
<h2>Information for Patients</h2>
<p class="First">A statement to patients and health care providers
is included on the product's bottle label. <span class=
"Bold"><span class="Emphasis">ALERT: Find out about medicines that
should NOT be taken with CRIXIVAN.</span></span> A Patient Package
Insert (PPI) for CRIXIVAN is available for patient information.</p>
<p>CRIXIVAN is not a cure for HIV-1 infection and patients may
continue to experience illnesses associated with HIV-1 infection,
including opportunistic infections. Patients should remain under
the care of a physician when using CRIXIVAN.</p>
<p>Patients should be advised to avoid doing things that can spread
HIV-1 infection to others.</p>
<ul>
<li><span class="Bold">Do not share needles or other injection
equipment.</span></li>
<li><span class="Bold">Do not share personal items that can have
blood or body fluids on them, like toothbrushes and razor
blades.</span></li>
<li><span class="Bold">Do not have any kind of sex without
protection.</span> Always practice safe sex by using a latex or
polyurethane condom to lower the chance of sexual contact with
semen, vaginal secretions, or blood.</li>
<li><span class="Bold">Do not breastfeed.</span> We do not know if
CRIXIVAN can be passed to your baby in your breast milk and whether
it could harm your baby. Also, mothers with HIV-1 should not
breastfeed because HIV-1 can be passed to the baby in the breast
milk.</li>
</ul>
<p>Patients should be advised to remain under the care of a
physician when using CRIXIVAN and should not modify or discontinue
treatment without first consulting the physician. Therefore, if a
dose is missed, patients should take the next dose at the regularly
scheduled time and should not double this dose. Therapy with
CRIXIVAN should be initiated and maintained at the recommended
dosage.</p>
<p>CRIXIVAN may interact with some drugs; therefore, patients
should be advised to report to their doctor the use of any other
prescription, non-prescription medication or herbal products,
particularly St. John's wort.</p>
<p>For optimal absorption, CRIXIVAN should be administered without
food but with water 1 hour before or 2 hours after a meal.
Alternatively, CRIXIVAN may be administered with other liquids such
as skim milk, juice, coffee, or tea, or with a light meal, e.g.,
dry toast with jelly, juice, and coffee with skim milk and sugar;
or corn flakes, skim milk and sugar (see <a href=
"#i4i_section_id_59d110fd-2d4f-4a1f-8bca-252a08546749">CLINICAL
PHARMACOLOGY, Effect of Food on Oral Absorption</a> and <a href=
"#i4i_dosage_admin_id_616e9e55-2879-4bca-ae8b-4d833f00d938">DOSAGE
AND ADMINISTRATION</a>). Ingestion of CRIXIVAN with a meal high in
calories, fat, and protein reduces the absorption of indinavir.</p>
<p>Patients receiving a phosphodiesterase type 5 (PDE5) inhibitor
(sildenafil, tadalafil, or vardenafil) should be advised that they
may be at an increased risk of PDE5 inhibitor-associated adverse
events including hypotension, visual changes, and priapism, and
should promptly report any symptoms to their doctors (see <a href=
"#i4i_contraindications_id_822eea92-c7b1-4462-83c0-948313a14695">CONTRAINDICATIONS</a>
and <a href=
"#i4i_interactions_id_9aee44b1-f055-4cb3-ab26-cf5aecf41683">WARNINGS,
Drug Interactions</a>).</p>
<p>Patients should be informed that redistribution or accumulation
of body fat may occur in patients receiving antiretroviral therapy
and that the cause and long-term health effects of these conditions
are not known at this time.</p>
<p>CRIXIVAN Capsules are sensitive to moisture. Patients should be
informed that CRIXIVAN should be stored and used in the original
container and the desiccant should remain in the bottle.</p>
</div>
<div class="Section" data-sectioncode="34073-7"><a name="PRE_DI"
id="PRE_DI"></a> <a name="section-7.6" id="section-7.6"></a>
<h2>Drug Interactions</h2>
<p class="First">Indinavir is an inhibitor of the cytochrome P450
isoform CYP3A4. Coadministration of CRIXIVAN and drugs primarily
metabolized by CYP3A4 may result in increased plasma concentrations
of the other drug, which could increase or prolong its therapeutic
and adverse effects (see <a href=
"#i4i_contraindications_id_822eea92-c7b1-4462-83c0-948313a14695">CONTRAINDICATIONS</a>
and <a href=
"#i4i_warnings_id_d7b709bb-7551-4a58-a56e-836a0bef4b58">WARNINGS</a>).</p>
<p>Indinavir is metabolized by CYP3A4. Drugs that induce CYP3A4
activity would be expected to increase the clearance of indinavir,
resulting in lowered plasma concentrations of indinavir.
Coadministration of CRIXIVAN and other drugs that inhibit CYP3A4
may decrease the clearance of indinavir and may result in increased
plasma concentrations of indinavir.</p>
<a name="id_72904cd2-afbb-4b66-9513-5113da0c8c4f" id=
"id_72904cd2-afbb-4b66-9513-5113da0c8c4f"></a>
<div class="scrollingtable">
<table width="740.000">
<caption><span>Table 8: Drugs That Should Not Be Coadministered
with CRIXIVAN</span></caption>
<colgroup>
<col width="40.4%">
<col width="59.6%"></colgroup>
<thead>
<tr class="First Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">Drug
Class: Drug Name</td>
<td class="Botrule Rrule" align="center" valign="top">Clinical
Comment</td>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="2">
<dl class="Footnote">
<dt><a href="#footnote-reference-15" name="footnote-15" id=
"footnote-15">*</a></dt>
<dd>Registered trademark of Pfizer, Inc.</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
Alpha 1-adrenoreceptor antagonist:<br>
alfuzosin</td>
<td class="Botrule Rrule" align="left" valign="top">Potentially
increased alfuzosin concentrations can result in hypotension.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
Antiarrhythmics:<br>
amiodarone</td>
<td class="Botrule Rrule" align="left" valign="top">CONTRAINDICATED
due to potential for serious and/or life-threatening reactions such
as cardiac arrhythmias.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
Antimycobacterial:<br>
rifampin</td>
<td class="Botrule Rrule" align="left" valign="top">May lead to
loss of virologic response and possible resistance to CRIXIVAN or
to the class of protease inhibitors or other coadministered
antiretroviral agents.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Ergot
derivatives:<br>
dihydroergotamine, ergonovine,<br>
ergotamine, methylergonovine</td>
<td class="Botrule Rrule" align="left" valign="top">CONTRAINDICATED
due to potential for serious and/or life-threatening reactions such
as acute ergot toxicity characterized by peripheral vasospasm and
ischemia of the extremities and other tissues.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">GI
motility agents:<br>
cisapride</td>
<td class="Botrule Rrule" align="left" valign="top">CONTRAINDICATED
due to potential for serious and/or life-threatening reactions such
as cardiac arrhythmias.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Herbal
products:<br>
St. John's wort (<span class="Italics">Hypericum
perforatum</span>)</td>
<td class="Botrule Rrule" align="left" valign="top">May lead to
loss of virologic response and possible resistance to CRIXIVAN or
to the class of protease inhibitors.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">HMG-CoA
Reductase inhibitors:<br>
lovastatin, simvastatin</td>
<td class="Botrule Rrule" align="left" valign="top">CONTRAINDICATED
due to an increased risk for serious reactions such as myopathy
including rhabdomyolysis.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
Neuroleptic:<br>
pimozide</td>
<td class="Botrule Rrule" align="left" valign="top">CONTRAINDICATED
due to potential for serious and/or life-threatening reactions such
as cardiac arrhythmias.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">PDE5
inhibitor:<br>
Revatio<a class="Sup" href="#footnote-15" name=
"footnote-reference-15" id="footnote-reference-15">*</a>
(sildenafil) [for treatment of pulmonary arterial
hypertension]</td>
<td class="Botrule Rrule" align="left" valign="top">A safe and
effective dose has not been established when used with CRIXIVAN.
There is increased potential for sildenafil-associated adverse
events (which include visual disturbances, hypotension, prolonged
erection, and syncope).</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Protease
inhibitor:<br>
atazanavir</td>
<td class="Botrule Rrule" align="left" valign="top">Both CRIXIVAN
and atazanavir are associated with indirect (unconjugated)
hyperbilirubinemia. Combinations of these drugs have not been
studied and coadministration of CRIXIVAN and atazanavir is not
recommended.</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
Sedative/hypnotics:<br>
Oral midazolam, triazolam, alprazolam</td>
<td class="Botrule Rrule" align="left" valign="top">CONTRAINDICATED
due to potential for serious and/or life-threatening reactions such
as prolonged or increased sedation or respiratory depression.</td>
</tr>
</tbody>
</table>
</div>
<a name="id_475b25fa-86e3-4b92-b606-66a613746db9" id=
"id_475b25fa-86e3-4b92-b606-66a613746db9"></a>
<div class="scrollingtable">
<table width="740.000">
<caption><span>Table 9: Established and Other Potentially
Significant Drug Interactions: Alteration in Dose or Regimen May Be
Recommended Based on Drug Interaction Studies or Predicted
Interaction (See also <a href=
"#i4i_clinical_pharmacology_id_7caf9387-ffb7-4044-bdcf-c354131c84b5">
CLINICAL PHARMACOLOGY</a> for magnitude of interaction, <a href=
"#i4i_warnings_id_d7b709bb-7551-4a58-a56e-836a0bef4b58">WARNINGS</a>
and <a href=
"#i4i_dosage_admin_id_616e9e55-2879-4bca-ae8b-4d833f00d938">DOSAGE
AND ADMINISTRATION</a>.)</span></caption>
<colgroup>
<col width="17.6%">
<col width="28.6%">
<col width="53.7%"></colgroup>
<thead>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">Drug Name</td>
<td class="Botrule Rrule" align="center" valign="top">Effect</td>
<td class="Botrule Rrule" align="center" valign="top">Clinical
Comment</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="center" colspan="3" valign="top">
<span class="Bold"><span class="Emphasis">HIV Antiviral
Agents</span></span></td>
</tr>
</thead>
<tfoot>
<tr class="Last">
<td align="left" colspan="3" valign="top">Note: ↑ = increase; ↓ =
decrease</td>
</tr>
<tr>
<td align="left" colspan="3">
<dl class="Footnote">
<dt><a href="#footnote-reference-16" name="footnote-16" id=
"footnote-16">*</a></dt>
<dd>Registered trademark of Pfizer, Inc.</dd>
<dt><a href="#footnote-reference-17" name="footnote-17" id=
"footnote-17">†</a></dt>
<dd>Registered trademark of Eli Lilly and Company.</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">Delavirdine</td>
<td class="Botrule Rrule" align="center" valign="top">↑ indinavir
concentration</td>
<td class="Botrule Rrule" align="left" valign="top">Dose reduction
of CRIXIVAN to 600 mg every 8 hours should be considered when
taking delavirdine 400 mg three times a day.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
Didanosine</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">Indinavir and
didanosine formulations containing buffer should be administered at
least one hour apart on an empty stomach.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
Efavirenz</td>
<td class="Botrule Rrule" align="center" valign="top">↓ indinavir
concentration</td>
<td class="Botrule Rrule" align="left" valign="top">The optimal
dose of indinavir, when given in combination with efavirenz, is not
known. Increasing the indinavir dose to 1000 mg every 8 hours does
not compensate for the increased indinavir metabolism due to
efavirenz.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
Nelfinavir</td>
<td class="Botrule Rrule" align="center" valign="top">↑ indinavir
concentration</td>
<td class="Botrule Rrule" align="left" valign="top">The appropriate
doses for this combination, with respect to efficacy and safety,
have not been established.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
Nevirapine</td>
<td class="Botrule Rrule" align="center" valign="top">↓ indinavir
concentration</td>
<td class="Botrule Rrule" align="left" valign="top">Indinavir
concentrations may be decreased in the presence of nevirapine. The
appropriate doses for this combination, with respect to efficacy
and safety, have not been established.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
Ritonavir</td>
<td class="Botrule Rrule" align="center" valign="top">↑ indinavir
concentration<br>
↑ ritonavir concentration</td>
<td class="Botrule Rrule" align="left" valign="top">The appropriate
doses for this combination, with respect to efficacy and safety,
have not been established. Preliminary clinical data suggest that
the incidence of nephrolithiasis is higher in patients receiving
indinavir in combination with ritonavir than those receiving
CRIXIVAN 800 mg q8h.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
Saquinavir</td>
<td class="Botrule Rrule" align="center" valign="top">↑ saquinavir
concentration</td>
<td class="Botrule Rrule" align="left" valign="top">The appropriate
doses for this combination, with respect to efficacy and safety,
have not been established.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" colspan="3" valign=
"top"><span class="Bold"><span class="Emphasis">Other
Agents</span></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
Antiarrhythmics:<br>
bepridil, lidocaine(systemic)<br>
and quinidine</td>
<td class="Botrule Rrule" align="center" valign="top">↑
antiarrhythmic agents concentration</td>
<td class="Botrule Rrule" align="left" valign="top">Caution is
warranted and therapeutic concentration monitoring is recommended
for antiarrhythmics when coadministered with CRIXIVAN.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
Anticonvulsants:<br>
carbamazepine, phenobarbital,<br>
phenytoin</td>
<td class="Botrule Rrule" align="center" valign="top">↓ indinavir
concentration</td>
<td class="Botrule Rrule" align="left" valign="top">Use with
caution. CRIXIVAN may not be effective due to decreased indinavir
concentrations in patients taking these agents concomitantly.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
Antidepressant:<br>
Trazodone</td>
<td class="Botrule Rrule" align="center" valign="top">↑ trazodone
concentration</td>
<td class="Botrule Rrule" align="left" valign="top">Concomitant use
of trazodone and CRIXIVAN may increase plasma concentrations of
trazodone. Adverse events of nausea, dizziness, hypotension and
syncope have been observed following coadministration of trazodone
and ritonavir. If trazodone is used with a CYP3A4 inhibitor such as
CRIXIVAN, the combination should be used with caution and a lower
dose of trazodone should be considered.</td>
</tr>
<tr class="Botrule">
<td class="Botrule Lrule Rrule" align="center" valign="top">
Anti-gout:<br>
Colchicine</td>
<td class="Botrule Rrule" align="center" valign="top">↑ colchicine
concentration</td>
<td class="Botrule Rrule" align="left" valign="top">Patients with
renal or hepatic impairment should not be given colchicine with
CRIXIVAN.<br>
<span class="Bold"><span class="Italics">Treatment of gout
flares:</span></span><br>
Co-administration of colchicine in patients on CRIXIVAN: 0.6 mg (1
tablet) x 1 dose, followed by 0.3 mg (half tablet) 1 hour later.
Dose to be repeated no earlier than 3 days.<br>
<span class="Bold"><span class="Italics">Prophylaxis of gout
flares:</span></span><br>
Co-administration of colchicine in patients on CRIXIVAN:<br>
If the original colchicine regimen was 0.6 mg twice a day, the
regimen should be adjusted to 0.3 mg once a day.<br>
If the original colchicine regimen was 0.6 mg once a day, the
regimen should be adjusted to 0.3 mg once every other day.<br>
<span class="Bold"><span class="Italics">Treatment of familial
Mediterranean fever (FMF):</span></span><br>
Co-administration of colchicine in patients on CRIXIVAN: Maximum
daily dose of 0.6 mg (may be given as 0.3 mg twice a day).</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">
Antipsychotics:<br>
Quetiapine</td>
<td class="Rrule" align="center" valign="top">↑ quetiapine</td>
<td class="Rrule" align="left"><span class=
"Bold Italics">Initiation of CRIXIVAN in patients taking
quetiapine:</span><br>
Consider alternative antiretroviral therapy to avoid increases in
quetiapine drug exposures. If coadministration is necessary, reduce
the quetiapine dose to 1/6 of the current dose and monitor for
quetiapine-associated adverse reactions. Refer to the quetiapine
prescribing information for recommendations on adverse reaction
monitoring.<br>
<span class="Bold Italics">Initiation of quetiapine in patients
taking CRIXIVAN:</span><br>
Refer to the quetiapine prescribing information for initial dosing
and titration of quetiapine.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">Calcium
Channel Blockers,<br>
Dihydropyridine: e.g., felodipine,<br>
nifedipine, nicardipine</td>
<td class="Botrule Rrule" align="center" valign="top">↑
dihydropyridine calcium channel blockers concentration</td>
<td class="Botrule Rrule" align="left" valign="top">Caution is
warranted and clinical monitoring of patients is recommended.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
Clarithromycin</td>
<td class="Botrule Rrule" align="center" valign="top">↑
clarithromycin concentration<br>
↑ indinavir concentration</td>
<td class="Botrule Rrule" align="left" valign="top">The appropriate
doses for this combination, with respect to efficacy and safety,
have not been established.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
Endothelin receptor antagonist:<br>
Bosentan</td>
<td class="Botrule Rrule" align="center" valign="top">↑ bosentan
concentration</td>
<td class="Botrule Rrule" align="left" valign="top">
Co-administration of bosentan in patients on CRIXIVAN or
co-administration of CRIXIVAN in patients on bosentan: Start at or
adjust bosentan to 62.5 mg once daily or every other day based upon
individual tolerability.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">HMG-CoA
Reductase<br>
Inhibitors: atorvastatin,<br>
rosuvastatin</td>
<td class="Botrule Rrule" align="center" valign="top">↑
atorvastatin concentration<br>
<br>
↑ rosuvastatin concentration</td>
<td class="Botrule Rrule" align="left" valign="top">The
atorvastatin and rosuvastatin doses should be carefully titrated;
use the lowest dose necessary with careful monitoring during
treatment with CRIXIVAN.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
Immunosuppressants: cyclosporine, tacrolimus, sirolimus</td>
<td class="Botrule Rrule" align="center" valign="top">↑
immunosuppressant agents concentration</td>
<td class="Botrule Rrule" align="left" valign="top">Plasma
concentrations may be increased by CRIXIVAN.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">Inhaled
beta agonist:<br>
Salmeterol</td>
<td class="Botrule Rrule" align="center" valign="top">↑
salmeterol</td>
<td class="Botrule Rrule" align="left" valign="top">Concurrent
administration of salmeterol with CRIXIVAN is not recommended. The
combination may result in increased risk of cardiovascular adverse
events associated with salmeterol, including QT prolongation,
palpitations and sinus tachycardia.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
Inhaled/nasal steroid:<br>
Fluticasone</td>
<td class="Botrule Rrule" align="center" valign="top">↑ fluticasone
concentration</td>
<td class="Botrule Rrule" align="left" valign="top">Concomitant use
of fluticasone propionate and CRIXIVAN may increase plasma
concentrations of fluticasone propionate. Use with caution.
Consider alternatives to fluticasone propionate, particularly for
long-term use.<br>
Fluticasone use is not recommended in situations where CRIXIVAN is
coadministered with a potent CYP3A4 inhibitor such as ritonavir
unless the potential benefit to the patient outweighs the risk of
systemic corticosteroid side effects.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
Itraconazole</td>
<td class="Botrule Rrule" align="center" valign="top">↑ indinavir
concentration</td>
<td class="Botrule Rrule" align="left" valign="top">Dose reduction
of CRIXIVAN to 600 mg every 8 hours is recommended when
administering itraconazole concurrently.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
Ketoconazole</td>
<td class="Botrule Rrule" align="center" valign="top">↑ indinavir
concentration</td>
<td class="Botrule Rrule" align="left" valign="top">Dose reduction
of CRIXIVAN to 600 mg every 8 hours should be considered.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
Midazolam (parenteral administration)</td>
<td class="Botrule Rrule" align="center" valign="top">↑ midazolam
concentration</td>
<td class="Botrule Rrule" align="left" valign="top">Concomitant use
of parenteral midazolam with CRIXIVAN may increase plasma
concentrations of midazolam. Coadministration should be done in a
setting which ensures close clinical monitoring and appropriate
medical management in case of respiratory depression and/or
prolonged sedation. Dosage reduction for midazolam should be
considered, especially if more than a single dose of midazolam is
administered. Coadministration of oral midazolam with CRIXIVAN is
CONTRAINDICATED (see <a href=
"#id_72904cd2-afbb-4b66-9513-5113da0c8c4f">Table 8</a>).</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
Rifabutin</td>
<td class="Botrule Rrule" align="center" valign="top">↓ indinavir
concentration<br>
↑ rifabutin concentration</td>
<td class="Botrule Rrule" align="left" valign="top">Dose reduction
of rifabutin to half the standard dose and a dose increase of
CRIXIVAN to 1000 mg every 8 hours are recommended when rifabutin
and CRIXIVAN are coadministered.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
Sildenafil</td>
<td class="Botrule Rrule" align="center" valign="top">↑ sildenafil
concentration<br>
(only the use of sildenafil at doses used for treatment of erectile
dysfunction has been studied with CRIXIVAN)</td>
<td class="Botrule Rrule" align="left" valign="top">May result in
an increase in PDE5 inhibitor-associated adverse events, including
hypotension, syncope, visual disturbances, and priapism.<br>
<span class="Bold"><span class="Italics">Use of sildenafil for
pulmonary arterial hypertension (PAH):</span></span><br>
Use of Revatio<a class="Sup" href="#footnote-16" name=
"footnote-reference-16" id="footnote-reference-16">*</a>
(sildenafil) is contraindicated when used for the treatment of
pulmonary arterial hypertension (PAH) [see CONTRAINDICATIONS].<br>
<span class="Bold"><span class="Italics">Use of sildenafil for
erectile dysfunction:</span></span><br>
Sildenafil dose should not exceed a maximum of 25 mg in a 48-hour
period in patients receiving concomitant CRIXIVAN therapy. Use with
increased monitoring for adverse events.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
Tadalafil</td>
<td class="Botrule Rrule" align="center" valign="top">↑ tadalafil
concentration</td>
<td class="Botrule Rrule" align="left" valign="top">May result in
an increase in PDE5 inhibitor-associated adverse events, including
hypotension, visual disturbances, and priapism.<br>
<span class="Bold"><span class="Italics">Use of tadalafil for
pulmonary arterial hypertension (PAH):</span></span><br>
The following dose adjustments are recommended for use of
Adcirca<a class="Sup" href="#footnote-17" name=
"footnote-reference-17" id="footnote-reference-17">†</a>
(tadalafil) with CRIXIVAN:<br>
Co-administration of Adcirca in patients on CRIXIVAN or
co-administration of CRIXIVAN in patients on Adcirca:<br>
Start at or adjust Adcirca to 20 mg once daily. Increase to 40 mg
once daily based upon individual tolerability.<br>
<span class="Bold"><span class="Italics">Use of tadalafil for
erectile dysfunction:</span></span><br>
Tadalafil dose should not exceed a maximum of 10 mg in a 72-hour
period in patients receiving concomitant CRIXIVAN therapy. Use with
increased monitoring for adverse events.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
Vardenafil</td>
<td class="Botrule Rrule" align="center" valign="top">↑ vardenafil
concentration</td>
<td class="Botrule Rrule" align="left" valign="top">Vardenafil dose
should not exceed a maximum of 2.5 mg in a 24-hour period in
patients receiving concomitant indinavir therapy.</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top">
Venlafaxine</td>
<td class="Rrule" align="center" valign="top">↓ indinavir
concentration</td>
<td class="Rrule" align="left" valign="top">In a study of 9 healthy
volunteers, venlafaxine administered under steady-state conditions
at 150 mg/day resulted in a 28% decrease in the AUC of a single 800
mg oral dose of indinavir and a 36% decrease in indinavir
C<span class="Sub">max</span>. Indinavir did not affect the
pharmacokinetics of venlafaxine and ODV. The clinical significance
of this finding is unknown.</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectioncode="34083-6"><a name=
"i4i_carcinogenesis_mutagenesis_fertility_id_d1120dc5-432e-4609-bcdf-15418f6ce855"
id=
"i4i_carcinogenesis_mutagenesis_fertility_id_d1120dc5-432e-4609-bcdf-15418f6ce855">
</a> <a name="section-7.7" id="section-7.7"></a>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity studies were conducted in mice and
rats. In mice, no increased incidence of any tumor type was
observed. The highest dose tested in rats was 640 mg/kg/day; at
this dose a statistically significant increased incidence of
thyroid adenomas was seen only in male rats. At that dose, daily
systemic exposure in rats was approximately 1.3 times higher than
daily systemic exposure in humans. No evidence of mutagenicity or
genotoxicity was observed in <span class="Italics">in vitro</span>
microbial mutagenesis (Ames) tests, <span class="Italics">in
vitro</span> alkaline elution assays for DNA breakage, <span class=
"Italics">in vitro</span> and <span class="Italics">in vivo</span>
chromosomal aberration studies, and <span class="Italics">in
vitro</span> mammalian cell mutagenesis assays. No
treatment-related effects on mating, fertility, or embryo survival
were seen in female rats and no treatment-related effects on mating
performance were seen in male rats at doses providing systemic
exposure comparable to or slightly higher than that with the
clinical dose. In addition, no treatment-related effects were
observed in fecundity or fertility of untreated females mated to
treated males.</p>
</div>
<div class="Section" data-sectioncode="42228-7"><a name=
"i4i_pregnancy_id_b1604860-5576-453e-8eab-64b159945be9" id=
"i4i_pregnancy_id_b1604860-5576-453e-8eab-64b159945be9"></a>
<a name="section-7.8" id="section-7.8"></a>
<h2>Pregnancy</h2>
<div class="Section" data-sectioncode="34077-8"><a name=
"i4i_teratogenic_id_7fcf6ae6-91d8-4a56-a3ca-ff2c59e11a68" id=
"i4i_teratogenic_id_7fcf6ae6-91d8-4a56-a3ca-ff2c59e11a68"></a>
<a name="section-7.8.1" id="section-7.8.1"></a></div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_bd8e8aea-daed-44a4-8ca7-80bb79652a96" id=
"i4i_section_id_bd8e8aea-daed-44a4-8ca7-80bb79652a96"></a> <a name=
"section-7.8.2" id="section-7.8.2"></a>
<h3>Pregnancy Category C:</h3>
<p class="First">Developmental toxicity studies were performed in
rabbits (at doses up to 240 mg/kg/day), dogs (at doses up to 80
mg/kg/day), and rats (at doses up to 640 mg/kg/day). The highest
doses in these studies produced systemic exposures in these species
comparable to or slightly greater than human exposure. No
treatment-related external, visceral, or skeletal changes were
observed in rabbits or dogs. No treatment-related external or
visceral changes were observed in rats. Treatment-related increases
over controls in the incidence of supernumerary ribs (at exposures
at or below those in humans) and of cervical ribs (at exposures
comparable to or slightly greater than those in humans) were seen
in rats. In all three species, no treatment-related effects on
embryonic/fetal survival or fetal weights were observed.</p>
<p>In rabbits, at a maternal dose of 240 mg/kg/day, no drug was
detected in fetal plasma 1 hour after dosing. Fetal plasma drug
levels 2 hours after dosing were approximately 3% of maternal
plasma drug levels. In dogs, at a maternal dose of 80 mg/kg/day,
fetal plasma drug levels were approximately 50% of maternal plasma
drug levels both 1 and 2 hours after dosing. In rats, at maternal
doses of 40 and 640 mg/kg/day, fetal plasma drug levels were
approximately 10 to 15% and 10 to 20% of maternal plasma drug
levels 1 and 2 hours after dosing, respectively.</p>
<p>Indinavir was administered to Rhesus monkeys during the third
trimester of pregnancy (at doses up to 160 mg/kg twice daily) and
to neonatal Rhesus monkeys (at doses up to 160 mg/kg twice daily).
When administered to neonates, indinavir caused an exacerbation of
the transient physiologic hyperbilirubinemia seen in this species
after birth; serum bilirubin values were approximately fourfold
above controls at 160 mg/kg twice daily. A similar exacerbation did
not occur in neonates after <span class="Italics">in utero</span>
exposure to indinavir during the third trimester of pregnancy. In
Rhesus monkeys, fetal plasma drug levels were approximately 1 to 2%
of maternal plasma drug levels approximately 1 hour after maternal
dosing at 40, 80, or 160 mg/kg twice daily.</p>
<p>Hyperbilirubinemia has occurred during treatment with CRIXIVAN
(see <a href=
"#i4i_precautions_id_2622dd5b-549b-40eb-9624-106a1482dcc0">PRECAUTIONS</a>
and <a href=
"#i4i_adverse_effects_id_00275f3b-05a5-434d-9872-84c9a123dbe5">ADVERSE
REACTIONS</a>). It is unknown whether CRIXIVAN administered to the
mother in the perinatal period will exacerbate physiologic
hyperbilirubinemia in neonates.</p>
<p>There are no adequate and well-controlled studies in pregnant
patients. CRIXIVAN should be used during pregnancy only if the
potential benefit justifies the potential risk to the fetus.</p>
<p>A CRIXIVAN dose of 800 mg every 8 hours (with zidovudine 200 mg
every 8 hours and lamivudine 150 mg twice a day) has been studied
in 16 HIV-infected pregnant patients at 14 to 28 weeks of gestation
at enrollment (study PACTG 358). Given the substantially lower
antepartum exposures observed and the limited data in this patient
population, indinavir use is not recommended in HIV-infected
pregnant patients (see <a href=
"#i4i_pregnancy_id_a2f05ba2-3961-4c48-8aa4-28f765dabbb2">CLINICAL
PHARMACOLOGY, Pregnant Patients</a>).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_ce6341aa-f988-4aa2-a2dd-0d1b6680cc52" id=
"i4i_section_id_ce6341aa-f988-4aa2-a2dd-0d1b6680cc52"></a> <a name=
"section-7.8.3" id="section-7.8.3"></a>
<h3>Antiretroviral Pregnancy Registry</h3>
<p class="First">To monitor maternal-fetal outcomes of pregnant
patients exposed to CRIXIVAN, an Antiretroviral Pregnancy Registry
has been established. Physicians are encouraged to register
patients by calling 1-800-258-4263.</p>
</div>
</div>
<div class="Section" data-sectioncode="34080-2"><a name=
"i4i_nursing_mothers_id_2ae550b9-785a-486b-9e40-a57b72f141d1" id=
"i4i_nursing_mothers_id_2ae550b9-785a-486b-9e40-a57b72f141d1"></a>
<a name="section-7.9" id="section-7.9"></a>
<h2>Nursing Mothers</h2>
<p class="First">Studies in lactating rats have demonstrated that
indinavir is excreted in milk. Although it is not known whether
CRIXIVAN is excreted in human milk, there exists the potential for
adverse effects from indinavir in nursing infants. Mothers should
be instructed to discontinue nursing if they are receiving
CRIXIVAN. This is consistent with the recommendation by the U.S.
Public Health Service Centers for Disease Control and Prevention
that HIV-infected mothers not breast-feed their infants to avoid
risking postnatal transmission of HIV.</p>
</div>
<div class="Section" data-sectioncode="34081-0"><a name=
"i4i_pediatric_use_id_9c13c485-0c6c-45c2-ae17-ec8110e4db9e" id=
"i4i_pediatric_use_id_9c13c485-0c6c-45c2-ae17-ec8110e4db9e"></a>
<a name="section-7.10" id="section-7.10"></a>
<h2>Pediatric Use</h2>
<p class="First">The optimal dosing regimen for use of indinavir in
pediatric patients has not been established. A dose of 500
mg/m<span class="Sup">2</span> every eight hours has been studied
in uncontrolled studies of 70 children, 3 to 18 years of age. The
pharmacokinetic profiles of indinavir at this dose were
<span class="Underline">not</span> comparable to profiles
previously observed in adults receiving the recommended dose (see
<a href=
"#i4i_pediatric_use_id_8e5d1fc5-1698-4034-a400-2fc18ce95e34">CLINICAL
PHARMACOLOGY, Pediatric</a>). Although viral suppression was
observed in some of the 32 children who were followed on this
regimen through 24 weeks, a substantially higher rate of
nephrolithiasis was reported when compared to adult historical data
(see <a href=
"#i4i_section_id_7f0b5c84-6d96-4bc2-b256-b23c888e28ed">WARNINGS,
Nephrolithiasis/Urolithiasis</a>). Physicians considering the use
of indinavir in pediatric patients without other protease inhibitor
options should be aware of the limited data available in this
population and the increased risk of nephrolithiasis.</p>
</div>
<div class="Section" data-sectioncode="34082-8"><a name=
"i4i_geriatric_use_id_a4543a5d-bbac-44bb-a987-2a961341cb79" id=
"i4i_geriatric_use_id_a4543a5d-bbac-44bb-a987-2a961341cb79"></a>
<a name="section-7.11" id="section-7.11"></a>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of CRIXIVAN did not include
sufficient numbers of subjects aged 65 and over to determine
whether they respond differently from younger subjects. In general,
dose selection for an elderly patient should be cautious,
reflecting the greater frequency of decreased hepatic, renal or
cardiac function and of concomitant disease or other drug
therapy.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">ADVERSE REACTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34084-4"><a name=
"i4i_adverse_effects_id_00275f3b-05a5-434d-9872-84c9a123dbe5" id=
"i4i_adverse_effects_id_00275f3b-05a5-434d-9872-84c9a123dbe5"></a>
<a name="section-8" id="section-8"></a>
<div class="Section" data-sectioncode="34092-7"><a name=
"i4i_clinical_studies_id_1ab32415-3a51-4a20-accb-ea49302b5068" id=
"i4i_clinical_studies_id_1ab32415-3a51-4a20-accb-ea49302b5068"></a>
<a name="section-8.1" id="section-8.1"></a>
<h2>Clinical Trials in Adults</h2>
<p class="First">Nephrolithiasis/urolithiasis, including flank pain
with or without hematuria (including microscopic hematuria), has
been reported in approximately 12.4% (301/2429; range across
individual trials: 4.7% to 34.4%) of patients receiving CRIXIVAN at
the recommended dose in clinical trials with a median follow-up of
47 weeks (range: 1 day to 242 weeks; 2238 patient-years follow-up).
The cumulative frequency of nephrolithiasis events increases with
duration of exposure to CRIXIVAN; however, the risk over time
remains relatively constant. Of the patients treated with CRIXIVAN
who developed nephrolithiasis/urolithiasis in clinical trials
during the double-blind phase, 2.8% (7/246) were reported to
develop hydronephrosis and 4.5% (11/246) underwent stent placement.
Following the acute episode, 4.9% (12/246) of patients discontinued
therapy. (See <a href=
"#i4i_warnings_id_d7b709bb-7551-4a58-a56e-836a0bef4b58">WARNINGS</a>
and <a href=
"#i4i_section_id_964d576f-de04-4baf-b06e-f3a596212da6">DOSAGE AND
ADMINISTRATION, Nephrolithiasis/Urolithiasis</a>.)</p>
<p>Asymptomatic hyperbilirubinemia (total bilirubin ≥2.5 mg/dL),
reported predominantly as elevated indirect bilirubin, has occurred
in approximately 14% of patients treated with CRIXIVAN. In &lt;1%
this was associated with elevations in ALT or AST.</p>
<p>Hyperbilirubinemia and nephrolithiasis/urolithiasis occurred
more frequently at doses exceeding 2.4 g/day compared to doses ≤2.4
g/day.</p>
<p>Clinical adverse experiences reported in ≥2% of patients treated
with CRIXIVAN alone, CRIXIVAN in combination with zidovudine or
zidovudine plus lamivudine, zidovudine alone, or zidovudine plus
lamivudine are presented in <a href=
"#id_24d52ad5-a3eb-4df5-b0dc-9c2b9ed0b379">Table 10</a>.</p>
<a name="id_24d52ad5-a3eb-4df5-b0dc-9c2b9ed0b379" id=
"id_24d52ad5-a3eb-4df5-b0dc-9c2b9ed0b379"></a>
<div class="scrollingtable">
<table class="Noautorules" width="745.000">
<caption><span>Table 10: Clinical Adverse Experiences Reported in
≥2% of Patients</span></caption>
<colgroup>
<col width="8.8%">
<col width="22.5%">
<col width="12.0%">
<col width="12.8%">
<col width="12.0%">
<col width="15.6%">
<col width="16.3%"></colgroup>
<thead>
<tr>
<td align="center" colspan="2" valign="top"></td>
<td align="center" colspan="3" valign="top">Study 028<br>
Considered Drug-Related and of Moderate or Severe Intensity</td>
<td align="center" colspan="2" valign="top">Study ACTG 320<br>
of Unknown Drug Relationship and of Severe or Life-threatening
Intensity</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top"></td>
<td align="center" valign="top">CRIXIVAN<br></td>
<td align="center" valign="top">CRIXIVAN<br>
plus<br>
Zidovudine<br></td>
<td align="center" valign="top">Zidovudine<br></td>
<td align="center" valign="top">CRIXIVAN plus<br>
Zidovudine plus Lamivudine<br></td>
<td align="center" valign="top">Zidovudine<br>
plus<br>
Lamivudine<br></td>
</tr>
<tr>
<td align="center" colspan="2" valign="top">Adverse Experience</td>
<td align="center" valign="top">Percent<br>
(n=332)</td>
<td align="center" valign="top">Percent<br>
(n=332)</td>
<td align="center" valign="top">Percent<br>
(n=332)</td>
<td align="center" valign="top">Percent<br>
(n=571)</td>
<td align="center" valign="top">Percent<br>
(n=575)</td>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="7">
<dl class="Footnote">
<dt><a href="#footnote-reference-18" name="footnote-18" id=
"footnote-18">*</a></dt>
<dd>Including renal colic, and flank pain with and without
hematuria</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody>
<tr>
<td align="left" colspan="7" valign="top"><span class=
"Italics">Body as a Whole</span></td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Abdominal pain</td>
<td align="center" valign="top">16.6</td>
<td align="center" valign="top">16.0</td>
<td align="center" valign="top">12.0</td>
<td align="center" valign="top">1.9</td>
<td align="center" valign="top">0.7</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Asthenia/fatigue</td>
<td align="center" valign="top">2.1</td>
<td align="center" valign="top">4.2</td>
<td align="center" valign="top">3.6</td>
<td align="center" valign="top">2.4</td>
<td align="center" valign="top">4.5</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Fever</td>
<td align="center" valign="top">1.5</td>
<td align="center" valign="top">1.5</td>
<td align="center" valign="top">2.1</td>
<td align="center" valign="top">3.8</td>
<td align="center" valign="top">3.0</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Malaise</td>
<td align="center" valign="top">2.1</td>
<td align="center" valign="top">2.7</td>
<td align="center" valign="top">1.8</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" colspan="7" valign="top"><span class=
"Italics">Digestive System</span></td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Nausea</td>
<td align="center" valign="top">11.7</td>
<td align="center" valign="top">31.9</td>
<td align="center" valign="top">19.6</td>
<td align="center" valign="top">2.8</td>
<td align="center" valign="top">1.4</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Diarrhea</td>
<td align="center" valign="top">3.3</td>
<td align="center" valign="top">3.0</td>
<td align="center" valign="top">2.4</td>
<td align="center" valign="top">0.9</td>
<td align="center" valign="top">1.2</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Vomiting</td>
<td align="center" valign="top">8.4</td>
<td align="center" valign="top">17.8</td>
<td align="center" valign="top">9.0</td>
<td align="center" valign="top">1.4</td>
<td align="center" valign="top">1.4</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Acid regurgitation</td>
<td align="center" valign="top">2.7</td>
<td align="center" valign="top">5.4</td>
<td align="center" valign="top">1.8</td>
<td align="center" valign="top">0.4</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Anorexia</td>
<td align="center" valign="top">2.7</td>
<td align="center" valign="top">5.4</td>
<td align="center" valign="top">3.0</td>
<td align="center" valign="top">0.5</td>
<td align="center" valign="top">0.2</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Appetite increase</td>
<td align="center" valign="top">2.1</td>
<td align="center" valign="top">1.5</td>
<td align="center" valign="top">1.2</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Dyspepsia</td>
<td align="center" valign="top">1.5</td>
<td align="center" valign="top">2.7</td>
<td align="center" valign="top">0.9</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Jaundice</td>
<td align="center" valign="top">1.5</td>
<td align="center" valign="top">2.1</td>
<td align="center" valign="top">0.3</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" colspan="7" valign="top"><span class=
"Italics">Hemic and Lymphatic System</span></td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Anemia</td>
<td align="center" valign="top">0.6</td>
<td align="center" valign="top">1.2</td>
<td align="center" valign="top">2.1</td>
<td align="center" valign="top">2.4</td>
<td align="center" valign="top">3.5</td>
</tr>
<tr>
<td align="left" colspan="7" valign="top"><span class=
"Italics">Musculoskeletal System</span></td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Back pain</td>
<td align="center" valign="top">8.4</td>
<td align="center" valign="top">4.5</td>
<td align="center" valign="top">1.5</td>
<td align="center" valign="top">0.9</td>
<td align="center" valign="top">0.7</td>
</tr>
<tr>
<td align="left" colspan="7" valign="top"><span class=
"Italics">Nervous System/Psychiatric</span></td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Headache</td>
<td align="center" valign="top">5.4</td>
<td align="center" valign="top">9.6</td>
<td align="center" valign="top">6.0</td>
<td align="center" valign="top">2.4</td>
<td align="center" valign="top">2.8</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Dizziness</td>
<td align="center" valign="top">3.0</td>
<td align="center" valign="top">3.9</td>
<td align="center" valign="top">0.9</td>
<td align="center" valign="top">0.5</td>
<td align="center" valign="top">0.7</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Somnolence</td>
<td align="center" valign="top">2.4</td>
<td align="center" valign="top">3.3</td>
<td align="center" valign="top">3.3</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" colspan="7" valign="top"><span class=
"Italics">Skin and Skin Appendage</span></td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Pruritus</td>
<td align="center" valign="top">4.2</td>
<td align="center" valign="top">2.4</td>
<td align="center" valign="top">1.8</td>
<td align="center" valign="top">0.5</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Rash</td>
<td align="center" valign="top">1.2</td>
<td align="center" valign="top">0.6</td>
<td align="center" valign="top">2.4</td>
<td align="center" valign="top">1.1</td>
<td align="center" valign="top">0.5</td>
</tr>
<tr>
<td align="left" colspan="7" valign="top"><span class=
"Italics">Respiratory System</span></td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Cough</td>
<td align="center" valign="top">1.5</td>
<td align="center" valign="top">0.3</td>
<td align="center" valign="top">0.6</td>
<td align="center" valign="top">1.6</td>
<td align="center" valign="top">1.0</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Difficulty breathing/<br>
dyspnea/<br>
shortness of breath</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">0.6</td>
<td align="center" valign="top">0.3</td>
<td align="center" valign="top">1.8</td>
<td align="center" valign="top">1.0</td>
</tr>
<tr>
<td align="left" colspan="7" valign="top"><span class=
"Italics">Urogenital System</span></td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">
Nephrolithiasis/urolithiasis<a class="Sup" href="#footnote-18"
name="footnote-reference-18" id="footnote-reference-18">*</a></td>
<td align="center" valign="top">8.7</td>
<td align="center" valign="top">7.8</td>
<td align="center" valign="top">2.1</td>
<td align="center" valign="top">2.6</td>
<td align="center" valign="top">0.3</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Dysuria</td>
<td align="center" valign="top">1.5</td>
<td align="center" valign="top">2.4</td>
<td align="center" valign="top">0.3</td>
<td align="center" valign="top">0.4</td>
<td align="center" valign="top">0.2</td>
</tr>
<tr>
<td align="left" colspan="7" valign="top"><span class=
"Italics">Special Senses</span></td>
</tr>
<tr>
<td class="Botrule" align="left" colspan="2" valign="top">Taste
perversion</td>
<td class="Botrule" align="center" valign="top">2.7</td>
<td class="Botrule" align="center" valign="top">8.4</td>
<td class="Botrule" align="center" valign="top">1.2</td>
<td class="Botrule" align="center" valign="top">0.2</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
</tbody>
</table>
</div>
<p>In Phase I and II controlled trials, the following adverse
events were reported significantly more frequently by those
randomized to the arms containing CRIXIVAN than by those randomized
to nucleoside analogues: rash, upper respiratory infection, dry
skin, pharyngitis, taste perversion.</p>
<p>Selected laboratory abnormalities of severe or life-threatening
intensity reported in patients treated with CRIXIVAN alone,
CRIXIVAN in combination with zidovudine or zidovudine plus
lamivudine, zidovudine alone, or zidovudine plus lamivudine are
presented in <a href=
"#id_f3e9989c-9dab-4242-a880-73ce9577b3c9">Table 11</a>.</p>
<a name="id_f3e9989c-9dab-4242-a880-73ce9577b3c9" id=
"id_f3e9989c-9dab-4242-a880-73ce9577b3c9"></a>
<div class="scrollingtable">
<table class="Noautorules" width="686.000">
<caption><span>Table 11: Selected Laboratory Abnormalities of
Severe or Life-threatening Intensity Reported in Studies 028 and
ACTG 320</span></caption>
<colgroup>
<col width="31.2%">
<col align="center" width="11.2%">
<col align="center" width="11.2%">
<col align="center" width="12.8%">
<col align="center" width="16.8%">
<col align="center" width="16.8%"></colgroup>
<thead>
<tr>
<td align="left" valign="top"></td>
<td align="center" colspan="3" valign="top">Study 028</td>
<td align="center" colspan="2" valign="top">Study ACTG 320</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" valign="top">CRIXIVAN</td>
<td align="center" valign="top">CRIXIVAN<br>
plus<br>
Zidovudine</td>
<td align="center" valign="top">Zidovudine</td>
<td align="center" valign="top">CRIXIVAN plus<br>
Zidovudine<br>
plus<br>
Lamivudine</td>
<td align="center" valign="top">Zidovudine<br>
plus<br>
Lamivudine</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" valign="top">Percent<br>
(n=329)</td>
<td align="center" valign="top">Percent<br>
(n=320)</td>
<td align="center" valign="top">Percent<br>
(n=330)</td>
<td align="center" valign="top">Percent<br>
(n=571)</td>
<td align="center" valign="top">Percent<br>
(n=575)</td>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="6">
<dl class="Footnote">
<dt><a href="#footnote-reference-19" name="footnote-19" id=
"footnote-19">*</a></dt>
<dd>Upper limit of the normal range.</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody>
<tr>
<td align="left" valign="top"><span class=
"Italics">Hematology</span></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Decreased hemoglobin<br>
&lt;7.0 g/dL</td>
<td align="center" valign="top">0.6</td>
<td align="center" valign="top">0.9</td>
<td align="center" valign="top">3.3</td>
<td align="center" valign="top">2.4</td>
<td align="center" valign="top">3.5</td>
</tr>
<tr>
<td align="left" valign="top">Decreased platelet count<br>
&lt;50 THS/mm<span class="Sup">3</span></td>
<td align="center" valign="top">0.9</td>
<td align="center" valign="top">0.9</td>
<td align="center" valign="top">1.8</td>
<td align="center" valign="top">0.2</td>
<td align="center" valign="top">0.9</td>
</tr>
<tr>
<td align="left" valign="top">Decreased neutrophils<br>
&lt;0.75 THS/mm<span class="Sup">3</span></td>
<td align="center" valign="top">2.4</td>
<td align="center" valign="top">2.2</td>
<td align="center" valign="top">6.7</td>
<td align="center" valign="top">5.1</td>
<td align="center" valign="top">14.6</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Blood
chemistry</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Increased ALT<br>
&gt;500% ULN<a class="Sup" href="#footnote-19" name=
"footnote-reference-19" id="footnote-reference-19">*</a></td>
<td align="center" valign="top">4.9</td>
<td align="center" valign="top">4.1</td>
<td align="center" valign="top">3.0</td>
<td align="center" valign="top">2.6</td>
<td align="center" valign="top">2.6</td>
</tr>
<tr>
<td align="left" valign="top">Increased AST<br>
&gt;500% ULN</td>
<td align="center" valign="top">3.7</td>
<td align="center" valign="top">2.8</td>
<td align="center" valign="top">2.7</td>
<td align="center" valign="top">3.3</td>
<td align="center" valign="top">2.8</td>
</tr>
<tr>
<td align="left" valign="top">Total serum bilirubin<br>
&gt;250% ULN</td>
<td align="center" valign="top">11.9</td>
<td align="center" valign="top">9.7</td>
<td align="center" valign="top">0.6</td>
<td align="center" valign="top">6.1</td>
<td align="center" valign="top">1.4</td>
</tr>
<tr>
<td align="left" valign="top">Increased serum amylase<br>
&gt;200% ULN</td>
<td align="center" valign="top">2.1</td>
<td align="center" valign="top">1.9</td>
<td align="center" valign="top">1.8</td>
<td align="center" valign="top">0.9</td>
<td align="center" valign="top">0.3</td>
</tr>
<tr>
<td align="left" valign="top">Increased glucose<br>
&gt;250 mg/dL</td>
<td align="center" valign="top">0.9</td>
<td align="center" valign="top">0.9</td>
<td align="center" valign="top">0.6</td>
<td align="center" valign="top">1.6</td>
<td align="center" valign="top">1.9</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Increased
creatinine<br>
&gt;300% ULN</td>
<td class="Botrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">0.6</td>
<td class="Botrule" align="center" valign="top">0.2</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_d541bb5c-75ef-40e0-941b-dee9113307e4" id=
"i4i_section_id_d541bb5c-75ef-40e0-941b-dee9113307e4"></a> <a name=
"section-8.2" id="section-8.2"></a>
<h2>Post-Marketing Experience</h2>
<p class="First"><span class="Italics">Body As A Whole:</span>
redistribution/accumulation of body fat (see <a href=
"#i4i_section_id_076ab369-986f-4e55-9a9f-c8bf2887ad6d">PRECAUTIONS,
Fat Redistribution</a>).</p>
<p><span class="Italics">Cardiovascular System:</span>
cardiovascular disorders including myocardial infarction and angina
pectoris; cerebrovascular disorder.</p>
<p><span class="Italics">Digestive System:</span> liver function
abnormalities; hepatitis including reports of hepatic failure (see
<a href=
"#i4i_warnings_id_d7b709bb-7551-4a58-a56e-836a0bef4b58">WARNINGS</a>);
pancreatitis; jaundice; abdominal distention; dyspepsia.</p>
<p><span class="Italics">Hematologic:</span> increased spontaneous
bleeding in patients with hemophilia (see <a href=
"#i4i_precautions_id_2622dd5b-549b-40eb-9624-106a1482dcc0">PRECAUTIONS</a>);
acute hemolytic anemia (see <a href=
"#i4i_warnings_id_d7b709bb-7551-4a58-a56e-836a0bef4b58">WARNINGS</a>).</p>
<p><span class="Italics">Endocrine/Metabolic:</span> new onset
diabetes mellitus, exacerbation of pre-existing diabetes mellitus,
hyperglycemia (see <a href=
"#i4i_warnings_id_d7b709bb-7551-4a58-a56e-836a0bef4b58">WARNINGS</a>).</p>
<p><span class="Italics">Hypersensitivity:</span> anaphylactoid
reactions; urticaria; vasculitis.</p>
<p><span class="Italics">Musculoskeletal System:</span> arthralgia,
periarthritis.</p>
<p><span class="Italics">Nervous System/Psychiatric:</span> oral
paresthesia; depression.</p>
<p><span class="Italics">Skin and Skin Appendage:</span> rash
including erythema multiforme and Stevens-Johnson syndrome;
hyperpigmentation; alopecia; ingrown toenails and/or paronychia;
pruritus.</p>
<p><span class="Italics">Urogenital System:</span>
nephrolithiasis/urolithiasis, in some cases resulting in renal
insufficiency or acute renal failure, pyelonephritis with or
without bacteremia (see <a href=
"#i4i_warnings_id_d7b709bb-7551-4a58-a56e-836a0bef4b58">WARNINGS</a>);
interstitial nephritis sometimes with indinavir crystal deposits;
in some patients, the interstitial nephritis did not resolve
following discontinuation of CRIXIVAN; renal insufficiency; renal
failure; leukocyturia (see <a href=
"#i4i_precautions_id_2622dd5b-549b-40eb-9624-106a1482dcc0">PRECAUTIONS</a>),
crystalluria; dysuria.</p>
</div>
<div class="Section" data-sectioncode="34075-2"><a name=
"i4i_lab_tests_id_dabe3277-045d-4f96-aef7-cb2434acb86d" id=
"i4i_lab_tests_id_dabe3277-045d-4f96-aef7-cb2434acb86d"></a>
<a name="section-8.3" id="section-8.3"></a>
<h2>Laboratory Abnormalities</h2>
<p class="First">Increased serum triglycerides; increased serum
cholesterol.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">OVERDOSAGE</a>
<div class="Section toggle-content closed" data-sectioncode=
"34088-5"><a name=
"i4i_overdosage_id_cba8c84c-b3be-4508-8339-fa071df6dbc1" id=
"i4i_overdosage_id_cba8c84c-b3be-4508-8339-fa071df6dbc1"></a>
<a name="section-9" id="section-9"></a>
<p class="First">There have been more than 60 reports of acute or
chronic human overdosage (up to 23 times the recommended total
daily dose of 2400 mg) with CRIXIVAN. The most commonly reported
symptoms were renal (e.g., nephrolithiasis/urolithiasis, flank
pain, hematuria) and gastrointestinal (e.g., nausea, vomiting,
diarrhea).</p>
<p>It is not known whether CRIXIVAN is dialyzable by peritoneal or
hemodialysis.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">DOSAGE AND ADMINISTRATION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34068-7"><a name=
"i4i_dosage_admin_id_616e9e55-2879-4bca-ae8b-4d833f00d938" id=
"i4i_dosage_admin_id_616e9e55-2879-4bca-ae8b-4d833f00d938"></a>
<a name="section-10" id="section-10"></a>
<p class="First">The recommended dosage of CRIXIVAN is 800 mg
(usually <span class="Bold"><span class=
"Emphasis">two</span></span> 400-mg capsules) orally every 8
hours.</p>
<p>CRIXIVAN must be taken at intervals of 8 hours. For optimal
absorption, CRIXIVAN should be administered without food but with
water 1 hour before or 2 hours after a meal. Alternatively,
CRIXIVAN may be administered with other liquids such as skim milk,
juice, coffee, or tea, or with a light meal, e.g., dry toast with
jelly, juice, and coffee with skim milk and sugar; or corn flakes,
skim milk and sugar. (See <a href=
"#i4i_section_id_59d110fd-2d4f-4a1f-8bca-252a08546749">CLINICAL
PHARMACOLOGY, Effect of Food on Oral Absorption</a>.)</p>
<p>To ensure adequate hydration, it is recommended that adults
drink at least 1.5 liters (approximately 48 ounces) of liquids
during the course of 24 hours.</p>
<div class="Section" data-sectioncode="34073-7"><a name=
"i4i_interactions_id_2255923e-9207-4283-80e6-d316dc3d9e3c" id=
"i4i_interactions_id_2255923e-9207-4283-80e6-d316dc3d9e3c"></a>
<a name="section-10.1" id="section-10.1"></a>
<h2>Concomitant Therapy</h2>
<p class="First">(See <a href=
"#i4i_interactions_id_d2bf28f1-de8a-42e5-8f0d-5511455a45a6">CLINICAL
PHARMACOLOGY, Drug Interactions</a>, and/or <a href=
"#PRE_DI">PRECAUTIONS, Drug Interactions</a>.)</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_167b8246-5532-4d98-83f5-e9e9051cecd4" id=
"i4i_section_id_167b8246-5532-4d98-83f5-e9e9051cecd4"></a> <a name=
"section-10.1.1" id="section-10.1.1"></a>
<h3>Delavirdine</h3>
<p class="First">Dose reduction of CRIXIVAN to 600 mg every 8 hours
should be considered when administering delavirdine 400 mg three
times a day.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_41ea03ea-71c2-4500-9e99-f6765a8aa9d7" id=
"i4i_section_id_41ea03ea-71c2-4500-9e99-f6765a8aa9d7"></a> <a name=
"section-10.1.2" id="section-10.1.2"></a>
<h3>Didanosine</h3>
<p class="First">If indinavir and didanosine are administered
concomitantly, they should be administered at least one hour apart
on an empty stomach (consult the manufacturer's product circular
for didanosine).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_56f56232-bd1b-45dd-b0ec-89e3da1c81fc" id=
"i4i_section_id_56f56232-bd1b-45dd-b0ec-89e3da1c81fc"></a> <a name=
"section-10.1.3" id="section-10.1.3"></a>
<h3>Itraconazole</h3>
<p class="First">Dose reduction of CRIXIVAN to 600 mg every 8 hours
is recommended when administering itraconazole 200 mg twice daily
concurrently.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_7d15234c-ab0a-4121-91e3-e577975c5d4a" id=
"i4i_section_id_7d15234c-ab0a-4121-91e3-e577975c5d4a"></a> <a name=
"section-10.1.4" id="section-10.1.4"></a>
<h3>Ketoconazole</h3>
<p class="First">Dose reduction of CRIXIVAN to 600 mg every 8 hours
is recommended when administering ketoconazole concurrently.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_558037d8-a32d-4bf5-9cf3-9b91c5d812f8" id=
"i4i_section_id_558037d8-a32d-4bf5-9cf3-9b91c5d812f8"></a> <a name=
"section-10.1.5" id="section-10.1.5"></a>
<h3>Rifabutin</h3>
<p class="First">Dose reduction of rifabutin to half the standard
dose (consult the manufacturer's product circular for rifabutin)
and a dose increase of CRIXIVAN to 1000 mg every 8 hours are
recommended when rifabutin and CRIXIVAN are coadministered.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_3ac79c87-4364-4c4a-85fe-f7d7e00bccac" id=
"i4i_section_id_3ac79c87-4364-4c4a-85fe-f7d7e00bccac"></a> <a name=
"section-10.2" id="section-10.2"></a>
<h2>Hepatic Insufficiency</h2>
<p class="First">The dosage of CRIXIVAN should be reduced to 600 mg
every 8 hours in patients with mild-to-moderate hepatic
insufficiency due to cirrhosis.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_964d576f-de04-4baf-b06e-f3a596212da6" id=
"i4i_section_id_964d576f-de04-4baf-b06e-f3a596212da6"></a> <a name=
"section-10.3" id="section-10.3"></a>
<h2>Nephrolithiasis/Urolithiasis</h2>
<p class="First">In addition to adequate hydration, medical
management in patients who experience nephrolithiasis/urolithiasis
may include temporary interruption (e.g., 1 to 3 days) or
discontinuation of therapy.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">HOW SUPPLIED</a>
<div class="Section toggle-content closed" data-sectioncode=
"34069-5"><a name=
"i4i_how_supplied_id_656a5b57-9f9c-41ff-9f64-d132c09ba941" id=
"i4i_how_supplied_id_656a5b57-9f9c-41ff-9f64-d132c09ba941"></a>
<a name="section-11" id="section-11"></a>
<p class="First">CRIXIVAN Capsules are supplied as follows:</p>
<p>No. 3756 — 200 mg capsules: semi-translucent white capsules
coded <span class="Bold"><span class="Emphasis">"CRIXIVAN™ 200
mg"</span></span> in blue. Available as:</p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span>
0006-0571-43 unit-of-use bottles of 360 (with desiccant).</p>
<p>No. 3758 — 400 mg capsules: semi-translucent white capsules
coded <span class="Bold"><span class="Emphasis">"CRIXIVAN™ 400
mg"</span></span> in green. Available as:</p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span>
0006-0573-62 unit-of-use bottles of 180 (with desiccant)</p>
<div class="Section" data-sectioncode="44425-7"><a name=
"i4i_storage_id_4492b50d-d489-4bd6-bbd0-74338424b9aa" id=
"i4i_storage_id_4492b50d-d489-4bd6-bbd0-74338424b9aa"></a> <a name=
"section-11.1" id="section-11.1"></a>
<h2>Storage</h2>
<p class="First"><span class="Italics">Bottles:</span> Store in a
tightly-closed container at room temperature, 15-30°C (59-86°F).
Protect from moisture.</p>
<p>CRIXIVAN Capsules are sensitive to moisture. CRIXIVAN should be
dispensed and stored in the original container. The desiccant
should remain in the original bottle.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">SPL UNCLASSIFIED SECTION</a>
<div class="Section toggle-content closed" data-sectioncode=
"42229-5"><a name="section-12" id="section-12"></a>
<p class="First">Dist. by: Merck Sharp &amp; Dohme Corp., a
subsidiary of<br>
<span class="Bold">MERCK &amp; CO., INC.,</span> Whitehouse
Station, NJ 08889, USA</p>
<p>For patent information:
www.merck.com/product/patent/home.html</p>
<p>Copyright © 1996, 1997, 1998, 1999, 2004 Merck Sharp &amp; Dohme
Corp., a subsidiary of <span class="Bold">Merck &amp; Co.,
Inc.</span><br>
All rights reserved.</p>
<p>Revised 03/2015</p>
<p>uspi-mk0639-c-1503r017</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PATIENT PACKAGE INSERT</a>
<div class="Section toggle-content closed" data-sectioncode=
"42230-3"><a name=
"i4i_patient_package_insert_id_ce2f4864-7fae-483b-a0dc-259550756ebf"
id=
"i4i_patient_package_insert_id_ce2f4864-7fae-483b-a0dc-259550756ebf">
</a> <a name="section-13" id="section-13"></a>
<p class="First"><span class="Bold"><span class=
"Emphasis">CRIXIVAN<span class="Sup">®</span> (indinavir sulfate)
Capsules</span></span><br>
Patient Information about<br>
<span class="Bold"><span class="Emphasis">CRIXIVAN
(KRIK-sih-van)</span></span><br>
for HIV (Human Immunodeficiency Virus) Infection<br>
Generic name: indinavir (in-DIH-nuh-veer) sulfate</p>
<p><span class="Bold"><span class="Emphasis">ALERT: Find out about
medicines that should NOT be taken with CRIXIVAN<span class=
"Sup">®</span>.</span></span> Please also read the section
"<a href="#Medicines_You_Should_Not_Take_With_Crixivan">MEDICINES
YOU SHOULD NOT TAKE WITH CRIXIVAN</a>".</p>
<p>Please read this information before you start taking CRIXIVAN.
Also, read the leaflet each time you renew your prescription, just
in case anything has changed. Remember, this leaflet does not take
the place of careful discussions with your doctor. You and your
doctor should discuss CRIXIVAN when you start taking your
medication and at regular checkups. You should remain under a
doctor's care when using CRIXIVAN and should not change or stop
treatment without first talking with your doctor.</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_6528df04-fe63-4e3e-85d0-72632e446e9a" id=
"i4i_section_id_6528df04-fe63-4e3e-85d0-72632e446e9a"></a> <a name=
"section-13.1" id="section-13.1"></a>
<h2><span class="Underline"><span class="Bold"><span class=
"Emphasis">What is CRIXIVAN?</span></span></span></h2>
<p class="First"><span class="Bold"><span class="Emphasis">CRIXIVAN
is an oral capsule used for the treatment of HIV (Human
Immunodeficiency Virus). HIV is the virus that causes AIDS
(acquired immune deficiency syndrome).</span></span> CRIXIVAN is a
type of HIV drug called a protease (PRO-tee-ase) inhibitor.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_5bb0077f-f137-4046-beb1-7bd65aecbba5" id=
"i4i_section_id_5bb0077f-f137-4046-beb1-7bd65aecbba5"></a> <a name=
"section-13.2" id="section-13.2"></a>
<h2><span class="Underline"><span class="Bold"><span class=
"Emphasis">How does CRIXIVAN work?</span></span></span></h2>
<p class="First">CRIXIVAN is a protease inhibitor that fights HIV.
CRIXIVAN can help reduce your chances of getting illnesses
associated with HIV. CRIXIVAN can also help lower the amount of HIV
in your body (called "viral load") and raise your CD4 (T) cell
count. CRIXIVAN may not have these effects in all patients.</p>
<p>CRIXIVAN is usually prescribed with other anti-HIV drugs such as
ZDV (also called AZT), 3TC, ddI, ddC, or d4T. CRIXIVAN works
differently from these other anti-HIV drugs. Talk with your doctor
about how you should take CRIXIVAN.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_fcbcc5b2-9a2d-4826-88c6-df5d346057c8" id=
"i4i_section_id_fcbcc5b2-9a2d-4826-88c6-df5d346057c8"></a> <a name=
"section-13.3" id="section-13.3"></a>
<h2><span class="Underline"><span class="Bold"><span class=
"Emphasis">How should I take CRIXIVAN?</span></span></span></h2>
<p class="First">There are six important things you must do to help
you benefit from CRIXIVAN:<br>
<br></p>
<ol>
<li><span class="Bold"><span class="Emphasis">Take CRIXIVAN
capsules every day as prescribed by your doctor.</span></span>
Continue taking CRIXIVAN unless your doctor tells you to stop. Take
the exact amount of CRIXIVAN that your doctor tells you to take,
right from the very start. To help make sure you will benefit from
CRIXIVAN, you must not skip doses or take "drug holidays". If you
don't take CRIXIVAN as prescribed, the activity of CRIXIVAN may be
reduced (due to resistance).<br>
<br></li>
<li><span class="Bold"><span class="Emphasis">Take CRIXIVAN
capsules every 8 hours around the clock, <span class=
"Bold"><span class="Italics"><span class="Emphasis">every
day</span></span></span>.</span></span> It may be easier to
remember to take CRIXIVAN if you take it at the same time every
day. If you have questions about when to take CRIXIVAN, your doctor
or health care provider can help you decide what schedule works for
you.<br>
<br></li>
<li><span class="Bold"><span class="Emphasis">If you miss a dose by
more than 2 hours, wait and then take the next dose at the
regularly scheduled time.</span></span> However, if you miss a dose
by less than 2 hours, take your missed dose immediately. Then take
your next dose at the regularly scheduled time. Do not take more or
less than your prescribed dose of CRIXIVAN at any one time.<br>
<br></li>
<li><span class="Bold"><span class="Emphasis">Take CRIXIVAN with
water.</span></span> You can also take CRIXIVAN with other
beverages such as <span class="Underline">skim</span> or
<span class="Underline">non-fat</span> milk, juice, coffee, or
tea.<br>
<br></li>
<li><span class="Bold"><span class="Emphasis">Ideally, take each
dose of CRIXIVAN without food but with water at least one hour
before or two hours after a meal.</span></span> Or you can take
CRIXIVAN with a <span class="Underline">light</span> meal. Examples
of light meals include:<br>
dry toast with jelly, juice, and coffee (with <span class=
"Underline">skim</span> or <span class="Underline">non-fat</span>
milk and sugar if you want)<br>
cornflakes with <span class="Underline">skim</span> or <span class=
"Underline">non-fat</span> milk and sugar<br>
Do not take CRIXIVAN at the same time as any meals that are high in
calories, fat, and protein (for example — a bacon and egg
breakfast). When taken at the same time as CRIXIVAN, these foods
can interfere with CRIXIVAN being absorbed into your bloodstream
and may lessen its effect.<br>
<br></li>
<li><span class="Bold"><span class="Emphasis">It is critical to
drink plenty of fluids while taking CRIXIVAN.</span></span> Adults
should drink at least six 8-ounce glasses of liquids (preferably
water) throughout the day, every day. Your health care provider
will give you further instructions on the amount of fluid that you
should drink. <span class="Bold"><span class="Emphasis">CRIXIVAN
can cause kidney stones.</span></span> Having enough fluids in your
body should help reduce the chances of forming a kidney stone. Call
your doctor or other health care provider if you develop kidney
pains (middle to lower stomach or back pain) or blood in the
urine.</li>
</ol>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_417aadf2-2945-456a-9668-0f56fa5e2d64" id=
"i4i_section_id_417aadf2-2945-456a-9668-0f56fa5e2d64"></a> <a name=
"section-13.4" id="section-13.4"></a>
<h2><span class="Underline"><span class="Bold"><span class=
"Emphasis">Does CRIXIVAN cure HIV or
AIDS?</span></span></span></h2>
<p class="First">CRIXIVAN does not cure HIV infection or AIDS and
you may continue to experience illnesses associated with HIV-1
infection, including opportunistic infections. You should remain
under the care of a doctor when using CRIXIVAN.</p>
<p>Avoid doing things that can spread HIV-1 infection.</p>
<ul>
<li><span class="Bold">Do not share needles or other injection
equipment.</span></li>
<li><span class="Bold">Do not share personal items that can have
blood or body fluids on them, like toothbrushes and razor
blades.</span></li>
<li><span class="Bold">Do not have any kind of sex without
protection.</span> Always practice safe sex by using a latex or
polyurethane condom to lower the chance of sexual contact with
semen, vaginal secretions, or blood.</li>
</ul>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_be0f5a6b-68ad-40e1-bda8-fa34f26c3a01" id=
"i4i_section_id_be0f5a6b-68ad-40e1-bda8-fa34f26c3a01"></a> <a name=
"section-13.5" id="section-13.5"></a>
<h2><span class="Underline"><span class="Bold"><span class=
"Emphasis">Who should not take CRIXIVAN?</span></span></span></h2>
<p class="First">Do not take CRIXIVAN if you have had a serious
allergic reaction to CRIXIVAN or any of its components.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_420e3d45-d563-4043-af10-6cfa996c21bc" id=
"i4i_section_id_420e3d45-d563-4043-af10-6cfa996c21bc"></a> <a name=
"section-13.6" id="section-13.6"></a>
<h2><span class="Underline"><span class="Bold"><span class=
"Emphasis">What other medical problems or conditions should I
discuss with my doctor?</span></span></span></h2>
<p class="First">Talk to your doctor if:</p>
<ul>
<li>You are pregnant or if you become pregnant while you are taking
CRIXIVAN. We do not yet know how CRIXIVAN affects pregnant women or
their developing babies.</li>
<li>You are breastfeeding. <span class="Bold">Do not
breastfeed.</span> We do not know if CRIXIVAN can be passed to your
baby in your breast milk and whether it could harm your baby. Also,
mothers with HIV-1 should not breastfeed because HIV-1 can be
passed to the baby in the breast milk.</li>
</ul>
<p>Also talk to your doctor if you have:</p>
<ul>
<li>Problems with your liver, especially if you have mild or
moderate liver disease caused by cirrhosis</li>
<li>Problems with your kidneys</li>
<li>Diabetes</li>
<li>Hemophilia</li>
<li>High cholesterol and you are taking cholesterol-lowering
medicines called "statins"</li>
</ul>
<p>Tell your doctor about any medicines you are taking or plan to
take, including non-prescription medicines, herbal products
including St. John's wort (<span class="Italics">Hypericum
perforatum</span>), or dietary supplements.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_5ee48f97-b8db-4f3b-937b-effa3d9f93d0" id=
"i4i_section_id_5ee48f97-b8db-4f3b-937b-effa3d9f93d0"></a> <a name=
"section-13.7" id="section-13.7"></a>
<p class="First"><span class="Underline"><span class="Bold">Can
CRIXIVAN be taken with other medications?</span></span></p>
<p><a name="Medicines_You_Should_Not_Take_With_Crixivan" id=
"Medicines_You_Should_Not_Take_With_Crixivan"></a><span class=
"Bold"><span class="Emphasis">MEDICINES YOU SHOULD NOT TAKE WITH
CRIXIVAN</span></span></p>
<a name="id_54736675-f030-4b71-84c3-6bd7076def42" id=
"id_54736675-f030-4b71-84c3-6bd7076def42"></a>
<div class="scrollingtable">
<table width="430.000">
<colgroup>
<col width="39.5%">
<col width="60.5%"></colgroup>
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top">Oral VERSED<span class=
"Sup">®</span><br>
(midazolam)</td>
<td align="left" valign="top">HALCION<span class="Sup">®</span><br>
(triazolam)</td>
</tr>
<tr>
<td align="left" valign="top">ORAP<span class="Sup">®</span><br>
(pimozide)</td>
<td align="left" valign="top">XANAX<span class="Sup">®</span><br>
(alprazolam)</td>
</tr>
<tr>
<td align="left" valign="top">PROPULSID<span class=
"Sup">®</span><br>
(cisapride)</td>
<td align="left" valign="top">REVATIO<span class="Sup">®</span><br>
(sildenafil for the treatment of pulmonary arterial
hypertension)</td>
</tr>
<tr>
<td align="left" valign="top">CORDARONE<span class=
"Sup">®</span><br>
(amiodarone)</td>
<td align="left" valign="top">UROXATRAL<span class=
"Sup">®</span><br>
(alfuzosin)</td>
</tr>
<tr>
<td align="left" valign="top">HISMANAL<span class=
"Sup">®</span><br>
(astemizole)</td>
<td align="left" valign="top">Ergot medications<br>
(e.g., Wigraine<span class="Sup">®</span>, Cafergot<span class=
"Sup">®</span>, D.H.E. 45<span class="Sup">®</span>,
Migranal<span class="Sup">®</span>, Ergotrate<span class=
"Sup">®</span>, and Methergine<span class="Sup">®</span>)</td>
</tr>
<tr class="Botrule Last">
<td></td>
<td>ZOCOR<span class="Sup">®</span> (simvastatin)<br>
MEVACOR<span class="Sup">®</span> (lovastatin)</td>
</tr>
</tbody>
</table>
</div>
<p>Taking CRIXIVAN with the above medications could result in
<span class="Underline">serious or life-threatening</span> problems
(such as irregular heartbeat or excessive sleepiness).</p>
<p>In addition, you should not take CRIXIVAN with the
following:<br>
<br></p>
<dl>
<dd>Rifampin, known as RIFADIN <span class="Sup">®</span>, RIFAMATE
<span class="Sup">®</span>, RIFATER <span class="Sup">®</span>, or
RIMACTANE <span class="Sup">®</span>.<br>
<br></dd>
<dd>There is also an increased risk of drug interactions between
CRIXIVAN and LIPITOR <span class="Sup">®</span> (atorvastatin) and
CRESTOR <span class="Sup">®</span> (rosuvastatin); talk to your
doctor before you take any of these cholesterol-reducing drugs with
CRIXIVAN.<br>
<br></dd>
<dd>Taking CRIXIVAN with REYATAZ <span class="Sup">®</span>
(atazanavir) is not recommended because they can both sometimes
cause increased levels of bilirubin in the blood.<br>
<br></dd>
<dd>Taking CRIXIVAN with St. John's wort ( <span class=
"Italics">Hypericum perforatum</span>), an herbal product sold as a
dietary supplement, or products containing St. John's wort is not
recommended. Taking St. John's wort has been shown to decrease
CRIXIVAN levels and may lead to increased viral load and possible
resistance to CRIXIVAN or cross resistance to other antiretroviral
drugs.<br></dd>
</dl>
<p>Before you take VIAGRA<span class="Sup">®</span> (sildenafil),
CIALIS<span class="Sup">®</span> (tadalafil), or
LEVITRA<span class="Sup">®</span> (vardenafil) with CRIXIVAN, talk
to your doctor about possible drug interactions and side effects.
If you take any of these medicines together with CRIXIVAN, you may
be at increased risk of side effects such as low blood pressure,
visual changes, and penile erection lasting more than 4 hours,
which have been associated with sildenafil, tadalafil, and
vardenafil. If an erection lasts longer than 4 hours, you should
seek immediate medical assistance to avoid permanent damage to your
penis. Your doctor can explain these symptoms to you.</p>
<p><span class="Bold"><span class="Emphasis">MEDICINES YOU CAN TAKE
WITH CRIXIVAN</span></span></p>
<a name="id_f82aeb31-9650-4c5b-805f-d5672e433bf2" id=
"id_f82aeb31-9650-4c5b-805f-d5672e433bf2"></a>
<div class="scrollingtable">
<table width="636.000">
<colgroup>
<col width="50.0%">
<col width="50.0%"></colgroup>
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top">RETROVIR®<br>
(zidovudine, ZDV also called AZT)<br>
<br></td>
<td align="left" valign="top">EPIVIR™<br>
(lamivudine, 3TC)</td>
</tr>
<tr>
<td align="left" valign="top">ZERIT<span class="Sup">®</span><br>
(stavudine, d4T)<br>
<br></td>
<td align="left" valign="top">isoniazid<br>
(INH)</td>
</tr>
<tr>
<td align="left" valign="top">BACTRIM<span class=
"Sup">®</span>/SEPTRA<span class="Sup">®</span><br>
(trimethoprim/sulfamethoxazole)<br>
<br></td>
<td align="left" valign="top">DIFLUCAN<span class=
"Sup">®</span><br>
(fluconazole)</td>
</tr>
<tr>
<td align="left" valign="top">BIAXIN<span class="Sup">®</span><br>
(clarithromycin)<br>
<br></td>
<td align="left" valign="top">ORTHO-NOVUM 1/35<span class=
"Sup">®</span><br>
(oral contraceptive)</td>
</tr>
<tr>
<td align="left" valign="top">TAGAMET<span class="Sup">®</span><br>
(cimetidine)<br>
<br></td>
<td align="left" valign="top">Methadone</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">
<p class="First">VIDEX<span class="Sup">®</span> (didanosine, ddI)
— If you take CRIXIVAN with VIDEX, take them at least one hour
apart.<br>
<br></p>
</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">
<p class="First">MYCOBUTIN<span class="Sup">®</span> (rifabutin) —
If you take CRIXIVAN with MYCOBUTIN, your doctor may adjust both
the dose of MYCOBUTIN and the dose of CRIXIVAN.<br>
<br></p>
</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">
<p class="First">NIZORAL<span class="Sup">®</span> (ketoconazole) —
If you take CRIXIVAN with NIZORAL, your doctor may adjust the dose
of CRIXIVAN.<br>
<br></p>
</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">
<p class="First">RESCRIPTOR<span class="Sup">®</span> (delavirdine)
— If you take CRIXIVAN with RESCRIPTOR, your doctor may adjust the
dose of CRIXIVAN.<br>
<br></p>
</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">
<p class="First">SPORANOX<span class="Sup">®</span> (itraconazole)
— If you take CRIXIVAN with SPORANOX, your doctor may adjust the
dose of CRIXIVAN.<br>
<br></p>
</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">
<p class="First">SUSTIVA™ (efavirenz) — If you take CRIXIVAN with
SUSTIVA, check with your doctor.<br>
<br></p>
</td>
</tr>
<tr class="Botrule Last">
<td align="left" colspan="2" valign="top">Intravenous
VERSED<span class="Sup">®</span> (midazolam) — If you take CRIXIVAN
with Intravenous VERSED<span class="Sup">®</span>, your doctor may
adjust the dose of VERSED<span class="Sup">®</span>.</td>
</tr>
</tbody>
</table>
</div>
<p><span class="Bold"><span class="Emphasis">Talk to your doctor
about any medications you are taking.</span></span></p>
<p>Antipsychotics: Tell your doctor if you are taking
antipsychotics (e.g., quetiapine).</p>
<p>Calcium Channel Blockers: Tell your doctor if you are taking
calcium channel blockers (e.g., amlodipine, felodipine).</p>
<p>Antiarrhythmics: Tell your doctor if you are taking
antiarrhythmics (e.g., quinidine).</p>
<p>Anticonvulsants: Tell your doctor if you are taking
anticonvulsants (e.g., phenobarbital, phenytoin, or
carbamazepine).</p>
<p>Steroids: Tell your doctor if you are taking steroids (e.g.,
dexamethasone).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_f5f63698-f8f6-47a1-9382-8dd02d230f20" id=
"i4i_section_id_f5f63698-f8f6-47a1-9382-8dd02d230f20"></a> <a name=
"section-13.8" id="section-13.8"></a>
<h2><span class="Underline"><span class="Bold"><span class=
"Emphasis">What are the possible side effects of
CRIXIVAN?</span></span></span></h2>
<p class="First"><span class="Underline">Like all prescription
drugs, CRIXIVAN can cause side effects.</span> The following is
<span class="Bold"><span class="Emphasis">not</span></span> a
complete list of side effects reported with CRIXIVAN when taken
either alone or with other anti-HIV drugs. Do not rely on this
leaflet alone for information about side effects. Your doctor can
discuss with you a more complete list of side effects.</p>
<p><span class="Bold"><span class="Emphasis">Some patients treated
with CRIXIVAN developed kidney stones. In some of these patients
this led to more severe kidney problems, including kidney failure
or inflammation of the kidneys or kidney infection which sometimes
spread to the blood. Drinking at least six 8-ounce glasses of
liquids (preferably water) each day should help reduce the chances
of forming a kidney stone</span></span> <span class=
"Bold"><span class="Emphasis">(</span></span>see <span class=
"Bold"><span class="Emphasis"><a href=
"#i4i_section_id_fcbcc5b2-9a2d-4826-88c6-df5d346057c8">How should I
take CRIXIVAN?</a></span></span><span class="Bold"><span class=
"Emphasis">).</span></span> Call your doctor or other health care
provider if you develop kidney pains (middle to lower stomach or
back pain) or blood in the urine.</p>
<p>Some patients treated with CRIXIVAN have had rapid breakdown of
red blood cells (hemolytic anemia) which in some cases was severe
or resulted in death.</p>
<p>Some patients treated with CRIXIVAN have had liver problems
including liver failure and death. Some patients had other
illnesses or were taking other drugs. It is uncertain if CRIXIVAN
caused these liver problems.</p>
<p>Diabetes and high blood sugar (hyperglycemia) have occurred in
patients taking protease inhibitors. In some of these patients,
this led to ketoacidosis, a serious condition caused by poorly
controlled blood sugar. Some patients had diabetes before starting
protease inhibitors, others did not. Some patients required
adjustments to their diabetes medication. Others needed new
diabetes medication.</p>
<p>In some patients with hemophilia, increased bleeding has been
reported.</p>
<p>Severe muscle pain and weakness have occurred in patients taking
protease inhibitors, including CRIXIVAN, together with some of the
cholesterol-lowering medicines called "statins". Call your doctor
if you develop severe muscle pain or weakness.</p>
<p>Changes in body fat have been seen in some patients taking
antiretroviral therapy. These changes may include increased amount
of fat in the upper back and neck ("buffalo hump"), breast, and
around the trunk. Loss of fat from the legs, arms and face may also
happen. The cause and long term health effects of these conditions
are not known at this time.</p>
<p>In some patients with advanced HIV infection (AIDS), signs and
symptoms of inflammation from opportunistic infections may occur
when combination antiretroviral treatment is started.</p>
<p>Clinical Studies</p>
<p>Increases in bilirubin (one laboratory test of liver function)
have been reported in approximately 14% of patients. Usually, this
finding has not been associated with liver problems. However, on
rare occasions, a person may develop yellowing of the skin and/or
eyes.</p>
<p>Side effects occurring in 2% or more of patients included:
abdominal pain, fatigue or weakness, low red blood cell count,
flank pain, painful urination, feeling unwell, nausea, upset
stomach, diarrhea, vomiting, acid regurgitation, increased or
decreased appetite, back pain, headache, dizziness, taste changes,
rash, itchy skin, yellowing of the skin and/or eyes, upper
respiratory infection, dry skin, and sore throat.</p>
<p>Swollen kidneys due to blocked urine flow occurred rarely.</p>
<p>Marketing Experience</p>
<p>Other side effects reported since CRIXIVAN has been marketed
include: allergic reactions; severe skin reactions; yellowing of
the skin and/or eyes; heart problems including heart attack;
stroke; abdominal swelling; indigestion; inflammation of the
kidneys; decreased kidney function; inflammation of the pancreas;
joint pain; depression; itching; hives; change in skin color; hair
loss; ingrown toenails with or without infection; crystals in the
urine; painful urination; numbness of the mouth; increased
cholesterol; pain and difficulty moving shoulder.</p>
<p>Tell your doctor promptly about these or any other unusual
symptoms. If the condition persists or worsens, seek medical
attention.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_6146d4ce-0d51-463b-bff1-abe13322ebef" id=
"i4i_section_id_6146d4ce-0d51-463b-bff1-abe13322ebef"></a> <a name=
"section-13.9" id="section-13.9"></a>
<h2><span class="Underline"><span class="Bold"><span class=
"Emphasis">How should I store CRIXIVAN
capsules?</span></span></span></h2>
<ul>
<li>Keep CRIXIVAN capsules in the bottle they came in and at room
temperature (59°-86°F).</li>
<li>Keep CRIXIVAN capsules dry by leaving the small desiccant in
the bottle. Keep the bottle closed.</li>
</ul>
<p class="First"><span class="Bold"><span class="Emphasis">This
medication was prescribed for your particular condition. Do not use
it for any other condition or give it to anybody else. Keep
CRIXIVAN and all medicines out of the reach of children. If you
suspect that more than the prescribed dose of this medicine has
been taken, contact your local poison control center or emergency
room immediately.</span></span></p>
<p>This leaflet provides a summary of information about CRIXIVAN.
If you have any questions or concerns about either CRIXIVAN or HIV,
talk to your doctor.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">SPL UNCLASSIFIED SECTION</a>
<div class="Section toggle-content closed" data-sectioncode=
"42229-5"><a name="section-14" id="section-14"></a>
<p class="First">Distributed by:<br>
Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co.,
Inc.<br>
Whitehouse Station, NJ 08889, USA</p>
<p>For patent information:
www.merck.com/product/patent/home.html</p>
<p>The trademarks depicted herein are owned by their respective
companies.</p>
<p>Copyright © 1996, 1999 Merck Sharp &amp; Dohme Corp., a
subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span><br>
All rights reserved.</p>
<p>Revised 03/2015</p>
<p>usppi-mk0639-c-1503r017</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL - Bottle Label - 100 mg</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="section-15" id="section-15"></a>
<div class="Figure"><img src=
"image.cfm?setid=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f&amp;name=crixivan-09.jpg"
alt="PRINCIPAL DISPLAY PANEL - Bottle Label - 100 mg"></div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL - Bottle Label - 200 mg</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name=
"i4i_Principal_display_panel_id_cf5a215d-f130-470d-aadf-714d914ee7de"
id=
"i4i_Principal_display_panel_id_cf5a215d-f130-470d-aadf-714d914ee7de">
</a> <a name="section-16" id="section-16"></a>
<p class="First">NDC 0006-0571-43</p>
<p><span class="Bold">Crixivan</span><span class="Sup">®</span><br>
<span class="Bold">(Indinavir Sulfate) Capsules<br>
200 mg</span></p>
<p><span class="Bold">ALERT<br>
Find out about medicines that should NOT be taken<br>
with CRIXIVAN.</span></p>
<p><span class="Bold">Note to Pharmacist:<br>
Do not cover ALERT box with Pharmacy label.</span></p>
<p>Each capsule contains indinavir 200 mg (corresponding to<br>
indinavir sulfate 250 mg). Store at room temperature,<br>
15-30°C (59-86°F). Keep container tightly closed.<br>
Protect from moisture.<br>
Bottle contains desiccant.</p>
<p>USUAL DOSAGE:<br>
See Package Insert.</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">360 Capsules</span></p>
<p>Lot</p>
<p>Exp.</p>
<div class="Figure"><img src=
"image.cfm?setid=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f&amp;name=crixivan-10.jpg"
alt="PRINCIPAL DISPLAY PANEL - Bottle Label - 200 mg"></div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL - Bottle Label - 400 mg</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name=
"i4i_Principal_display_panel_id_36c654a6-e332-47da-9717-0231e82e418c"
id=
"i4i_Principal_display_panel_id_36c654a6-e332-47da-9717-0231e82e418c">
</a> <a name="section-17" id="section-17"></a>
<p class="First">NDC 0006-0573-62</p>
<p><span class="Bold">Crixivan</span><span class="Sup">®</span><br>
<span class="Bold">(Indinavir Sulfate) Capsules<br>
400 mg</span></p>
<p><span class="Bold">ALERT<br>
Find out about medicines that should NOT be taken<br>
with CRIXIVAN.</span></p>
<p><span class="Bold">Note to Pharmacist:<br>
Do not cover ALERT box with Pharmacy label.</span></p>
<p>Each capsule contains indinavir 400 mg (corresponding to
indinavir<br>
sulfate 500 mg). Store at room temperature, 15-30°C (59-86°F).<br>
Keep container tightly closed.<br>
Protect from moisture.<br>
Bottle contains desiccant.</p>
<p>USUAL DOSAGE: See Package Insert.</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">180 Capsules</span></p>
<p>Lot</p>
<p>Exp.</p>
<div class="Figure"><img src=
"image.cfm?setid=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f&amp;name=crixivan-11.jpg"
alt="PRINCIPAL DISPLAY PANEL - Bottle Label - 400 mg"></div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">INGREDIENTS AND APPEARANCE</a>
<div class="DataElementsTables toggle-content">
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>CRIXIVAN</strong><br>
<span class="contentTableReg">indinavir sulfate capsule</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0006-0570</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>INDINAVIR SULFATE</strong> (UNII:
771H53976Q) (INDINAVIR ANHYDROUS - UNII:9MG78X43ZT)</td>
<td class="formItem">INDINAVIR ANHYDROUS</td>
<td class="formItem">100 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong> (UNII:
3SY5LH9PMK)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong> (UNII:
2G86QN327L)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong> (UNII:
15FIX9V2JP)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (semi-translucent white)</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (capsule)</td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">CRIXIVAN;100;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:0006-0570-62</td>
<td class="formItem">180 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020685</td>
<td class="formItem">03/13/1996</td>
<td class="formItem">12/31/2012</td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>CRIXIVAN</strong><br>
<span class="contentTableReg">indinavir sulfate capsule</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0006-0571</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>INDINAVIR SULFATE</strong> (UNII:
771H53976Q) (INDINAVIR ANHYDROUS - UNII:9MG78X43ZT)</td>
<td class="formItem">INDINAVIR ANHYDROUS</td>
<td class="formItem">200 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong> (UNII:
3SY5LH9PMK)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong> (UNII:
2G86QN327L)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong> (UNII:
15FIX9V2JP)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (semi-translucent white)</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (capsule)</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">CRIXIVAN;200;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:0006-0571-43</td>
<td class="formItem">360 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020685</td>
<td class="formItem">03/13/1996</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>CRIXIVAN</strong><br>
<span class="contentTableReg">indinavir sulfate capsule</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0006-0573</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>INDINAVIR SULFATE</strong> (UNII:
771H53976Q) (INDINAVIR ANHYDROUS - UNII:9MG78X43ZT)</td>
<td class="formItem">INDINAVIR ANHYDROUS</td>
<td class="formItem">400 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong> (UNII:
3SY5LH9PMK)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong> (UNII:
2G86QN327L)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong> (UNII:
15FIX9V2JP)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (semi-translucent white)</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (capsule)</td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">CRIXIVAN;400;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:0006-0573-62</td>
<td class="formItem">180 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020685</td>
<td class="formItem">03/13/1996</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Labeler -</span> Merck Sharp &amp; Dohme Corp.
(001317601)</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Establishment</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Name</th>
<th class="formTitle" scope="col">Address</th>
<th class="formTitle" scope="col">ID/FEI</th>
<th class="formTitle" scope="col">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Merck Sharp &amp; Dohme Corp.</td>
<td class="formItem"></td>
<td class="formItem">001705110</td>
<td class="formItem">MANUFACTURE(0006-0571, 0006-0573) , API
MANUFACTURE(0006-0571, 0006-0573)</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Establishment</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Name</th>
<th class="formTitle" scope="col">Address</th>
<th class="formTitle" scope="col">ID/FEI</th>
<th class="formTitle" scope="col">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Patheon Pharmaceuticals Inc.</td>
<td class="formItem"></td>
<td class="formItem">005286822</td>
<td class="formItem">MANUFACTURE(0006-0571, 0006-0573)</td>
</tr>
</tbody>
</table>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
</ul>
<div class="control-nav"><a class="open-all" href="#">View All
Sections</a><a class="close-all" href="#">Close All
Sections</a></div>
</div>
</div>
</article>
<div class="articlefooternav">
<h2>Find additional resources</h2>
<strong>(also available in the <a href="#leftmenu">left
menu</a>)</strong>
<h3>Safety</h3>
<p><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a>, <a href=
"http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety
Recalls</a>, <a href=
"http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22INDINAVIR%20ANHYDROUS%22+%29"
target="_blank">Presence in Breast Milk</a></p>
<h3>Related Resources</h3>
<p><a href=
"http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&amp;query=INDINAVIR%20ANHYDROUS"
target="_blank">Medline Plus</a>, <a href=
"//www.clinicaltrials.gov/ct/search?submit=Search&amp;term=INDINAVIR%20ANHYDROUS"
target="_blank">Clinical Trials</a>, <a href="#pubmed-menu" id=
"pubmed-bottom">PubMed</a>, <a href=
"http://www.drugbank.ca/search?utf8=%E2%9C%93&amp;query=INDINAVIR+SULFATE&amp;search_type=drugs&amp;button="
target="_blank">Biochemical Data Summary</a></p>
<h3>More Info on this Drug</h3>
<p><a href="#modal-label-archives" class="modal-open">View Label
Archives</a>, <a href="#modal-rx-norm" class=
"modal-open">RxNorm</a>, <a href="#modal-label-rss" class=
"modal-open">Get Label RSS Feed</a></p>
</div>
</div>
<div class="divider"></div>
</div>
</div>
<!-- Label Archives Modal -->
<div class="mfp-hide modal" id="modal-label-archives">
<div class="modal-wrapper">
<header>
<h2>View Label Archives for this drug</h2>
</header>
<div class="top">
<h3 class="long-title">CRIXIVAN- indinavir sulfate capsule<br></h3>
<h4>Number of versions: 13</h4>
</div>
<div class="modal-content">
<table class="modal">
<tbody>
<tr>
<th>Published Date <a class="tip" rel="tooltip" href="#" title=
"&lt;b&gt;Published Date&lt;/b&gt; - The date that a drug label is published on DailyMed for public view. This is distinct from &lt;b&gt;Updated Date&lt;/b&gt;*. &lt;br&gt;&lt;br&gt; *&lt;b&gt;Updated Date&lt;/b&gt; (also known as &lt;b&gt;Effective Time&lt;/b&gt;) - The label revision date included in the SPL.">
(What is this?)</a></th>
<th>Version</th>
<th>Files</th>
</tr>
<tr>
<td>Apr 13, 2015</td>
<td>21 (current)</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=171836">download</a></td>
</tr>
<tr>
<td>Feb 28, 2014</td>
<td>19</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=132612">download</a></td>
</tr>
<tr>
<td>Jun 11, 2012</td>
<td>17</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=80895">download</a></td>
</tr>
<tr>
<td>Mar 8, 2012</td>
<td>16</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=74714">download</a></td>
</tr>
<tr>
<td>Dec 2, 2010</td>
<td>14</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=43407">download</a></td>
</tr>
<tr>
<td>May 7, 2010</td>
<td>12</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=19032">download</a></td>
</tr>
<tr>
<td>Apr 20, 2010</td>
<td>11</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=18616">download</a></td>
</tr>
<tr>
<td>Dec 3, 2008</td>
<td>6</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=9419">download</a></td>
</tr>
<tr>
<td>Jul 2, 2008</td>
<td>5</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=8512">download</a></td>
</tr>
<tr>
<td>Feb 15, 2008</td>
<td>4</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=7029">download</a></td>
</tr>
<tr>
<td>Mar 1, 2007</td>
<td>3</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=3522">download</a></td>
</tr>
<tr>
<td>Jan 5, 2007</td>
<td>2</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=2971">download</a></td>
</tr>
<tr>
<td>Oct 20, 2006</td>
<td>1</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=2133">download</a></td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<!-- RxNorm Modal -->
<div class="mfp-hide modal" id="modal-rx-norm">
<div class="modal-wrapper">
<header>
<h2>RxNorm</h2>
</header>
<div class="top">
<h3 class="long-title">CRIXIVAN- indinavir sulfate capsule<br></h3>
</div>
<div class="modal-content">
<table class="modal">
<tbody>
<tr>
<th></th>
<th>RxCUI</th>
<th>RxNorm NAME</th>
<th>RxTTY</th>
</tr>
<tr class="psn-rxtty">
<td>1</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=153127">153127</a></td>
<td>Crixivan 200 MG Oral Capsule</td>
<td>PSN</td>
</tr>
<tr>
<td>2</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=153127">153127</a></td>
<td>Indinavir 200 MG Oral Capsule [Crixivan]</td>
<td>SBD</td>
</tr>
<tr>
<td>3</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=153127">153127</a></td>
<td>Crixivan 200 MG (as indinavir sulfate 250 MG) Oral Capsule</td>
<td>SY</td>
</tr>
<tr>
<td>4</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=153127">153127</a></td>
<td>Crixivan 200 MG Oral Capsule</td>
<td>SY</td>
</tr>
<tr class="psn-rxtty">
<td>5</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=153128">153128</a></td>
<td>Crixivan 400 MG Oral Capsule</td>
<td>PSN</td>
</tr>
<tr>
<td>6</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=153128">153128</a></td>
<td>Indinavir 400 MG Oral Capsule [Crixivan]</td>
<td>SBD</td>
</tr>
<tr>
<td>7</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=153128">153128</a></td>
<td>Crixivan 400 MG (as indinavir sulfate 500 MG) Oral Capsule</td>
<td>SY</td>
</tr>
<tr>
<td>8</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=153128">153128</a></td>
<td>Crixivan 400 MG Oral Capsule</td>
<td>SY</td>
</tr>
<tr class="psn-rxtty">
<td>9</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=283103">283103</a></td>
<td>indinavir sulfate 100 MG Oral Capsule</td>
<td>PSN</td>
</tr>
<tr>
<td>10</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=283103">283103</a></td>
<td>Indinavir 100 MG Oral Capsule</td>
<td>SCD</td>
</tr>
<tr>
<td>11</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=283103">283103</a></td>
<td>indinavir 100 MG (indinavir sulfate 125 MG) Oral Capsule</td>
<td>SY</td>
</tr>
<tr class="psn-rxtty">
<td>12</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=310986">310986</a></td>
<td>indinavir sulfate 200 MG Oral Capsule</td>
<td>PSN</td>
</tr>
<tr>
<td>13</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=310986">310986</a></td>
<td>Indinavir 200 MG Oral Capsule</td>
<td>SCD</td>
</tr>
<tr>
<td>14</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=310986">310986</a></td>
<td>indinavir 200 MG (indinavir sulfate 250 MG) Oral Capsule</td>
<td>SY</td>
</tr>
<tr class="psn-rxtty">
<td>15</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=310988">310988</a></td>
<td>indinavir sulfate 400 MG Oral Capsule</td>
<td>PSN</td>
</tr>
<tr>
<td>16</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=310988">310988</a></td>
<td>Indinavir 400 MG Oral Capsule</td>
<td>SCD</td>
</tr>
<tr>
<td>17</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=310988">310988</a></td>
<td>indinavir 400 MG (indinavir sulfate 500 MG) Oral Capsule</td>
<td>SY</td>
</tr>
<tr>
<td>18</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=541058">541058</a></td>
<td>Indinavir 100 MG Oral Capsule [Crixivan]</td>
<td>SBD</td>
</tr>
<tr>
<td>19</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=541058">541058</a></td>
<td>Crixivan 100 MG (as indinavir sulfate 125 MG) Oral Capsule</td>
<td>SY</td>
</tr>
<tr>
<td>20</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=541058">541058</a></td>
<td>Crixivan 100 MG Oral Capsule</td>
<td>SY</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<!-- Label RSS Modal -->
<div class="mfp-hide modal" id="modal-label-rss">
<header>
<h2>Get Label RSS Feed for this Drug</h2>
</header>
<div class="top">
<h3 class="long-title">CRIXIVAN- indinavir sulfate capsule<br></h3>
</div>
<div class="modal-content">
<h4>To receive this label RSS feed</h4>
<p>Copy the URL below and paste it into your RSS Reader
application.</p>
<p><a href=
"https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f"
target=
"_blank">https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f</a></p>
<h4>To receive all DailyMed Updates for the last seven days</h4>
<p>Copy the URL below and paste it into your RSS Reader
application.</p>
<p><a href="https://dailymed.nlm.nih.gov/dailymed/rss.cfm" target=
"_blank">https://dailymed.nlm.nih.gov/dailymed/rss.cfm</a></p>
<h4>What will I get with the DailyMed RSS feed?</h4>
<p>DailyMed will deliver notification of updates and additions to
Drug Label information currently shown on this site through its RSS
feed.</p>
<p>DailyMed will deliver this notification to your desktop, Web
browser, or e-mail depending on the RSS Reader you select to use.
To view updated drug label links, paste the RSS feed address (URL)
shown below into a RSS reader, or use a browser which supports RSS
feeds, such as Safari for Mac OS X.</p>
<h4>How to discontinue the RSS feed</h4>
<p>If you no longer wish to have this DailyMed RSS service, simply
delete the copied URL from your RSS Reader.</p>
<a href="/dailymed/rss-updates.cfm" class="rss-icon"></a> <a href=
"/dailymed/rss-updates.cfm">More about getting RSS News &amp;
Updates from DailyMed</a></div>
</div>
<!-- RxImage no more notification modal -->
<div class="mfp-hide modal" id="no-pill-photo-warning-modal">
<div class="modal-content">
<h4>Why is DailyMed no longer displaying pill images on the Search
Results and Drug Info pages?</h4>
<br>
<p>Due to inconsistencies between the drug labels on DailyMed and
the pill images provided by <a href=
"https://rximage.nlm.nih.gov/docs/doku.php?id=rximageapi_support"
target="_blank">RxImage</a>, we no longer display the RxImage pill
images associated with drug labels.</p>
<p>We anticipate reposting the images once we are able identify and
filter out images that do not match the information provided in the
drug labels.</p>
</div>
</div>
<!-- this div is only for jQuery -->
<div class="search-results">
<div class="filter-drop"></div>
</div>
<div class="webview"></div>
<div class="hide-on-mobile"></div>
<div class="mobilenav no-js">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li>Search
<ul>
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Labels Archives</a></li>
<li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Index Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
<footer class="mainFooter">
<div class="container">
<div class="three columns">
<div class="nihnlmlogoprint"><img src=
"/dailymed/images/nihnlmlogoprint.png" alt="NIH NLM Logo"></div>
<a href="//www.nlm.nih.gov/" class="logo" title=
"National Library of Medicine | National Institutes of Health"><img src="/dailymed/images/footer-logo.png"
width="109" height="37" alt=
"National Library of Medicine | National Institutes of Health"
title=
"National Library of Medicine | National Institutes of Health"></a></div>
<div id="share" class="thirteen columns">
<div class="footer-links">
<ul class="primary">
<li><a href="/dailymed/about-dailymed.cfm" title=
"About DailyMed">About DailyMed</a><span>|</span></li>
<li><a href="/dailymed/contact-us.cfm" title="Contact Us">Contact
Us</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/copyright.html" title="Copyright"
target="_blank" rel="bookmark">Copyright</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/privacy.html" title="Privacy"
target="_blank" rel="bookmark">Privacy</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/accessibility.html" title=
"Web Accessibility" target="_blank" rel="bookmark">Web
Accessibility</a></li>
</ul>
<ul class="secondary">
<li><a href="http://www.nih.gov/" title=
"National Institutes of Health" target="_blank" rel=
"bookmark">National Institutes of Health</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/" title=
"U.S. National Library of Medicine" target="_blank" rel=
"bookmark">U.S. National Library of Medicine</a><span>|</span></li>
<li><a href="http://www.hhs.gov/" title=
"Health &amp; Human Services" target="_blank" rel="bookmark">Health
&amp; Human Services</a></li>
</ul>
<ul class="secondary mobile">
<li><a href="http://www.nih.gov/" title=
"National Institutes of Health" target="_blank" rel=
"bookmark">NIH</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/" title=
"U.S. National Library of Medicine" target="_blank" rel=
"bookmark">NLM</a><span>|</span></li>
<li><a href="http://www.hhs.gov/" title=
"Health &amp; Human Services" target="_blank" rel="bookmark">Health
&amp; Human Services</a></li>
</ul>
<div class="social">Share <!-- AddThis Button BEGIN -->
 <noscript>: JavaScript needed for Sharing tools</noscript>
<div class=
"addthis_toolbox addthis_default_style addthis_16x16_style">
<a class="email-share" href=
"mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0ACRIXIVAN%2D%20Indinavir%20Sulfate%20Capsule%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3De19405d9%2Dd9a1%2D4072%2D5b9e%2D40cd3ae4bf1f%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E"
title="Share by Email"></a> <a class="addthis_button_facebook"></a>
<a class="addthis_button_twitter"></a> <a class=
"at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share"
href=
"//www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed"
target="_blank" style="width: 16px; height: 16px"><span style=
"left: -9999px; position: absolute;">Bookmark &amp; Share</span>
<img style="width:17px; margin-top: -2px;" src=
"/dailymed/images/addthis-image.jpg" alt=
"Bookmark &amp; Share"></a></div>
<!-- AddThis Button END --></div>
</div>
</div>
</div>
<div class="divider"></div>
</footer>
<div class="divider"></div>
</div>
<div class="to-top"></div>
<!-- this div is only for jQuery -->
<div class="search-results">
<div class="filter-drop"></div>
</div>
<div class="webview"></div>
<div class="hide-on-mobile"></div>
<script type="text/javascript" src=
"//ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js">
</script> <script type="text/javascript">
        if (typeof jQuery == 'undefined')
        {  
            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-1.10.2.min.js">\x3C/script>');
        }
</script> <script type="text/javascript">
        var basepath = "/dailymed";
;
        var availableClasses =  new Array();
;
        for(var i = 0; i < availableClasses.length; i++){
                availableClasses[i] = availableClasses[i].replace(/"/g, '').trim();
        }
        var labeltitle = "CRIXIVAN- indinavir sulfate capsule <br>";
;
        var emailLink = "";
;
        var emailrequest = "0";
;
</script> <script src=
"/dailymed/scripts/javascript-html-attribute-encoding.min.js">
</script> <script src="/dailymed/scripts/spin.min.js">
</script> <script src="/dailymed/scripts/scripts.min.js?v=2">
</script> <script type='text/javascript' src=
"//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/jquery-ui.min.js">
</script> <script type="text/javascript">
        if (typeof jQuery.ui == 'undefined')
        {
            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-ui-1.10.4.custom.min.js">\x3C/script>');
            document.write('\x3Clink rel="stylesheet" type="text/css" media="all" href="/dailymed/css/jquery-ui-1.10.4.custom.min.css">');
        }
        else{
            document.write('<link rel="stylesheet" href="//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/themes/smoothness/jquery-ui.min.css">');
        }
</script> <script type='text/javascript' src=
'/dailymed/scripts/jquery.elevateZoom-3.0.8.min.js'>
</script> <script type="text/javascript" src=
"/dailymed/scripts/jquery.placeholder.min.js">
</script> <script src=
"//www.accessdata.fda.gov/spl/stylesheet/spl.js" type=
"text/javascript" charset="utf-8">
/* */
</script> <!-- Magnific Popup core JS file -->
 <script src="/dailymed/scripts/jquery.magnific-popup.min.js">
</script> <script type="text/javascript">
var addthis_config = {"data_track_addressbar":false};
</script> <script type="text/javascript" src=
"//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5">
</script> <script>
 var ignore_onbeforeunload = false;

 $("a").on('click',function(){
    if(ignore_onbeforeunload){
        ignore_onbeforeunload = false;
    }
})

$("a[href^='mailto'], a[href$='zip']").on('click',function(){
    ignore_onbeforeunload = true;
});


$(window).on('beforeunload', function(){
    if (!ignore_onbeforeunload){
        // Only run the loading icon if changing the page takes longer than 200ms
        setTimeout(function(){
            // Fade in the grey screen
            $('body').prepend($('<div class="loading-wrapper" style="width: 100%;height: 100%;background-color: rgba(0, 0, 0, 0.50);position: fixed;top:0;z-index: 100000;"><\/div>').fadeIn('fast'));
            var opts = {
                  lines: 12 // The number of lines to draw
                , length: 14 // The length of each line
                , width: 5 // The line thickness
                , radius: 14 // The radius of the inner circle
                , scale: 1 // Scales overall size of the spinner
                , corners: 1 // Corner roundness (0..1)
                , color: '#fff' 
                , opacity: 0.25 // Opacity of the lines
                , rotate: 0 // The rotation offset
                , direction: 1 // 1: clockwise, -1: counterclockwise
                , speed: 1 // Rounds per second
                , trail: 60 // Afterglow percentage
                , fps: 20 // Frames per second when using setTimeout() as a fallback for CSS
                , zIndex: 2e9 // The z-index (defaults to 2000000000)
                , className: 'spinner' // The CSS class to assign to the spinner
                , top: '50%' // Top position relative to parent
                , left: '50%' // Left position relative to parent
                , shadow: false // Whether to render a shadow
                , hwaccel: false // Whether to use hardware acceleration
                , position: 'absolute' // Element positioning
                }
            var spinner = new Spinner(opts).spin();
            $('.loading-wrapper').append(spinner.el);
        }, 200);
    }

    //ignore_onbeforeunload = false;
});
</script> <!-- START OF SmartSource Data Collector TAG -->
<!-- Copyright (c) 1996-2012 Webtrends Inc.  All rights reserved. -->
<!-- Version: 9.4.0 -->
<!-- Tag Builder Version: 3.3  -->
<!-- Created: 1/25/2012 11:57:33 PM -->
<script type="text/javascript" src=
"/dailymed/scripts/webtrends.min.js">
</script> 
<!-- =================================================================================== -->
<!-- Warning: The two script blocks below must remain inline. Moving them to an external -->
<!-- JavaScript include file can cause serious problems with cross-domain tracking.      -->
<!-- =================================================================================== -->
<script type="text/javascript">
//<![CDATA[
var _tag=new WebTrends();
_tag.dcsGetId();
//]]>
</script> <script type="text/javascript">
//<![CDATA[
_tag.dcsCustom=function(){
// Add custom parameters here.
//_tag.DCSext.param_name=param_value;
_tag.DCSext.dcsid=_tag.dcsid
}
_tag.trackAllEvents=true;
_tag.dcsCollect();
//]]>
</script> <noscript>
<div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src=
"//wtsdc.nlm.nih.gov/dcsm7fmt310000o265ioub7ib_2b7v/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.4.0&amp;dcssip=dailymed.nlm.nih.gov&amp;dcsid=dcsm7fmt310000o265ioub7ib_2b7v"></div>
</noscript> <!-- END OF SmartSource Data Collector TAG -->
 <script type="text/javascript">
    setTimeout(function(){var a=document.createElement("script");
    var b=document.getElementsByTagName("script")[0];
    a.src=document.location.protocol+"//dnn506yrbagrg.cloudfront.net/pages/scripts/0027/2050.js?"+Math.floor(new Date().getTime()/3600000);
    a.async=true;a.type="text/javascript";b.parentNode.insertBefore(a,b)}, 1);
</script> <script type="text/javascript">
    function getParameterByName(name) {
        name = name.replace(/[\[]/, "\\[").replace(/[\]]/, "\\]");
        var regex = new RegExp("[\\?&]" + name + "=([^&#]*)"),
            results = regex.exec(location.search);
        return results === null ? "" : decodeURIComponent(results[1].replace(/\+/g, " "));
    }
    /* Tracking label type on search pages */
    function CE_READY() {
        if(!getParameterByName('labeltype')){
           CE2.set(1, "No Label Type");
        }
        else{
            var labeltype = getParameterByName('labeltype');
            if(labeltype == 'all'){
                CE2.set(1, "All");
            }
            else if(labeltype == 'human'){
                CE2.set(1, "Human");
            }
            else if(labeltype == 'animal'){
                CE2.set(1, "Animal");
            }
            else{
                CE2.set(1, "Unknown");
            }
        }
    }
</script> <!-- DAP Universal Analytics -->
 <script language="javascript" id="_fed_an_ua_tag" src=
"/dailymed/scripts/Universal-Federated-Analytics-Min.2.01.js?agency=HHS&amp;subagency=NIH&amp;enhlink=true&amp;dclink=true">
</script> <script src="/dailymed/scripts/preview-text.min.js">
</script>
</body>
</html>
